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ABSTRACT
Human African trypanosomiasis (HAT), commonly called African sleeping
sickness, is caused by bloodstream form Trypanosoma brucei and has the potential to
affect millions of people in sub-Saharan Africa. Treatments have existed for the past fifty
years, but are characterized by severe adverse side-effects and poor efficacy.
Trypanosomes generate ATP through glycolysis, or the metabolism of glucose, which is
catalyzed by enzymes called hexokinases (TbHK1 and TbHK2) in trypanosomes.
Through high-throughput screenings (HTS) and structure-activity relationships (SAR),
both hexokinases could be targeted with small molecules to inhibit the first step in the
glycolytic pathway of trypanosomes. Of the two hexokinases, TbHK1 has shown promise
as a target for the development of trypanocides.
The first half of this thesis will report the syntheses of several derivatives of
potent TbHK1 inhibitors, ebselen and benzamidobenzoic acid (BABA). Ebselen, or 2phenyl-1,2-benzisoselenazol-3(2H)-one, is a drug that is currently in trials for patients
suffering from hearing loss or bipolar disorder that has also demonstrated potency against
trypanosomes with an IC50 of 0.05 ± 0.03 µM. BABA is a novel therapeutic derivative that
was revealed to be a hit through SAR efforts. The final aim is the coupling of the
inhibitors to a peptidic scaffold via solid phase peptide synthesis (SPPS). The results of
the bioassays conducted on these conjugates will be described and presented with future
directions to expand the role of these inhibitors toward other tropical diseases.
The Diels-Alder reaction is a carbon-carbon bond forming reaction in which a
dienophile (e.g., alkene or alkyne) and a diene undergo a [4+2] cycloaddition to produce
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cyclohexene adducts with predictable regiochemistry. The aim of this work is to employ
chiral boronate esters that have absolute stereocenters to propagate chiral information in
intramolecular Diels-Alder (IMDA) reactions to establish new absolute stereocenters,
while retaining the absolute stereocenters originally present on the original chiral
boronate esters. The second half of this thesis will present the synthesis of a novel
boronate ester possessing both diene and dienophile components to participate in an
IMDA cycloaddition, concluding with future research suggestions.

iii

DEDICATION
This dissertation is dedicated to the memory of my beloved grandmother,
Diwaliben Raghabhai Paragji (1923-2014), and to my parents, Manoj and Veena
Gordhan, for their continued love, support, and guidance.

iv

ACKNOWLEDGMENTS
First and foremost, a special thank you to my advisor, Dr. Daniel Whitehead, for
his profound support and invaluable advice toward both my Ph.D. study as well as my
career aspirations. Over the five years I worked for him, I was a witness to Dr.
Whitehead’s incredible breadth of knowledge in chemistry that I aspire to one day
possess. I will forever be indebted to the man who taught me what it truly means to be an
independent research scientist, who helped me become a better writer, and who helped
me see the positives through the many experimental shortcomings associated with a
graduate scientific education. Most importantly, he taught me working in lab was worth it
“…as long as you’re having fun.” His mentorship was crucial for me to reach this station
in my academic career, especially as I chased my elusive first scientific publication. His
patience was especially appreciated when I accidentally crafted a fifty page Ph.D.
candidacy document, and even more so in the culmination of this thesis. I could not have
imagined a better advisor to have worked for during my graduate experience at Clemson.
I extend my thanks to the other members of my committee: Dr. James Morris, Dr.
Modi Wetzler, and Dr. Andrew Tennyson, for their encouragement, advice, insightful
comments, and tough questions. I especially thank Dr. James Morris for his continued
support and his mentorship as I progressed through my training as a medicinal chemist.
To Timothy Lex, Maria Swasy, and Anthony Santilli for their collegial spirit and
our many shared memories.
To my Alma Mater, Clemson University, for giving me the opportunity to pursue
a graduate education and for providing me a place I could call home for five years.

v

To the staff of the Department of Chemistry, including Robin Wilmott, Christine
Dinger, and Heather Shelton, for their positive spirit and their willingness to assist me.
To Dr. Alex Kitt, for his invaluable NMR expertise. To Dr. Sean O’Connor and David
Ryan Dorsey, thank you for letting me “borrow” chemicals for my reactions and for
letting me take advantage of the organic lab infrared spectrometers in the preparation of
this thesis.
To the continued love and support from my closest friends: Ben and Allison
Campbell, Jason Jakiela, Laura Welti, Dr. Ahmer Ansari, Will and Sarah Burke White,
William Brewer, Josh Smith, and Austin Blackwell.
To my two roommates in graduate school and my fellow Clemson alumni, Alex
Belch and Paul Watters.
A special thanks to Dr. Alfredo Picado and Emmanuel Amoah for all the soccer
games we watched in lab as well as the graduate school and chemistry tips.
I want to thank my incredible parents, Manoj and Veena Gordhan, who made
sacrifices beyond measure of themselves to allow me to have a shot at a better education
and a better life. I love you both dearly. Finally, I dedicate this dissertation to my beloved
grandmother, Diwaliben Raghabhai Paragji (1923-2014), who taught me to brew my first
cup of chai all those years ago and who raised me into the man I am today. Your love,
your memory, and your wisdom will always be a part of me.

vi

TABLE OF CONTENTS
Page
TITLE PAGE .................................................................................................................... i
ABSTRACT..................................................................................................................... ii
DEDICATION ................................................................................................................ iv
ACKNOWLEDGMENTS ............................................................................................... v
LIST OF TABLES .......................................................................................................... ix
LIST OF FIGURES ........................................................................................................ xi
LIST OF SCHEMES .................................................................................................... xiv
CHAPTER
I.

EVALUATION OF SUBSTITUTED EBSELEN
DERIVATIVES AS ANTI-TRYPANOSOMAL
DRUGS .................................................................................................... 1
1.1 Introduction ........................................................................................ 1
1.2 Solid Phase Peptide Synthesis (SPPS) ............................................. 14
1.2.1 Applications ............................................................................... 14
1.2.2 Synthetic Methods .................................................................... 17
1.3 Results and Discussion .................................................................... 18
1.3.1 Completed EbSe/EbS Syntheses ................................................ 18
1.4 Completed Syntheses and Definition of Variables .......................... 23
1.4.1 Ebselen Peptide-Drug Conjugates ............................................. 24
1.5 Conclusions and Future Directions .................................................. 34
1.6 Experimental .................................................................................... 38
1.6.1 Trypanosome growth and viability assays ................................. 38
1.6.2 Synthesis of drugs and peptide-drug conjugates ........................ 39
1.6.3 General procedure for solid phase peptide
synthesis of I-40 to I-49............................................................. 58
1.7 References ........................................................................................ 62

vii

Table of Contents (Continued)
II.

Page

SYNTHESIS AND EVALUATION OF POTENT
TRYPANOCIDES BASED ON
BENZAMIDOBENZOIC ACID (BABA)
INHIBITOR SCAFFOLD...................................................................... 64
2.1 Introduction ...................................................................................... 64
2.2 Results and Discussion .................................................................... 74
2.2.1 Completed BABA Syntheses ...................................................... 74
2.3 Completed Peptide Syntheses and Definition of
Variables .......................................................................................... 87
2.3.1 Evaluation of PTS1-Conjugated BABA
Conjugates.................................................................................. 91
2.3.2 FITC-Coupled PTS1-BABA Peptide
Conjugates.................................................................................. 96
2.4 Conclusions and Future Directions ................................................ 103
2.5 Experimental .................................................................................. 110
2.5.1 Trypanosome growth and viability assays ............................... 110
2.5.2 Synthesis of drugs and peptide-drug conjugates ...................... 111
2.5.3 General procedure for solid phase peptide
synthesis of II-28 to II-40 ....................................................... 131
2.6 References ...................................................................................... 133

III.

SYNTHESIS AND UTILITY OF A NOVEL CHIRAL
BORONATE ESTER IN THE
INTRAMOLECULAR DIELS-ALDER REACTION ........................ 138
3.1 Introduction .................................................................................... 138
3.1.1 A Brief Background of Selective
Dihydroxylation of Dienes and Trienes ................................... 155
3.2 Results and Discussion .................................................................. 158
3.2.1 Synthetic Aims ......................................................................... 158
3.3 Conclusions and Future Directions ................................................ 169
3.4 Experimental .................................................................................. 173
3.4.1 Completed Synthesis................................................................ 173
3.5 References ...................................................................................... 192

APPENDICES ............................................................................................................. 194
A:
B:
C:

Appendix A: NMR Spectra for Chapter One ............................................. 195
Appendix B: NMR Spectra for Chapter Two ............................................ 212
Appendix C: NMR Spectra for Chapter Three .......................................... 224

viii

LIST OF TABLES
Table

Page

1.1

WT = wild-type; ND = not detected. The key residues
listed are C327(A/S) and C369(A/S). The former loses
activity upon mutation; the latter maintains an enzymatic
activity above the threshold for detection. ................................................... 12

1.2

Biological data on EbSe and EbS derivatives and
peptide-drug conjugates of EbSe and EbS derivatives. ................................ 33

1.3

MALDI-TOF data for peptides I-40 to I-49. ............................................... 61

2.1

SAR data for substituted analogues of II-1. ................................................ 69

2.2

Biological data on BABA derivatives and PTS1-BABA
peptide conjugates. ....................................................................................... 96

2.3

Biological data for FITC-tagged peptide conjugates. ................................ 100

2.4

MALDI-TOF data for peptides II-28 to II-40. Please
note that the [M]+ m/z is shown for peptides II-28 to
+
II-39 while the [M+Na] m/z is shown for peptide II-40. ......................... 134

3.1

Several examples of a DA reaction between
cyclopentadiene (III-1) and a vinyl boronate acid or ester
(shown above), used as a chiral auxiliary, are displayed. .......................... 143

3.2

Cycloaddition (see Scheme 3.4) of diene III-9 with
1
maleimides (R = Ph or Me) followed by a tandem
allylboration with a benzaldehyde derivative (4-substituted
2
aryl ring with R ). ...................................................................................... 146

3.3

Endo:exo ratios (see Scheme 3.6) afforded by the Diels-Alder
cycloaddition between III-15 or III-16 and excess
cyclopentadienone...................................................................................... 149

3.4

Data for competitive kinetic experiment (see Scheme 3.7)
between III-15, III-19, and excess cyclopentadiene III-1
showing preference for ortho product........................................................ 150

ix

List of Tables (Continued)
Table

Page

3.5

Remote 1,8-stereoinduction (numbering shown in
Figure 3.3) reflected in the Diels-Alder cycloaddition
between III-22 to III-25 and excess cyclopentadienone.
Reaction with III-24 was stirred for 3 days in DCM at
room temperature and reaction with III-25 stirred in
DCM at room temperature. .................................................................. 151

3.6

Dihydroxylation results for conjugated diene III-36a. ........................ 156

3.7

Dihydroxylation results for conjugated diene III-36b......................... 156

3.8

Data for dihydroxylation (see Scheme 3.12) of triene
III-39 showing preference for unbranched esters. ............................... 158

x

LIST OF FIGURES
Figure

Page

1.1

Lifecycle of trypanosomes in tsetse fly and mammalian
host. ................................................................................................................ 4

1.2

Three Cys-reactive compounds studied by Joice et al.
are shown above: TbHK1 inhibitors EbSe (I-1) and EbS
(I-2) and reducing agent dithiothreitol (DTT). Other
active benzisothiazolinone derivatives, I-3 to I-6, arising
from the HTS are also shown. Known inhibitors of
mammalian hexokinases, lonidamine and
tris-(2-carboxyethyl)phosphine (TCEP), are also shown............................... 9

1.3

Proposed reversible pathway for Ebselen-based oxidation
of Cys residues in TbHK1............................................................................ 10

1.4

Synthesized EbSe and EbS peptide-drug conjugates. Of
the conjugates screened, I-44 and I-45 were moderately
effective against TbHK1 and whole cell trypanosomes,
respectively. ................................................................................................. 27

1.5

Synthesized EbSe and EbS peptide-drug conjugates with
a diethylene glycol tether in lieu of a diglycine tether. ................................ 28

1.6

Ebselen scaffold bearing an N-para-carboxymethyl
substitution. .................................................................................................. 36

2.1

Key features of the BABA derivatives are shown on the
left; ML205 (II-1) lead drug candidate (IC50 = 0.98 ±
0.07 µM) shown on right. ............................................................................ 65

2.2

Retrosynthetic analysis of successful synthetic strategy
affording desired BABA methyl ester II-8 (outlined in
detail below) and PTS1-BABA conjugates II-9a and II-9b. ........................ 75

2.3

Synthesized BABA peptide conjugates (II-28 to II-35).
Of the conjugates screened, II-29 showed mild inhibition
of TbHK1. Conjugate II-30 showed high potency against
whole cell trypanosomes and conjugate II-31 showed high
potency against TbHK1. .............................................................................. 92

xi

List of Figures (Continued)
Figure

Page

2.4

Peptide conjugates prepared bearing FITC to identify
localization within glycosomal compartment of
trypanosomes. ............................................................................................ 100

2.5

Localization of conjugate II-37 into the glycosome of
procyclic T. brucei. (A) DIC image of procyclic T.
brucei. (B) Green fluorescent PTS1-FITC-BABA
conjugate II-37 localized into glycosomes. (C) PTS2mCherry localized into glycosomes (D) Merged images
of B and C. ................................................................................................. 101

2.6

Localization of conjugate II-37 into the glycosome of
BSF T. brucei. (A) DIC image of live BSF T. brucei.
(B) PTS2-mCherry localized into glycosomes. (C) Green
fluorescent PTS1-FITC-BABA conjugate II-37 localized
into glycosomes. (D) Merged images of B and C. (E)
Merged image of A-C. ............................................................................... 102

2.7

Localization of conjugate II-39 into the glycosome of
procyclic and BSF T. brucei. (A) DIC image of procyclic
T. brucei. (B) PTS2-mCherry localized into
glycosomes. (C) Green fluorescent PTS1-FITC-BABA
conjugate II-39 localized into glycosomes. (D) Merged
images of B and C. (E) DIC image of BSF T. brucei.
(F) PTS2-mCherry localized into glycosomes. (G) Green
fluorescent PTS1-FITC-BABA conjugate II-39 localized
into glycosomes. (H) Merged images of F and G. ..................................... 103

2.8

General structures for peptoid and peptidine. ............................................ 107

2.9

PTS-FITC bound to (+)-biotin (II-40) to assay whether
the PTS does in fact bind to TbHK1 as desired. ........................................ 109

3.1

General schemes shown for traditional Diels-Alder (top)
and an inverse electron demand Diels-Alder (bottom).
Wavy bonds are used to indicate that a mixture of endo:exo
products would be observed....................................................................... 139

3.2

Examples of vinyl derivatives that can participate in the
Diels-Alder cycloaddition. ......................................................................... 140

xii

List of Figures (Continued)
Figure
3.3

Page
Chiral 2-boronoacrylanilide derivatives prepared by
Kennedy and Hall. Numbering for 1,8-stereoinduction
on III-22 according to Kennedy and Hall.................................................. 151

xiii

LIST OF SCHEMES
Scheme

Page

1.1

General peptide structure shown on left bearing the PTS,
a tether (either diglycine or diethylene glycol), and the
Ebselen derivative. The Ebselen derivatives generated
are shown on the right (top to bottom) bearing an N-acetyl,
N-aryl, or heterocyclic substitution with the carboxylic
acid. First, the Ebselen derivatives were synthesized to
determine the most effective position of the carboxylic
acid (via in vitro testing of the methyl ester and carboxylic
acid). Then, the Ebselen carboxylic acid derivative was
attached to the peptide scaffold (shown on the left). ................................... 17

1.2

Ebselen (I-1) synthesis following protocol by Balkrishna,
et al. (top); attempted oxidation of EbSe (bottom). ..................................... 19

1.3

First EbS derivative (I-12) preparation according to
21
protocol provided by Dou, et al. First EbS derivative
methyl ester I-13 synthesized from I-9 in 38% yield. ................................. 20

1.4

First EbSe derivative preparation beginning with
diazotization of anthranilic acid, followed by acylation
of the diselenide, terminating with hydrolysis of methyl
ester (I-18) affording acid I-19. ................................................................... 20

1.5

Synthesis of second EbS and EbSe derivatives (I-27
and I-28) that demonstrated low cell toxicity toward
the trypanosomes. ........................................................................................ 21

1.6

Synthesis of EbS derivatives (I-36 and I-37) and EbSe
derivatives (I-38 and I-39) with meta and para N-arylsubstitutions. ................................................................................................ 23

1.7

General protocol for Fmoc Solid Phase Peptide Synthesis
of C-LKAGG-N sequence (shown on top). The coupling
of two glycine moieties can be replaced with the single
coupling of a diethylene glycol unit. The Fmoc protecting
group is cleaved from the second glycine for overnight
coupling with the desired drug, either an EbS/EbSe/BABA
(see Chapter Two) derivative (shown on bottom). ....................................... 26

xiv

List of Schemes (Continued)
Scheme

Page

2.1

On the right is II-1 to which a carboxyarene could be
appended in lieu of the bromine to allow for the
incorporation of a peptide (carboxylic acid of interest
is highlighted in blue). Note that the tert-butyl group
(highlighted red) on II-1 could also be replaced with a
carboxylic acid to form another BABA analog that would
allow for incorporation of a peptide bond in that position.
Although the carboxylic acid highlighted in green is the
therapeutically active residue in II-1, as well as BABA,
we envisioned attaching a peptidic scaffold to the
carboxylic acid on II-1. On the left are two of the peptidic
scaffolds that were envisioned for coupling to the
synthesized BABA derivatives bearing either a diglycine
or diethylene glycol tether with a PTS1 consisting of
C-LKA-N. .................................................................................................... 72

2.2

In order to visualize delivery of the PTS1-BABA conjugates
in the trypanosome, we envisioned coupling FITC to the
PTS1 on two peptide conjugates shown on the right.
We also envisioned producing a PTS1-BABA conjugate
wherein the fluorescent dye was installed adjacent to the
PTS1 using a lysine-glycine tether, rather than a diglycine
tether............................................................................................................. 74

2.3

Bromination of 2-amino-4-chloro-methyl benzoate (II-10),
followed by acylation and hydrolysis of II-3. The synthesis
of iodinated derivative II-4 also shown. Both II-3 and II-4
were used in subsequent reactions with similar results. .............................. 76

2.4

Several methods for the esterification of carboxylic acid
II-1 were attempted. Intramolecular hydrogen-bond
framework emphasized in left-most figure. ................................................. 78

2.5

Suzuki coupling of tert-butyl ester II-12 and
4-carboxyphenylboronic acid. Carboxylic acid highlighted
red to emphasize functionality required for SPPS; ester
highlighted blue to emphasize masked carboxylic acid that
will be revealed post-SPPS. ......................................................................... 79

xv

List of Schemes (Continued)
Scheme

Page

2.6

Failed Suzuki coupling between II-11 and 4-carboxy- or
4-methoxycarbonyl-phenylboronic acid (top). Suzuki
coupling between II-11 and 4-methoxycarbonylphenyl
boronic acid was successful in adding third aryl ring, but
hydrolyzed methyl ester ortho to amide (bottom). ...................................... 80

2.7

Suzuki coupling of II-3 with 4-carboxyphenylboronic
acid (affording II-16) and 4-methoxycarbonylphenylboronic
acid (affording II-17). .................................................................................. 82

2.8

Acylation of II-16 and II-17 with 4-tert-butyl benzoyl
chloride (II-6). ............................................................................................. 82

2.9

Alternative method for the acylation of aniline derivative
II-16 with 4-tert-butyl benzoyl chloride. ..................................................... 83

2.10

Suzuki coupling of II-3 with 4-benzyloxycarbonylphenylboronic
acid yielding II-19; acylation of II-19 with 4-tert-butyl
benzoyl chloride (II-6); deprotection of II-20 with
hydrogen gas and palladium on carbon. ...................................................... 84

2.11

Suzuki coupling of II-4 with 4-tert-butyloxycarbonylphenylboronic
acid yielding II-21; acylation of II-21 with 4-tert-butyl
benzoyl chloride to afford bis-ester II-22; deprotection of
II-22 with trifluoroacetic acid. ..................................................................... 85

2.12

Hydrolysis of methyl ester II-8 to diacid II-23. Note that
II-1p in Table 2.1 is the same as II-23. ....................................................... 86

2.13

Acylation of terephthalic acid (II-24) with brominated
aniline derivative II-3 affording II-26 in modest yield.
Hydrolysis of II-26 with aqueous lithium hydroxide
affords diacid II-27. ..................................................................................... 87

2.14

Hydrolysis of PTS1-BABA-diglycine methyl ester II-28
to afford PTS1-BABA-diglycine carboxylic acid II-29. .............................. 88

xvi

List of Schemes (Continued)
Scheme

Page

2.15

Hydrolysis of PTS1-BABA-diethylene glycol methyl
ester II-30 afforded PTS1-BABA-diethylene glycol
carboxylic acid II-31 in >99% yield. ........................................................... 89

2.16

Hydrolysis of PTS1-BABA-diglycine methyl ester of II-32
affording PTS1-BABA-diglycine carboxylic acid II-33. ............................. 90

3.1

Diels-Alder cycloaddition between cyclopentadiene (3 eq)
and diethyl boronotartrate (1 eq) to afford norbornenyl
alcohol III-3. .............................................................................................. 141

3.2

Diels-Alder cycloaddition between isoprene and dibutyl
ethylene boronate. ...................................................................................... 142

3.3

Diels-Alder between 2-methyl-1,3-butadienylboropinacolate
(III-4) and methyl acrylate, followed by hydrolysis of the
pinacol ester with trimethylamine-N-oxide. .............................................. 144

3.4

Tandem [4+2] cycloaddition between diene III-5 or III-9
1
and maleimide (see Table 3.2 for R ). ....................................................... 145

3.5

Cycloaddition between diene III-9 and oxazolidinone
dienophile III-13 followed by addition of 4-nitrobenzaldehyde to afford b-hydroxyalkylated cyclohexenyl
derivative III-14......................................................................................... 147

3.6

Endo:exo ratios afforded by the Diels-Alder between
excess cyclopentadiene and acrylanilide III-15 or III-16.
Highlighted in the box is the internal coordination of the
boronate ester and the carbonyl of the acrylanilide. .................................. 149

3.7

Competitive kinetic experiment between acrylanilide
derivative III-15 and III-19 and excess cyclopentadiene
in deuterated benzene at room temperature. .............................................. 150

3.8

Intramolecular Diels-Alder cycloaddition on trienes
III-26a and III-26b following thermal activation. .................................... 153

xvii

List of Schemes (Continued)
Scheme

Page

3.9

Intramolecular Diels-Alder cycloaddition on trienes III26a and III-26b in the presence of a Lewis acid, ethyl
aluminum dichloride. ................................................................................. 153

3.10

Intramolecular Diels-Alder cycloaddition following
transesterification between boronic acid III-31 and alcohol
III-32. The resulting cyclohexenyl derivative III-34 was
then oxidized to the diol III-35.................................................................. 154

3.11

Dihydroxylation studies of conjugated diene III-36a and
III-36b. ...................................................................................................... 155

3.12

Dihydroxylation studies of conjugated diene III-39. ................................ 158

3.13

Proposed synthetic route for novel chiral boronate ester
that can participate in IMDA cycloaddition. .............................................. 160

3.14

Synthesis of diene using ROMP catalysis. Route was
abandoned due to low yield. ...................................................................... 161

3.15

Oxidation and Wittig of 6-bromo-1-hexanol; generation
of phosphonium bromide; attempt at Wittig. ............................................. 162

3.16

Generation of phosphonium bromide and Wittig of
bromoacid (shown for bromobutyric acid). ............................................... 162

3.17

Attempt at alkylation and decarboxylation of diethyl
malonate. .................................................................................................... 162

3.18

Retooled synthesis of diene for higher mass yield.
Synthesis was further retooled upon discovering failures
with the intramolecular Diels-Alder........................................................... 164

3.19

Hydroboration and hydrolysis of 2-methyl-1-buten-3-yne
affording desired boronic acid III-69. ....................................................... 164

3.20

General scheme for failed Diels-Alder attempts;
TFE = 2,2,2-trifluoroethanol. ..................................................................... 165

xviii

List of Schemes (Continued)
Scheme

Page

3.21

Alternative route that was repeated involving THP
protection, Swern, and Wittig reactions on 1,6-hexanediol
III-70. ........................................................................................................ 166

3.22

Attempted alkylation of alkyl iodide III-78 with enamine
III-77. ........................................................................................................ 167

3.23

Alkylation of III-61 with ethyl 4-bromocrotonate. ................................... 167

3.24

Synthesis of boronate ester III-86 for use in the IMDA
cycloaddition. Asterisks used to emphasize absolute
stereocenters set as a result of this methodology. ...................................... 169

3.25

Alternate synthetic strategy appending boronate ester
diene in exo fashion to a,b-unsaturated ester dienophile
(III-96). ...................................................................................................... 171

3.26

Addition of two methyl groups on III-79 to facilitate
gem-dimethyl effect for IMDA. ................................................................. 171

xix

CHAPTER ONE
EVALUATION OF SUBSTITUTED EBSELEN DERIVATIVES AS ANTITRYPANOSOMAL DRUGS
1.1

INTRODUCTION
Human African Trypanosomiasis (HAT), or African Sleeping Sickness, is caused

by the bloodstream form (BSF) of Trypanosoma brucei (i.e. trypanosomes) and is
transmitted by a tsetse fly vector.1 Two subspecies of T. brucei exist that infect humans:
T. b. gambiense, responsible for West African sleeping sickness, and T. b. rhodesiense,
responsible for East African sleeping sickness.1,2,3 The disease has the potential to affect
millions in sub-Saharan Africa, and has periodically resulted in between 50,000 to 70,000
annual deaths despite declining numbers of infections and fatalities more recently.4 The
range of HAT is limited to sub-Saharan Africa as this is a suitable habitat for the tsetse
fly.5 The disease is endemic to remote, rural regions and can be acquired through
common daily activities that allow interaction with the fly, including farming, hunting,
fishing, or even washing clothes.5 Between 1920 and 1940, several African nations
invested in vector control (i.e. controlling the population of tsetse flies through the
combination of insecticide spraying and the introduction of sterile fly specimens) and
active surveillance of infected individuals.5 By these means, the disease was almost
eliminated in 1960. Nonetheless, political revolution and unrest in several key nations in
the region, such as the Democratic Republic of the Congo, Angola, southern Sudan, and
Uganda, led to a decrease in these surveillance activities and a re-emergence of the
disease.5

1

Treatments for HAT have existed for approximately one hundred years, but are
marked by serious adverse side-effects, such as acute toxicity, neural disorders, and in
some cases, death.4 In other cases, the treatments are difficult to administer or are not
well characterized in terms of their mechanism of action.6 In other cases, the therapeutics
currently available are ineffective against the late stages of the disease once the
trypanosomes cross the blood-brain barrier. Eflornithine, active against the late-stage T.
b. rhodesiense disease, is air-sensitive and the dosage regime can require up to 30 days.5
Adverse side-reactions are frequent and this drug is not used against T. b. gambiense
where Onchocerca species, microorganisms that cause river blindness, may exist.5 The
most widely-used therapeutic for the treatment of the later stages of disease is called
melarsoprol and is active against T. b. gambiense, and is the only available drug for the
later stages associated with T. b. rhodesiense.5 Due to its being an arsenical drug,
adverse nervous system reactions are frequent and can be life-threatening.5 The only new
molecule for treatment of the disease to arise in the clinic over the past sixty years is
eflornithine, which is indicated for the second (meningoencephalitic) stage of the disease
resulting from T. b. gambiense infection. Eflornithine is preferred due to its reduced host
toxicity as compared to melarsoprol.5 Nevertheless, this drug is not without its
drawbacks. The typical treatment course for a T. b. gambiense infection with eflornithine
comprises four 2h infusions of a 400 mg/kg dose administered daily for two weeks due to
the drug’s short half-life. Therefore, a single patient treated with eflornithine will require
hundreds of grams of the drug for effective treatment.5 Further, the drug is ineffective
against T. b. rhodesiense infections, and oral administration limits its potency.1,3,5,7,8
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As shown in Figure 1.1, the T. brucei infection cycle begins with an infected
tsetse fly injecting metacyclic trypomastigotes into a mammalian host. The injected
metacyclic trypomastigotes transform into BSF trypomastigotes, which multiply in the
blood, spinal fluid, and lymph nodes of the host. The lifecycle is completed when a
feeding tsetse fly takes a blood sample from the host. The blood sample harbors short,
stumpy trypomastigotes, a form pre-adapted for life in the insect vector, that migrate to
the tsetse fly’s midgut and transform into procyclic trypomastigotes. The multiplying
procyclic trypomastigotes migrate to the salivary glands and transform into epimastigotes
and the cycle begins anew.8,9 Newly-hatched flies are not infected with trypanosomes but
rather must feed on an infected mammalian host to become infected.5 The parasite life
cycle in the fly is rarely observed in the field with only 0.1% of the tsetse fly population
carrying a fully matured infection that can be transmitted from the vector to the host.5

3

9

Figure 1.1: Lifecycle of trypanosomes in tsetse fly and mammalian host.

Infection with trypanosomes in a human host occurs in two stages. The first stage
is infection of the host’s blood and lymphatic system, or the haemolymphatic stage. The
second stage is infection and inflammation of the host’s nervous system, or the
meningoencephalitic stage. The infection with T. b. gambiense is characterized by a
chronic disease state that progresses rather slowly over the course of a few years, while T.
b. rhodesiense infections induce an acute disease state that exhibits a much more rapid
progression resulting in death within a few weeks or months in untreated cases.5
A chancre caused by a tsetse fly bite occurs in ~19% of patients infected with T.
b. rhodesiense but is rarely seen with T. b. gambiense. The leading signs of trypanosome
infection include: fever, headache, pruritus (or severe itching), lymphadenopathy (or
swelling of the lymph nodes), and hepatosplenomegaly (or swelling of the liver and/or
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spleen). Fever in infected hosts can last from a day to a week, separated by fever-free
intervals lasting a few days and up to longer than a month. A fever is rarely observed in
the later stages of the disease. The leading symptom of the later stages is the one that
gives the disease its name, sleep disorder, via interruption of the circadian rhythm (or
sleep cycle) of an infected host. Other symptoms include Parkinson-like movements due
to muscular hypertension or even psychiatric symptoms, such as irritability, aggressive
behavior, or psychotic reactions, occasionally leading to the incorrect admission of some
patients into psychiatric wards.5
The clinical diagnosis of T. b. gambiense infection relies on laboratory
examinations, because of insufficient clinical presentations of disease associated with this
strain of the microorganism (recall that a chancre is only produced for a small number of
cases of T. b. rhodesiense infection). The diagnosis cycle occurs in three parts: screening,
diagnostic confirmation, and staging. Since the late 1970s, a card agglutination test
(CATT) has been used for the diagnosis of T. b. gambiense infections, allowing for the
screening of hundreds of patients daily with a high degree of sensitivity and specificity.
Other methods, including immunofluorescence or immunosorbent enzyme-linked assays,
are used in non-endemic countries for screening of clinical features that suggest infection
by trypanosomes. These tests are not fully accurate, therefore health professionals are
told to search for clinical presentations in individuals with negative tests, such as the
formation of a chancre. There is no serological screening available for the detection of T.
b. rhodesiense infection. Inspection of a blood smear under a microscope can be used for
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the diagnosis of T. b. gambiense infection due to the higher density of the BSF parasite in
the host’s bloodstream.5
With respect to emerging therapeutic strategies, the modern approach for treating
HAT employs molecular target-based therapeutics that can be selectively directed toward
trypanosomes.6 BSF trypanosomes generate energy, in the form of adenosine
triphosphate (ATP), through glycolysis.3 The first step of glycolysis involves the
phosphorylation of glucose via the transfer of a phosphoryl group from ATP to the 6’
hydroxyl group on glucose.3 The enzymes that catalyze this process are called
hexokinases. In trypanosomes, the hexokinases (HKs), which are organized into
hexamers that are called TbHK1 and TbHK2. It is important to note here that BSF,
metacyclic, and procyclic trypomastigotes (described above) perform glycolysis in the
glycosome, a membrane-enclosed organelle that houses the HKs along with the rest of
their glycolysis machinery.7-9 Inhibition of trypanosomal HKs in BSF parasites is lethal
to the microorganism.2
RNAi-induced (RNA interference) silencing of TbHK1 was previously used
against BSF trypanosomes to demonstrate growth inhibition of the parasite.10 The RNAiinduced silencing of TbHK2 is also lethal to BSF parasites, confirming that both TbHK1
and TbHK2 are essential to the parasite. TbHK1-specific RNAi was accomplished via
targeting of a unique region in the TbHK1 3’ UTR (untranslated region). After two days
of treatment, TbHK1 in BSF parasites was silenced and the cells began to die.2 The
genetic validation afforded by this study demonstrated that TbHK1 can serve as a suitable
target for therapeutic inhibition in BSF parasites.2

6

In addition, the gene sequence for TbHK1 reveals just a 30-33% amino acid
similarity to yeast, plants, and mammalian hexokinases.2,6 Known inhibitors of
mammalian hexokinases have demonstrated some weak inhibition of TbHK1 and exhibit
trypanocidal effects at high concentrations.2 TbHK is also susceptible to a wide range of
other inhibitors in vitro including fatty acids and small molecules, such as pyrophosphate.
However, many of these compounds must be used in high concentrations to effect cell
toxicity; a potent therapeutic should be effective in the sub-micromolar range.2,8-10 One
such therapeutic is lonidamine (Figure 1.2), exhibiting an IC50 (half-maximal inhibitory
concentration) of 850 µM against recombinant TbHK1 (rTbHK1; obtained from
Escherichia coli or yeast) and 965 µM against authentic TbHK1 (obtained directly from
T. brucei).2 TCEP (i.e. tris-(2-carboxyethyl)phosphine) (Figure 1.2) also exhibits potent
TbHK1 inhibition as an irreversible disulfide-reactive reagent (IC50 = 6.6 ± 0.4 µM).3
Further, a high throughput screen of 220,233 compounds resulted in ten inhibitory “hits,”
including six structurally similar isobenzothiazolinones (Figure 1.2).3,11
The high-throughput screening (HTS) conducted by Sharlow et al. of over
220,233 compounds was carried out to discover potent small-molecule inhibitors of
TbHK1.3,7,12 Three scaffolds were pursued for Strcuture-Activity Relationship (SAR)
Analysis from the HTS endeavor: isobenzothiazolinone, isobenzoselenazolinone, and
benzamidobenzoic

acid

(i.e.

BABA;

discussed

in

Chapter

Two).3

Six

isobenzoselenazolinone derivatives were initially identified in the high-throughput
screening for TbHK1 inhibition (Figure 1.2). One of six isobenzothiazolinone candidates
was ebselen (i.e. 2-phenyl-1,2-benzisoselenazol-3(2H)-one, or EbSe [I-1], Figure 1.2), a

7

drug that is non-toxic to humans and is currently used in clinical trials for the treatment of
ischemic stroke.3,7 Ebselen demonstrated high potency against rTbHK1 with an IC50 of
0.05 ± 0.03 µM.3,7 Another effective target, EbS (i.e. 2-phenyl-1,2-benzisothiazol-3(2H)one, [I-2]), which replaces the selenium in Ebselen with sulfur, demonstrated an IC50 of
2.0 ± 0.5 µM against rTbHK1.3,7 One candidate, compound I-3, with a halogen
substitution on the heterocycle aryl ring and a methyl group on the N-aryl ring, had an
IC50 value of 4.2 ± 1.0 µM against rTbHK1.7 Another candidate, I-4, bearing a thiazole
coupled to an ethyl ester, had a higher IC50 of 9.3 ± 0.3 µM against the enzyme, whereas
I-5, bearing a thiazole without any substitution pattern, had an even higher IC50 of 16.9
± 0.1 µM.7 Replacement of the N-aryl ring with an acetamido-adamantyl group, as in I-6,
afforded a lead drug candidate with an IC50 of 2.6 ± 0.2 µM.7 Of the six lead drug
candidates, only I-1 and I-2 were moderately potent against the BSF parasite,
demonstrating growth inhibition of 51 ± 0.16% and 48 ± 0.15%, respectively.7
Compounds I-3 and I-6 demonstrated a growth inhibition of 47 ± 0.15%, while the other
two I-4 and I-5 were below 30%.7 A follow-up study by Joice et al. revealed that
incubation of TbHK1 with EbSe and EbS inhibitors led to a five-fold decrease in
enzymatic activity.3 This loss of HK activity remained irreversible despite a 200–fold
dilution of enzyme and inhibitor.3
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Figure 1.2: Three Cys-reactive compounds studied by Joice et al. are shown above: TbHK1
inhibitors EbSe (I-1) and EbS (I-2) and reducing agent dithiothreitol (DTT). Other active
benzisothiazolinone derivatives, I-3 to I-6, arising from the HTS are also shown. Known inhibitors
of mammalian hexokinases, lonidamine and tris-(2-carboxyethyl)phosphine (TCEP), are also
3,7
shown.

One hypothesis for the efficacy of EbSe toward the inhibition of TbHK1 is the
formation of selenyl-sulfide (Se-S) adducts with Cys residues, leading to the eventual
oxidation of certain Cys residues in the enzyme to their corresponding sulfonic acid
analogs. Indeed, a similar inhibition of human indoleamine 2,3-dioxygenase (IDO) with
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EbSe was accomplished by the covalent modification of several Cys residues that altered
the enzyme’s conformation.13 A MS-MS study by Joice et al. confirmed that two Cys
residues, C327 and C369, are critical for enzymatic structure and activity.3 This study
demonstrated that Ebselen modifies two Cys residues by oxidizing the thiol side-chain of
C327 and C369. Mutagenesis of the modified Cys residues revealed that only C327 was
indispensable, indicating it is the oxidation of C327 that is detrimental toward TbHK1
activity. A proposed mechanism for the oxidation of the Cys side-chain is depicted in
Figure 1.3. In this pathway, a nucleophilic attack of the Cys thiol opens the heterocycle
of EbSe, followed by a proton transfer and hydrolysis, culminating in oxidation of the
Cys thiol. An important note regarding the proposed pathway shown in Figure 1.3 is that
the conjugation of EbSe to Cys residues would be reversible until hydrolysis, thus
supporting the observation that promiscuous Cys oxidation does not occur.3
O
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Figure 1.3: Proposed reversible pathway for Ebselen-based oxidation of Cys residues in TbHK1.
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Further, Joice et al. demonstrated that TbHK1 could be mutated via replacement
of key cysteine residues with either alanine or serine. Enzymatic activity was measured
post-mutation and was compared to wild-type TbHK1 (0.60 ± 0.03 mmol min-1 µg-1).
The results of this study are shown in Table 1.1. Cysteine residues were mutated at the
following positions: 212; 242; 327; 386; 369; 401; 402; and 445.3 No TbHK1 activity
was detected for the C212A, C327A, and C386A mutants. Enzymatic activity was
slightly reduced in the C369A, C401A, and C402A mutants, and the C242A and C445A
mutants exhibited similar activity to the wild-type enzyme. All of the active variants (i.e.
the C242A, C369A, C401A, C402A, and C445A mutants) were effectively inhibited by
EbSe and TCEP with no difference in sensitivity to the therapeutics as compared to wildtype TbHK1.3
In further experiments, the cysteine residues at positions 212, 327, and 386 were
mutated to serine. It should be noted that C to A mutations in these positions returned
inactive enzymes. Following the mutation, it was observed that the C212S mutant had a
reduced enzymatic activity while the C327S and C386S mutants exhibited activity barely
above the threshold for detection (numerical value not listed in Table 1.1). Furthermore,
the C212S mutant remained sensitive to inhibition after EbSe treatment. This work
provides further support for the importance of the C327 residue for enzymatic activity;
whereas the C369 site can be modified without a significant decrease in enzymatic
activity or change in sensitivity in therapeutic-mediated inhibition (with EbSe and tris-[2carboxyethyl]phosphine [TCEP]).3
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Table 1.1: WT = wild-type; ND = not detected. The key residues listed are C327(A/S) and C369(A/S).
The former loses activity upon mutation; the latter maintains an enzymatic activity above the threshold
3
for detection.

Based on the HTS endeavor by Sharlow et al., as well as the MS-MS study
conducted by Joice et al. (described above), it was determined that cysteine residues at
positions 327 and 369 were crucial toward the function of TbHK1.3,11,14 As such, a
mechanism of TbHK1 inhibition by EbSe can be proposed, as is shown above in Figure
1.3.3 It is important to take into account that a single crystalline structure of TbHK1 has
yet to be determined as the enzyme typically exists as a hexamer held together by
disulfide linkages.3 Nonetheless, important conclusions can be made regarding the mode
of inhibition by EbSe with respect to TbHK1.
If EbSe is a suicide inhibitor of TbHK1, a covalent interaction between the potent
selenium-bearing oxidizing agent EbSe and cysteine (Cys) residues would result in the
overall oxidation of the latter.3,11,14 Were the interaction between EbSe and Cys noncovalent, then a dilution of the sample might result in a modest return of HK activity.3
The lack of observable HK activity upon dilution suggests an irreversible, covalent
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interaction between EbSe and Cys. Following incubation of the HK with EbSe or EbS, the
reducing agent dithiothreitol (DTT; Figure 1.2) was added to the whole cell assay.3 If the
interaction between EbSe and Cys is reversible, then DTT would sever the interaction
between EbSe and Cys via reduction.3 Experimentally, addition of DTT allowed for only
a modest recovery of HK activity.3 These studies provided further evidence toward the
hypothesis that the interaction between EbSe and Cys is covalent and essentially
irreversible (proposed mechanism shown in Figure 1.3). As was stated previously, this
loss in hexokinase activity is irreversible following a 200-fold dilution, suggesting that a
covalent modification of TbHK1 occurs.3
The HTS endeavor by Sharlow et al. lead to the discovery of potent structurebased inhibitors of TbHK1 based on EbSe.3 The data gathered in a later work by Joice et
al. indicates that EbSe can oxidize key cysteine residues in TbHK1, specifically C327
and C369, to the corresponding sulfonic acid, which in turn significantly decreases
enzymatic activity.3 In an effort to optimize the potency of EbSe against TbHK1 leading
to trypanocidal activity, a series of novel EbSe inhibitors will be discussed below in terms
of both their synthesis and inhibitory capabilities. To reiterate, the derivatives must meet
certain criteria to be considered as potent inhibitors of rTbHK1. First, the inhibitor will
be highly selective and lethal against trypanosomes, i.e. will be highly trypanocidal.
Second, the inhibitor will exhibit low or zero host toxicity. Although the latter point was
not validated in this work, it is a concern for the development of potent trypanocidal
therapeutics. Both the first and second criteria will ensure that the toxic effects of the
inhibitors will be felt by the trypanosomes, not the host. Third, the desired concentration
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of the inhibitor will be in the single-digit micromolar range, which serves as a reflection
of the potency of the drug candidate while minimizing host toxicity.
Lin, et al. demonstrated that molecular cargo tagged to a fluorescent peptide
bearing a peroxisomal targeting sequence (PTS1) could be targeted to the glycosome (this
will be elaborated upon in greater detail in Section 1.2).15 This is crucial for the targeted
delivery strategy that will be described later in this thesis, as the discovery of a potent
small molecule enzyme inhibitor that meets the aforementioned criteria is rendered
useless if it is not permeable across the cellular membrane of the trypanosome. The
inhibitor must permeate across the cellular membrane and localize within the glycosome
in trypanosomes to demonstrate its full potency, established by a prescreening of the
inhibitor prior to coupling to a peptide sequence. Central to our strategy, the inhibitor, for
example EbSe, was synthesized such that it bears a free carboxylic acid. This carboxylic
acid was tagged with a peptide bearing a PTS1 via the routine formation of an amide
bond using Solid Phase Peptide Synthesis (SPPS; synthetic methods described in Section
1.2.2). The peptide-inhibitor conjugate, based on the success of the report by Lin, et al.,
can cross the cellular membrane and localize within the glycosome to demonstrate
efficacy against both hexokinase and the whole cell organism.15
1.2

SOLID PHASE PEPTIDE SYNTHESIS (SPPS)

1.2.1

APPLICATIONS
The desired peptide-drug conjugate can be broken into three sections based on

work reported by Lin, et al.15 The three sections are the Peroxisomal Targeting Sequence
(PTS1), the modification site, and the tether. The PTS1 is the critical region of the
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peptide that ensures that the molecular cargo reaches the glycosome.15,16 Work by
Subramani et al. indicated that a tripeptide (C/A/S)-(K/R/H)-(L/I)-COOH can serve as a
PTS1 when present at the C-terminus of a protein.16 The PTS1 in this work consists of CLKA-N based on previous work by Lin, et al., in which this sequence was successfully
used to deliver a sensor for determining the pH of the glycosome via fluorescence.15 The
fluorescent probe was successfully shown to be localized within the glycosome of
trypanosomes in the same work.15
Ebselen, I-1, and its sulfur analogue, I-2, were determined to be potent against the
TbHK1 enzyme. However, these two lead candidates were only moderately active against
the BSF parasite (see discussion above).7 To enhance the potency of these drug
candidates, we endeavored to use a peptide sequence bearing a PTS1, a tether, and an
Ebselen derivative. We thought that incorporation of a peptidic scaffold would maintain
the activity of the Ebselen drug candidate against the enzyme while improving its
potency against the BSF parasite by means of the PTS1-mediated passage of the drug
cargo across the cell membrane and into the glycosome. It was hypothesized that
incorporation of an electron-withdrawing carboxylic acid handle onto the Ebselen
scaffold might 1.) render the molecule more susceptible to cysteine attack by TbHK1 (i.e.
by enhanced electrophilicity of the selenium-nitrogen or sulfur-nitrogen heterocycle via
inductive withdrawal of electron density by the carboxylic acid functionality), and 2.)
allow for the installation of a peptide handle by conventional solid-phase peptide
synthesis. Because the modification site is on the N-terminus of the peptide, any amino
acid or drug derivative with a free carboxylic acid that is amenable to side-chain
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modification can be used as part of the peptide-drug conjugate synthesis. Therefore, the
first aim of this thesis work was to produce a library of Ebselen derivatives bearing a
carboxylic acid to determine the optimal positioning of the electron-withdrawing group
as reflected by potency against the enzyme and the BSF parasite through a pre-screening
of the carboxylic acid and corresponding methyl ester derivatives (Scheme 1.1). It was
thought that this electron-withdrawing functional group could replace the N-aryl ring or
be positioned on either the N-aryl or the core arene of the scaffold to produce three sets of
Ebselen drug derivatives. Our design incorporated a tether region that was employed to
ensure that the molecular cargo (i.e. the therapeutic) is distal to the PTS1 as per the work
by Morris and Christensen and Subramani et al.15,16 Based on the HTS and the work by
Lin, et al., the peptide sequence of C-LKAGG-N was selected as the desired PTS1-linker
for the initial evaluation of our strategy.15 Two additional peptides were produced in
which the diglycine linker was replaced with a diethylene glycol linker (Scheme 1.1).
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Scheme 1.1: General peptide structure shown on left bearing the PTS, a tether (either diglycine or
diethylene glycol), and the Ebselen derivative. The Ebselen derivatives generated are shown on the
right (top to bottom) bearing an N-acetyl, N-aryl, or heterocyclic substitution with the carboxylic acid.
First, the Ebselen derivatives were synthesized to determine the most effective position of the
carboxylic acid (via in vitro testing of the methyl ester and carboxylic acid). Then, the Ebselen
carboxylic acid derivative was attached to the peptide scaffold (shown on the left).

1.2.2

SYNTHETIC METHODS
The carboxylic acid functional group was necessary on the small molecule

inhibitor as it is amenable to incorporation of a peptide sequence via formation of an
amide bond using the highly active uronium reagent HCTU and Hünig’s base in DMF,
standard reagents used for Solid Phase Peptide Synthesis (SPPS).15-17 SPPS involves the
use of Fmoc amino acids with free carboxylic acids that are activated by a uronium
reagent. The peptide on the resin, the solid phase, is an Fmoc-protected amine. Following
addition of 20-30% 4-methylpiperidine in DMF, the Fmoc group is cleaved to reveal a
free amine that reacts with the activated carboxylic acid. This process is repeated as
necessary for incorporation of all desired moieties. Once the synthesis is complete, the
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peptide can be cleaved off the resin using an acidic medium that reveals a carboxylic acid
on the C-terminus. This approach describes a peptide synthesized in a C- to N-fashion.1518

Beyond SPPS, the carboxylic acid serves another important role. As part of the

bioassays, the carboxylic acid and its ester can be screened against TbHK1 and
trypanosomes to elucidate the influence of anionic charged species (i.e. carboxylates), or
more broadly, the influence of electron withdrawing substituents (i.e. esters and
carboxylic acids) on the efficacy of the drug scaffold against both the enzyme and the
whole cell BSF parasites.
1.3

RESULTS AND DISCUSSION

1.3.1

COMPLETED EbSe/EbS SYNTHESES
EbSe, or 2-phenyl-1,2-benzisoselenazol-3(2H)-one, was synthesized on a cost-

efficient, gram scale according to a protocol by Balkrishna, et al.19 EbSe was synthesized
to evaluate the effectiveness of freshly prepared EbSe compared to expensive,
commercial EbSe, which can cost upwards of $200 per gram (Scheme 1.2). As was
previously discussed, EbSe (the selenium analog) has an IC50 of 0.05 ± 0.03 µM toward
trypanosomes and EbS (the sulfur analog) has an IC50 of 2.0 ± 0.5 µM.3 Furthermore,
oxidation of the freshly prepared EbSe was attempted with hydrogen peroxide to assess
the utility of the corresponding selenoxide congener of EbSe as an inhibitor toward the
trypanosomes; however, this was unsuccessful (Scheme 1.2).20 A series of derivatives
were

prepared

that

maintained

the

integral
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TbHK1.2,3,7,11,12
CuI (0.25 eq)
1,10-phenanthroline (0.25 eq)
Se powder (1.5 eq)
K 2CO 3 (1.88 eq)

O
N
H
I

I-7

DMF, reflux overnight
53%

O
N
Se
I-1; Ebselen

O

O
30% H 2O2 (1.2 eq)

N
Se
I-1

DCM, 0 ˚C to rt, overnight
I-8

N
Se
O

Scheme 1.2: Ebselen (I-1) synthesis following protocol by Balkrishna, et al. (top); attempted oxidation
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of EbSe (bottom).

We envisioned using a carboxylic acid handle to facilitate coupling of the
EbSe/EbS derivatives to a peptide sequence via SPPS as was discussed in Section 1.2.
The peptide sequence that was targeted was C-LKAGG-[EbSe or EbS]-N. The first EbS
derivative (I-12) was synthesized according to a one-pot protocol provided by Dou, et al.
The corresponding ester I-13 was isolated by acylation of the nitrogen atom of I-9 in
38% yield (Scheme 1.3).21 The synthesis of the first EbSe derivative (I-19) commenced
with the diazotization of anthranilic acid (I-14) in Scheme 1.4.22-24 The diazonium salt (I15) was treated with disodium diselenide to provide diselenide I-16 which was then
treated with thionyl chloride under reflux to afford compound I-17. Selenenyl chloride I17 was acylated with the methyl ester of glycine to afford I-18 in a modest 20% yield.2224

Hydrolysis of the methyl ester in I-18 with lithium hydroxide provided EbSe derivative

I-19 in 73% yield.21 Both the EbSe and EbS derivatives were coupled to the peptide
sequence, C-LKAGG-[EbSe or EbS]-N, as described in future sections.
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Scheme 1.3: First EbS derivative (I-12) preparation according to protocol provided by Dou, et al. First
EbS derivative methyl ester I-13 synthesized from I-9 in 38% yield.
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Scheme 1.4: First, EbSe derivative preparation beginning with diazotization of anthranilic acid, followed
21-24
by acylation of the diselenide, terminating with hydrolysis of methyl ester (I-18) affording acid I-19.

For the other EbSe and EbS targets, the syntheses involved the formation of
important sulfur-nitrogen or selenium-nitrogen heterocycles, respectively, based on an
efficient copper-catalyzed method.25 The synthetic protocol for the second EbSe and EbS
derivatives is shown in Scheme 1.5. The symmetrical, commercially available, 2-bromo1,3-dimethylbenzene I-20 was oxidized to the 1,3-dicarboxylic acid I-21 in 35% yield by
action of potassium permanganate.26 Fischer esterification of I-21 with methanol and
sulfuric acid returned the dimethyl ester I-22 in 49% yield.26 The symmetrical dimethyl
ester was then hydrolyzed with sodium hydroxide to afford monoacid I-23.27 Monoacid
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I-23 was converted to the corresponding amide I-24 in 50% yield by a two-step process
involving conversion of the acid chloride followed by amidation with aniline. Amide I-24
was then cyclized by a convenient copper (I) iodide protocol in the presence of sulfur
powder to afford I-25 in 52% yield.25 The difficulty with this EbS derivative (I-25), and
with other derivatives reported herein, is the low yield afforded by this cyclization
protocol. Subsequent efforts focused on the optimization of this cyclization step based on
literature precedents.28 The EbS methyl ester was hydrolyzed with lithium hydroxide
monohydrate to provide carboxylic acid I-27 in 77% yield.29,30 In a similar fashion, the
EbSe methyl ester I-26 was obtained, albeit in a poor 12% yield, and was subsequently
hydrolyzed to afford I-28 in 82% yield.29,30
O
KMnO 4 (4.3 eq)
Br
I-20

tBuOH/H 2O (1:1)
reflux
35%

O
3% H 2SO 4
OH in MeOH

Br
HO

49%

CuI (0.5 eq)
1,10-phenanthroline (0.5 eq)

NPh
X
RO

O

S or Se powder (1.2 eq)
K 2CO 3 (1.25 eq)
MeO
DMF, 110 ˚C

I-25, X = S, R = Me (52%)
I-26, X = Se, R = Me (12%)
I-27, X = S, R = H (77%)
I-28, X = Se, R = H (82%)

Br

reflux

O I-21

O
O

OMe

Br
O
I-24

NaOH (1.1 eq)
MeOH:acetone (1:3)
48 h, rt
63%

I-22
MeO

O

1. SOCl 2 (1.1 eq.)
Et N (2 eq)
NHPh DCM,3 0 ˚C, 30 m
2. PhNH 2 (3 eq),
Et 3N (2 eq)
DCM, 0 ˚C to rt

O
OH
Br
MeO

I-23

O

50%

LiOH H 2O (5 eq)
THF:MeOH:H2O (2:1:1)
40 h, rt

Scheme 1.5: Synthesis of second EbS and EbSe derivatives (I-27 and I-28) that demonstrated low cell
25-30
toxicity toward the trypanosomes.

Further varieties of EbSe/EbS derivatives could be obtained by incorporating the
carboxylic acid functionality onto the N-aryl ring. The synthesis of several EbSe and EbS
analogues are shown in Schemes 1.6. Using ortho-iodobenzoic acid I-29 as a starting
material, a variety of N-aryl functionalized Ebselen analogues were quickly obtained in
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moderate yields. Ortho-iodobenzoic acid I-29 was converted to its corresponding acid
chloride by action of thionyl chloride followed by amidation by methyl para-amino
benzoate affording amide I-30 in 89% yield. Similarly, addition of methyl meta-amino
benzoate to the acid chloride of I-29 afforded amide I-31 in 62% yield. Following
synthesis of amide I-30, it was reacted with sulfur powder in the presence of the
aforementioned copper (I) iodide/1,10-phenanthroline catalyst to afford I-32 in 55%
yield. Hydrolysis of methyl ester I-32 in the presence of lithium hydroxide monohydrate
afforded I-36 in 79% yield. Amide I-31 was reacted with sulfur mediated by the same
copper (I) iodide/1,10-phenanthroline catalyst to provide I-33 in 65% yield. The methyl
ester was then hydrolyzed with lithium hydroxide monohydrate to give I-37 in 71%
yield.25,29,30
The EbSe derivatives were synthesized in a similar fashion to the EbS derivatives
I-38 and I-39. Amide I-30 was cyclized with the copper (I) iodide/1,10-phenanthroline
catalyst in the presence of selenium powder to afford I-34 in 46% yield. Methyl ester I34 was hydrolyzed by action of lithium hydroxide monohydrate to provide I-38 in 84%
yield. Amide I-31 was cyclized using copper (I) iodide/1,10-phenanthroline with
selenium to afford I-35 in 43% yield. Hydrolysis of the methyl ester in heterocycle I-35
with lithium hydroxide monohydrate provided acid I-39 in 91% yield. The carboxylic
acids (I-36, I-37, I-38, and I-39) were subsequently used for amide coupling to a peptide
sequence. Attempts to migrate the carbonyl distal with respect to either the seleniumcarbon or sulfur-carbon bond, and meta with respect to the amide bond of the
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heterocycle, were not successful for the EbS derivative and succeeded only once for the
EbSe derivative in ~10% yield, afterward proving difficult to reproduce.

CO2H SOCl2 (1.1 eq)
NEt 3 (2.0 eq)
I
I-29

DCM, 0 ˚C, 30 m

p- or m-amino
methyl benzoate
(1.1 eq)
NEt 3 (2.0 eq)

O

DCM, N 2, rt

I

CO2Me
N
H

I-30, p-CO2Me, (89%)
I-31, m-CO2Me, (62%)
CuI (0.5 eq)
1,10-phenanthroline (0.5 eq)
S or Se powder (1.2 eq)
K 2CO 3 (1.25 eq)
DMF, 110 ˚C
O

O
LiOH H 2O (5 eq)

N
X

I-36,
I-37,
I-38,
I-39,

CO2H

X = S, p-CO2H (79%)
X = S, m-CO2H (71%)
X = Se, p-CO2H (84%)
X = Se, m-CO2H (91%)

THF:MeOH:H2O (2:1:1)
40 h, rt

N
X

I-32,
I-33,
I-34,
I-35,

CO2Me

X = S, p-CO2Me (55%)
X = S, m-CO2Me (65%)
X = Se, p-CO2Me (46%)
X = Se, m-CO2Me (43%)

Scheme 1.6: Synthesis of EbS derivatives (I-36 and I-37) and EbSe derivatives (I-38 and I-39) with meta
25,29,30
and para N-aryl-substitutions.

1.4

COMPLETED SYNTHESES AND DEFINITION OF VARIABLES
Two goals were accomplished as part of the efforts described in this chapter. The

first goal was completed with the synthesis of potent TbHK1 inhibitors based on an EbSe
and EbS scaffold. Ebselen (I-1 in Scheme 1.2 above) has three potential locations for
substitution. The first location is substitution of the N-aryl ring with an N-carboxylmethyl
group (Schemes 1.3 and 1.4). This allowed for the elucidation of the importance of the Naryl functionality in vitro. The second location is the aromatic ring of the
benzisoselenazolinone core and the third location is the N-aryl ring. This produced three
sets of EbSe derivatives: one set with N-carboxymethyl substitution (I-12 and I-19 in
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Scheme 1.3 and Scheme 1.4, respectively); a second set with substitution on the
benzisoselenazolinone ring (I-27 and I-28 in Scheme 1.5); and a third set with N-aryl
substitution (I-36 to I-39 in Scheme 1.6). These EbSe derivatives were coupled to a
peptide sequence using SPPS, previously described in Section 1.2.
The synthesized inhibitors were coupled to a peptide sequence of C-LKAGG-N or
C-LKA(ethylene glycol)-N using SPPS. This effort produced ten peptide-drug conjugates
which were evaluated against both TbHK1 and trypanosomes in whole-cell assays (see
below, Section 1.4.1). This screening yielded three results: percent TbHK1 inhibition,
percent BSF growth inhibition, and BSF EC50. The non-conjugated drugs and peptidedrug conjugates were screened against TbHK1 and BSF parasites at a standard
concentration of 10 µM (the limit of detection). The rTbHK1 cultures are incubated with
the drug or peptide-drug conjugates with the percent inhibition of the enzyme being
recorded. BSF growth inhibition refers to the cell percentage in a trypanosome culture
that has been affected by either the drug or the peptide-drug conjugate. BSF EC50 refers
to a measure of drug or peptide-drug conjugate potency against trypanosomes over a
specified exposure time period.
1.4.1

EBSELEN PEPTIDE-DRUG CONJUGATES
The synthesis of the peptide-conjugated EbSe derivatives followed the general

method illustrated in Scheme 1.7.15-18,30 Figures 1.4 and 1.5 shows the synthesized EbSe
and EbS peptide-drug derivatives that were screened against TbHK1 and whole cell
trypanosomes (I-40 to I-49). The data concerning the non-conjugated EbSe/EbS
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derivatives and the peptide-conjugated EbSe/EbS derivatives is described in detail below.
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Scheme 1.7: General protocol for Fmoc Solid Phase Peptide Synthesis of C-LKAGG-N sequence
(shown on top). The coupling of two glycine moieties can be replaced with the single coupling of a
diethylene glycol unit. The Fmoc protecting group is cleaved from the second glycine for overnight
coupling with the desired drug, either an EbS/EbSe/BABA (see Chapter Two) derivative (shown on
15-18
bottom).
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Figure 1.4: Synthesized EbSe and EbS peptide-drug conjugates. Of the conjugates screened, I-44 and
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I-45 were moderately effective against TbHK1 and whole cell trypanosomes, respectively.
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Figure 1.5: Synthesized EbSe and EbS peptide-drug conjugates with a diethylene glycol tether in lieu
15-18,30
of a diglycine tether.

As was previously stated, the data gathered from the non-conjugated drug
derivatives and the peptide-drug conjugates was broken into three categories: percent
TbHK1 inhibition, percent BSF growth inhibition, percent cell viability, and BSF EC50
(Table 1.2).30 Percent TbHK1 inhibition (determined at 10 µM) refers to the amount of
TbHK1 from the rTbHK1 culture that was inhibited. Referring to Table 1.2, only a few
of the non-conjugated EbSe derivatives inhibited TbHK1 in preliminary trials. Both EbS
ester I-13 and its acid I-12 were weakly active against TbHK1 showing 12.83 ± 7.45%
and 0.87 ± 7.94% inhibition of the enzyme, respectively. EbSe I-26 (with the ester placed
ortho to the selenium on the benzisoselenazolinone ring) demonstrated 2.67 ± 5.12%
inhibition of TbHK1 activity. EbS ester I-32 with a para-N-aryl substitution
demonstrated 22.78 ± 3.75% TbHK1 inhibition. EbS ester I-33 with an ester at the meta
position on the N-aryl ring effected 1.65 ± 0.30% TbHK1 inhibition. EbSe ester I-34
(with a para-N-aryl substitution) demonstrated 78.96 ± 2.81% TbHK1 inhibition. EbSe
acid I-38 (with a para-N-aryl substitution) exhibited 17.18 ± 14.55% TbHK1 inhibition.
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EbSe acid I-39 with a carboxylic acid at the meta position on the N-aryl ring
demonstrated 18.50 ± 2.84% TbHK1 inhibition. With respect to the non-conjugated drug
derivatives, it seems that the least potent EbSe candidates were those with substitution on
the benzisothiazolinone and benzisoselenazolinone rings. The most potent analogues of
EbSe were those with N-aryl substitution, as evidenced by EbS ester I-32 and EbSe ester
I-34. Of the peptide-drug conjugates, only peptide-drug conjugate I-44 (of drug
derivative I-32) and I-46 (of drug derivative I-12) displayed any activity against TbHK1
(10.42 ± 0.55% for I-44 and 3.74 ± 3.79% for I-46 in Table 1.2). Conjugation to a
peptide sequence did not increase the potency of the inactive non-conjugated EbSe/EbS
analogues.
The percent BSF growth inhibition (determined at 10 µM) refers to the percent of
the trypanosomes (in a whole cell assay) that have been killed by the non-conjugated
EbSe/EbS analogues or the peptide-drug conjugate. Of the N-carboxymethylated EbS
derivatives, EbS methyl ester I-13 revealed a BSF growth inhibition of 98.33 ± 1.28%
and its corresponding acid I-12 effected a BSF growth inhibition of 77.64 ± 4.26%. Of
the substituted EbSe and EbS analogues, the esters EbS I-25 and EbSe I-26 exhibited
52.50 ± 4.89% and 55.61 ± 7.45% BSF growth inhibition, respectively. The acid analog
I-27 showed 10.94 ± 10.90% trypanosome growth inhibition and I-28 was ineffective
against trypanosome growth inhibition. Of the N-aryl substituted methyl esters, EbS I-32
exhibited 66.45 ± 10.94% BSF growth inhibition. EbS acid I-36 (of the ester I-32) was
ineffective against trypanosome growth. Next, EbS I-33 demonstrated 8.77 ± 22.09%
growth inhibition. EbS acid I-37 (of the ester I-33) displayed 15.84 ± 47.32% growth
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inhibition of trypanosomes. EbSe ester I-34 (substitution at the para position on N-aryl
ring) showed 38.6 ± 3.75% BSF growth inhibition and its acid I-38 showed a decreased
potency against BSF growth inhibition of 11.98 ± 17.40%. EbSe ester I-35 inhibited
18.02 ± 20.81% BSF growth inhibition and its acid I-39 was ineffective against
trypanosomes.
Of the non-conjugated drug derivatives, it is evident that the esters of the Ncarboxymethylated EbS derivative I-13; the core heterocycle substituted esters I-25 and
I-27; and the N-aryl substituted EbSe and EbS analogues (specifically I-32 and I-34)
were most potent against BSF growth inhibition. The acid I-12 of EbS derivative I-13
also demonstrated significant BSF growth inhibition. One reason can be attributed to the
difference in potency between a neutral compound (the ester) and an ionic compound (the
acid) in both TbHK1 assays and BSF growth inhibition assays. This dichotomy may be
attributed to poor passage of the compound(s) across the cellular membrane, the
phospholipid bilayer. The exterior membrane of the bilayer is a charged region and the
interior membrane is neutral. As a result, ionic compounds (such as carboxylic acids) will
have more difficult passage into cells compared to neutral compounds (such as esters).
This would help explain why the EbSe and EbS esters were more potent against
trypanosomes as compared to their acid counterparts, the exception being EbS derivative
I-12. To further understand the legitimacy of this supposition, it is important to look at
the potency against BSF growth inhibition of the EbSe and EbS peptide-drug conjugates.
Peptide-drug conjugate I-43 of EbSe I-39 demonstrated 28.44 ± 5.31% BSF growth
inhibition. Peptide-drug conjugate I-44 of EbS I-36 showed 26.35 ± 8.20% BSF growth
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inhibition. Peptide-drug conjugate I-45 of EbSe I-38 exhibited 44.11 ± 7.67% BSF
growth inhibition. Peptide-drug conjugate I-47 of EbSe I-19 displayed 34.42 ± 3.12%
BSF growth inhibition. Interestingly, the EbSe peptide-drug conjugates with N-aryl
substitution were potent against BSF growth inhibition. EbSe peptide-drug conjugate I-45
showed a BSF growth inhibition of 44.11 ± 7.67%. EbS peptide-drug conjugate I-46
showed a BSF growth inhibition of 27.95 ± 2.83%. As is evidenced by this data, the Ncarboxymethyl substituted EbSe peptide-drug conjugate I-47 was more potent against
trypanosomes than I-44 and I-46, but not I-45. The data shows that the N-carboxylmethyl
substituted EbSe peptide-drug conjugates were equal to or greater in potency than the Naryl substituted analogues. EbS peptide-drug conjugates I-40, I-41, and I-42 were
ineffective against BSF growth inhibition. Referring to the supposition mentioned earlier
comparing neutral and electrostatic compounds, it is important to note that the peptidedrug conjugates described are charged species and exhibited a moderate level of growth
inhibition against trypanosomes. These conjugates, though charged, have to pass through
the bilayer to exhibit this moderate level of growth inhibition. It is apparent that the
peptide (PTS1 sequence, glycine tether, and the modification site) conjugated to the EbSe
and EbS derivatives demonstrates potency against trypanosome growth inhibition.
Nonetheless, it is uncertain how the peptide-drug conjugates facilitate passage of the
drugs across the bilayer (as per the work conducted by Morris and Christensen).15,30
A desired TbHK1 inhibitor (i.e. enzyme inhibitor) will be in the single-digit
micromolar range and will exhibit low host toxicity. The TbHK1 IC50 value represents
the concentration of the drug necessary to reduce the enzyme’s activity by 50%. The only
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EbSe candidate for which an IC50 was detected was derivative I-34. EbSe ester I-34 (para
N-aryl substitution) displayed a TbHK1 IC50 of 3.16 ± 0.06 µM. On the other hand, the
other EbS derivatives displayed an IC50 of greater than 10 µM. An IC50 could not be
determined for any of the EbSe and EbS peptide-drug conjugates, as these values were
over the limit of detection of 10 µM.
As stated previously, a desired enzyme inhibitor will be in the single-digit
micromolar range and will exhibit low host toxicity and this criterion is true for desired
BSF inhibitors (i.e. whole cell inhibitors). Therefore, a good BSF EC50 will be an
inhibitor that kills at least fifty percent of a trypanosome culture at the single-digit
micromolar range. The EbS acid I-12 exhibited a high BSF EC50 of 6.27 ± 0.54 µM and
its corresponding methyl ester I-13 demonstrated potency through a BSF EC50 of 0.28
± 0.07 µM. EbS ester I-32 exhibited a BSF EC50 of 3.79 ± 0.06 µM. The other EbSe and
EbS drug derivatives were past the limit of detection of 10 µM. In the future, low host
toxicity will have to be assessed when these assays move toward in vivo trials.
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Structure

TbHK1%
inhibition (10
µM)

TbHK1 IC 50
(10 µM)

% BSF Growth
Inhibition (10 µM)

BSF EC 50
(µM)

I-12

0.87 ± 7.94

>10

77.64 ± 4.26

7.24 ± 0.45

I-13

12.83 ± 7.45

>10

98.33 ± 1.28

0.28 ± 0.07

I-18

0

>10

0

>10

I-19

0

>10

0

>10

I-25

17.98 ± 0.36

>10

52.50 ± 4.89

~10

I-26

2.67 ± 5.12

>10

55.61 ± 7.45

>10

I-27

11.77 ± 0.34

>10

I-28

0

>10

I-32

22.78 ± 3.75

>10

I-33

1.65 ± 0.30

I-34

x

10.94 ± 10.90
0

x

~10
>10

66.45 ± 10.94
0%

7.44 ± 1.90

>10

8.77 ± 22.09

>10

78.96 ± 2.81

3.16 ± 0.06

38.60 ± 3.75

>10

I-35

0

>10

18.02 ± 20.81

>10

I-36

0

>10

0

>10

I-37

0

>10

15.84 ± 47.32

>10

I-38

17.18 ± 14.55

>10

11.98 ± 17.40

>10

I-39

18.50 ± 2.84

>10

0

>10

I-40

0

>10

0
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I-41

0
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0

>10

I-42

0
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0
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I-43

0
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28.44 ± 5.31

>10

I-44

10.42 ± 0.55

>10

26.35 ± 8.20

>10

I-45

0

>10

44.11 ± 7.67

>10

I-46

3.74 ± 3.79

>10

27.95 ± 2.83

>10

I-47

1.71 ± 9.51

>10

34.42 ± 3.12

>10

I-48

0

>10

35.43 ± 13.11

>10

I-49

0

>10

25.00 ± 3.62

>10

x

Table 1.2: Biological data on EbSe and EbS derivatives and peptide-drug conjugates of EbSe and EbS
30
derivatives.
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1.5

CONCLUSIONS AND FUTURE DIRECTIONS
In summary, a number of the EbSe and EbS acids (I-12, I-19, I-27, I-28, I-36, I-

37, I-38, and I-39) were ineffective against the TbHK1 enzyme in vitro. EbSe acids I-27
was modestly active, demonstrating 11.77 ± 0.34% inhibition. The corresponding esters
(I-13, I-25, I-26, I-32, and I-33) showed modest activity against TbHK1, with EbSe ester
I-34 showing the greatest enzyme inhibition (ca. 78.96 ± 2.81%). The peptide-drug
conjugates were mostly inactive against the enzyme, with the most detectable enzymatic
activity (10.42 ± 0.55% inhibition) coming from peptide-drug conjugate I-44 (i.e. the
analog of EbS ester I-32). Furthermore, conjugation to a peptide sequence did not
increase the potency of the inactive non-conjugated EbSe analogues toward TbHK1.30
The esters were more potent against BSF growth inhibition, with EbS ester I-13
demonstrating almost complete inhibition of BSF growth. Note that EbS acid I-12
bearing an N-carboxymethyl substituent showed 77.64 ± 4.26% BSF growth inhibition.30
Installation of a methyl ester on the core aryl ring of the heterocycle (I-25 and I-26)
afforded EbSe and EbS analogues that displayed 52.50 ± 4.89% and 55.61 ± 7.45% BSF
growth inhibition, respectively. N-aryl substitution in the para position yielded a
moderately active EbS derivative I-32 against BSF growth inhibition (66.45 ± 10.94%).
Conjugation of our EbSe and EbS derivatives to a peptide conjugate bearing a
peroxisome targeting sequence did not enhance the potency against BSF growth
inhibition, contrary to our hypothesis that initiated this study. In addition, the most active
EbS derivative I-13 lost most of its efficacy when coupled to a peptide, going from 98.33
± 1.28% to 27.95 ± 2.83% BSF growth inhibition (refer to I-46 in Table 1.2). As a result,
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we concluded that our peptide-drug strategy did not enhance the overall potency of the
EbSe/EbS drug class against either the TbHK1 or BSF parasites.
At this point it is unclear whether the failure of this particular strategy was due to
reduced potency of the peptide-modified drug at its cellular target or whether the PTS1
was unable to facilitate transfer of the drug conjugate across the cell membrane. It is also
unclear whether the electron withdrawing carbonyl installed on the Ebselen scaffold
makes the therapeutic too unstable, i.e. prone to decomposition. It is interesting to note
that I-12 and I-13 with the acetoxy substitution in lieu of the N-aryl ring were ineffective
against the enzyme but were highly potent against the parasite. Compound I-34, on the
other hand, was moderately effective against the enzyme with an IC50 of 3.16 ± 0.06 µM.
Positioning of the electron-withdrawing group on the N-aryl ring enhances potency
against the enzyme, with positioning of a carboxylmethyl group enhancing potency
against the BSF parasite (see Figure 1.6). Perhaps, electron-donating groups could be
incorporated on the Ebselen scaffold to offset the electron withdrawing character of the
carbonyl moiety. Based on these results, the next candidate worth evaluating would be an
EbS derivative bearing a N-para-carboxylmethyl substitution on the N-aryl moiety as this
would combine both of the positive substitution patterns from the two major leads, I-13
and I-32. This compound and its corresponding carboxylic acid should be evaluated
against both the enzyme and the BSF parasite.
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Figure 1.6: Ebselen scaffold bearing an N-para-carboxymethyl substitution.

The key to enhancing the Ebselen drug suite, and their corresponding peptide
conjugates, is to have a more detailed understanding of their mechanism of action (i.e. the
biochemistry of the therapeutics). As such, the effect of the PTS1 has not yet been
determined with respect to transport of molecular cargo across the trypanosomal
membrane. Furthermore, we do not understand whether the most active Ebselen
derivatives (I-12, I-13, and I-32) are directly interacting with the target enzyme, TbHK1,
if they are interacting elsewhere in the trypanosome, or if they are rendered inactive via
oxidation to a sulfoxide or selenoxide species within the trypanosome.
We have found that several of our carboxylic acid and methyl ester EbSe and EbS
derivatives are potent against the BSF parasites (see Table 1.2). Although incorporation
of a methyl ester moiety onto the N-phenyl substituent leads to modest inhibition of BSF
growth, it is the use of an N-carboxymethyl substituent in lieu of the N-phenyl appendage
that leads to the greatest impact on growth inhibition. The reason for the lower activity of
the peptide-drug conjugate has yet to be determined and could be attributed to poor
passage of the peptide-drug conjugate across the cell membrane. Perhaps the poor
passage of our peptide-drug conjugates is due to interactions of the conjugate with the
surface glycoproteins on the trypanosome.5 Furthermore, our hypothesis of substituting
the diglycine tether for the more polar diethylene glycol tether did not enhance potency of
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the Ebselen peptide-drug conjugates as evidenced by the data for I-48 and I-49 (although
I-44 was weakly active against the enzyme, TbHK1).
The next phase of this thesis work should be to maintain the diglycine tether as
this tether allowed for the detection of weak enzyme and/or BSF parasite activity. The
most effective Ebselen derivatives to use for future peptide scaffolds would be either I-13
or I-32. The PTS1, however, should be altered with homologous amino acids. In the first
position, leucine can be replaced with isoleucine for a different set of peptide-drug
conjugates. The lysine is the most variable position of the PTS1 with its ability to
accommodate a variety of amino acids bearing acidic side-chains (at neutral pH), such as
histidine, asparagine, or glutamine. The alanine can be substituted with a similarly-sized
amino acid bearing a non-polar side-chain, such as valine. The next phase of the work
related to the Ebselen drug suite should focus on producing a library of peptides that vary
at the PTS1 using the two most active Ebselen drug derivatives presented in this thesis
work to assess whether the failed hypothesis reported here was due to a poorly selected
PTS1. Use of an alternate PTS1 may render the Ebselen drug suite as potent against the
trypanosomal glycolytic machinery.
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1.6

EXPERIMENTAL

1.6.1

TRYPANOSOME GROWTH AND VIABILITY ASSAYS

BSF 90-13 T. brucei, a 427 strain, was grown as described previously.31,32 To score
viability, parasites (1 x 104/mL BSF) were seeded into 96-well clear-bottomed
polystyrene plates in 200 µl HMI-9 supplemented with 10% fetal bovine serum and 10%
Serum Plus (Sigma-Aldrich, St. Louis, MO) and grown in the presence of compound (2
µl) or equivalently diluted carrier for 3 days in 5% CO2 at 37oC. All assays were
performed in triplicate. After incubation (72 hr, at 37 °C), CellTiter-Blue (Promega) was
added and fluorescence measured (560Ex/590Em).
Purification of Bacterially Expressed TbHK1 and enzyme assay:
For purification of bacterially expressed TbHK1 (rTbHK1), a starter culture of E. coli
M15(pREP) harboring pQE30 (Qiagen, Valencia, CA) with the TbHK1 gene cloned in
frame of a 6-His tagging sequence was grown to an OD of ~1 and then induced for 24 hr
at room temperature with 0.25 µM isopropyl β-D-1-thiogalactopyranoside (IPTG) and
purified as described previously.33
HK assays were performed in triplicate as described using a coupled reaction to
measure enzyme activity.33,34 In short, the coupled assay uses glucose-6-phosphate
dehydrogenase (G6PDH) to convert glucose-6-phosphate (G6-P) generated by HK to 6phosphogluconate with coincident reduction of NADP to NADPH, which is monitored
spectrophotometrically at 340 nm. Note that EbSe was found to be ineffective in a
counterscreen for inhibition of G6PDH.

Kinetic analyses were performed using

KaleidaGraph 4.1 (Synergy Software, Reading, PA).

38

1.6.2

SYNTHESIS OF DRUGS AND PEPTIDE-DRUG CONJUGATES

All reagents were purchased from commercial suppliers and used without further
purification. All isolated products were purified via flash column chromatography using
silica gel SDS 60 C.C. 40-63 µm. 1H and

13

C NMR spectra were collected at ambient

temperature on a 300 (Bruker Avance) or 500 MHz NMR spectrometer (Bruker Avance
or JEOL Eclipse). Chemical shifts are reported in parts per million (ppm) and referenced
to residual solvent peaks (i.e., d 7.28 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3;
2.54 ppm for 1H NMR, 40.45 ppm for

13

C NMR in DMSO-d6). Data are presented as

follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet),
and integration. Infrared (IR) spectra, reported in cm-1, were collected using a Fourier
transform spectrophotometer. Compounds I-1,19 I-12,21 I-13,21 I-16,22-24 I-17,22-24 I-18,2224

, I-21,26 I-22,27 I-23,28 and I-3225 were prepared using known methods and exhibited

spectral data consistent with previously reported syntheses.

Synthesis of I-19
O
N
Se
HO

O

To a dry, 20 mL vial was I-18 (142 mg, 0.5 mmol, 1 equiv), and 1.8 mL 1,4dioxane. The solution was cooled to 0 ˚C and then 1 M aq. LiOH (0.5 mL, 1.1 mmol, 2
equiv) was added. The solution was stirred for 1.5 h under N2 at 0 ˚C. The solvent was
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evaporated and then 1 mL of 10% HCl was added. The aqueous layer was extracted with
ethyl acetate (3 x 15 mL). The combined organics were dried over sodium sulfate,
filtered, and concentrated by rotary evaporation to isolate I-19 as an off-white solid in
73% yield (98 mg).

Compound I-19
1

H-NMR (500 MHz, DMSO-d6): d 8.76-8.75 (1H, s), 7.51-7.39 (4H, m), 3.91-3.90 (2H,

d, J 5 Hz); 13C-NMR (125 MHz, DMSO-d6): d 171.5, 167.2, 136.8, 131.6, 130.6, 130.3,
129.7, 127.6, 41.1; IR (cm-1; NaCl salt plate): 3254, 3062, 2921, 2851, 1735, 1638, 1595,
1533, 1466, 1432, 1401, 1349, 1318, 1241, 1085, 1054, 1002, 750, 725, 689; melting
point = decomposes above 173 ˚C.

Synthesis of I-24
O
NHPh
Br
O

OCH3

To a dry, 250 mL round-bottomed flask was added I-23 (1.4 g, 5.4 mmol, 1
equiv), triethylamine (1.1 mL, 8.1 mmol, 1.5 equiv), and 10 mL anhydrous DCM. The
solution was cooled to 0 ˚C. Then, thionyl chloride (1 M in DCM) (5.9 mL, 5.9 mmol,
1.1 equiv) was added slowly by syringe. The solution was stirred at 0 ˚C for 30 min., then
the solvent was evaporated in vacuo. The residue was then re-dissolved in 10 mL
anhydrous DCM and triethylamine was added (1.1 mL, 8.1 mmol, 1.5 equiv). Then,
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aniline (1.5 mL, 16.2 mmol, 3.0 equiv) was added slowly at 0 ˚C to the acid chloride and
the solution was allowed to warm to room temperature. The solution was then refluxed
overnight under N2, then cooled to room temperature and evaporated. The residue was
taken up in 50 mL ethyl acetate and then washed with 50 mL aq. saturated sodium
bicarbonate. The aqueous layer was washed with ethyl acetate (2 x 50 mL). The
combined organics were washed with 50 mL saturated brine. The brine layer was then
washed with ethyl acetate (2 x 25 mL). The combined organics were dried over sodium
sulfate, filtered, and evaporated onto silica. The residue was purified via column
chromatography with 0-35% ethyl acetate in hexanes to afford I-24 in 50% yield (926
mg).

Compound I-24
1

H-NMR (500 MHz, CDCl3): d 7.77-7.75 (1H, d, J 10 Hz), 7.68-7.62 (3H, m), 7.62 (s,

1H), 7.49-7.47 (1H, t, J 5, 15 Hz), 7.42-7.39 (2H, t, J 5, 15 Hz), 7.22-7.21 (1H, s), 3.98
(3H, s); 13C-NMR (125 MHz, CDCl3): d 166.8, 165.5, 140.5, 137.5, 134.5, 131.9, 131.5,
129.3, 127.8, 125.2, 120.2, 117.9, 52.9; IR (cm-1; NaCl salt plate): 3282, 3134, 3061,
2952, 1733, 1661, 1599, 1543, 1498, 1443, 1414, 1328, 1295, 1257, 1203, 1138, 1097,
1029, 981, 907, 854, 806, 756, 725, 693; melting point = 132-133 ˚C; Rf (35% ethyl
acetate:hexanes) = 0.33.
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Synthesis of I-25
O
NPh
S
O

OCH3

To a dry, 100 mL round-bottomed flask was added 2 mL anhydrous DMF, copper
(I) iodide (29 mg, 0.15 mmol, 0.5 equiv), and 1,10-phenanthroline (27 mg, 0.15 mmol,
0.5 equiv). The mixture was then stirred for 15 minutes at room temperature.
After 15 minutes, I-24 (100 mg, 0.3 mmol, 1 equiv), sulfur powder (12 mg, 3.75
mmol, 1.25 equiv), and anhydrous potassium carbonate (50 mg, 3.6 mmol, 1.2 equiv) (i.e.
dried in oven overnight at 140 ˚C) were added sequentially. The solution was stirred at
room temperature for 15 minutes under nitrogen and then brought to 110 ˚C and stirred
overnight.
The reaction mixture was cooled to room temperature and then poured into 100
mL saturated brine. The suspension was stirred at room temperature until a thin organic
layer of DMF and product was detected above the aqueous layer (typically within three to
four hours). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The
combined organics were dried with sodium sulfate, filtered, and evaporated onto silica.
The reaction mixture was purified via column chromatography with 0-45% ethyl acetate
in hexanes to afford I-25 in 52% yield (44 mg).
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Compound I-25
1

H-NMR (300 MHz, CDCl3): d 8.34-8.32 (1H, d, J 6 Hz), 8.28-8.27 (1H, d, J 3 Hz),

7.78-7.76 (2H, d, J 6 Hz), 7.58-7.55 (1H, t, J 6, 9 Hz), 7.52-7.49 (2H, t, J 6, 9 Hz), 7.377.34 (1H, t, J 3, 9 Hz), 4.07 (3H, s); 13C-NMR (75 MHz, CDCl3): d 166.7, 163.4, 142.5,
137.2, 132.9, 131.7, 129.4, 127.1, 126.9, 125.9, 124.5, 121.7, 53.2; IR (cm-1; NaCl salt
plate): 2956, 2920, 2850, 1686, 1662, 1638, 1589, 1561, 1543, 1509, 1459, 1439, 1377,
1323, 1289, 1098, 736; melting point = 185-186 ˚C; Rf (1:1 EtOAc:Hex.) = 0.58. HRMS
(C15H11NO3S): EXPECTED: 285.3170; FOUND: 286.0552.

Synthesis of I-26
O
NPh
Se
O

OCH3

To a dry, 100 mL round-bottomed flask was added 3 mL anhydrous DMF, copper
(I) iodide (100 mg, 0.53 mmol, 0.5 equiv), and 1,10-phenanthroline (95 mg, 0.53 mmol,
0.5 equiv). The mixture was then stirred for 15 minutes at room temperature.
After 15 minutes, I-24 (350 mg, 1.05 mmol, 1.0 equiv), selenium powder (104
mg, 1.31 mmol, 1.25 equiv), and anhydrous potassium carbonate (174 mg, 1.26 mmol,
1.2 equiv) (dried in oven overnight at 140 ˚C) were added sequentially. The solution was
stirred at room temperature for 15 minutes under nitrogen, then brought to 110 ˚C and
stirred overnight.
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The reaction mixture was cooled to room temperature and then poured into 100
mL saturated brine. The suspension was stirred at room temperature until a thin organic
layer of DMF and product was detected above the aqueous layer (typically within three or
four h). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined
organics were dried with sodium sulfate, filtered, and evaporated onto silica. The reaction
mixture was purified via column chromatography with 0-55% ethyl acetate in hexanes to
afford I-26 in 12% yield (41 mg).

Compound I-26
1

H-NMR (500 MHz, CDCl3): d 12.73 (1H, s), 8.56-8.52 (1H, d, J 20 Hz), 8.09-8.06 (1H,

d, J 15 Hz), 7.75-7.72 (2H, d, J 15 Hz), 7.42-7.36 (2H, t, J 15, 30 Hz), 7.18-7.07 (2H, m),
4.03 (3H, s);

13

C-NMR (125 MHz, CDCl3): d 171.3, 159.5, 138.9, 138.3, 133.9, 129.1,

124.4, 121.5, 120.6, 119.8, 112.9, 53.0; IR (cm-1; NaCl salt plate): 3363, 2922, 2851,
1680, 1597, 1546, 1498, 1442, 1321, 1267, 1199, 1151, 1076, 756, 691; melting point =
78-85 ˚C; Rf (1:1 EtOAc:Hex) = 0.64-0.55. HRMS (C15H11NO3Se): EXPECTED:
332.9904; FOUND: 333.9983.

Synthesis of I-27
O
NPh
S
O

OH

44

To a dry, 20 mL vial was added I-25 (44 mg, 0.15 mmol, 1 equiv), lithium
hydroxide monohydrate (32 mg, 0.75 mmol, 5 equiv), and 10 mL THF:methanol:H2O
(2:1:1). The reaction mixture was stirred at room temperature for 40 hr. Saturated
aqueous ammonium chloride (5 mL) and H2O (4 mL) were then added and the aqueous
layer was extracted with ethyl acetate (2 x 50 mL) and chloroform/methanol (5:1; 2 x 30
mL). The combined organics were dried with sodium sulfate, filtered, and evaporated to
afford I-27 in 77% yield (32 mg).

Compound I-27
1

H-NMR (300 MHz, CDCl3): d 8.32-8.29 (1H, d, J 9 Hz), 8.27-8.24 (1H, d, J 9 Hz),

7.76-7.68 (3H, m), 7.57-7.52 (2H, t, J 6, 15 Hz), 7.41-7.37 (1H, t, J 6, 12 Hz); 13C-NMR
(75 MHz, CDCl3): d 168.3, 163.1, 142.0, 137.5, 133.7, 131.2, 129.9, 127.5, 127.3, 126.4,
124.8; IR (cm-1; KBr pellet): 3061, 2920, 2847, 2629, 1734, 1676.05, 1653, 1617, 1585,
1560, 1507, 1490, 1479, 1438, 1421, 1349, 1326, 1267, 1243, 1199, 1162, 1112, 1052,
1024, 908, 758, 745, 691; melting point = decomposes above 260 ˚C. HRMS
(C14H9NO3S): EXPECTED: 271.0303 FOUND: 272.0199.

Synthesis of I-28
O
NPh
Se
O

OH

45

To a dry, 20 mL vial was added I-26 (32 mg, 0.097 mmol, 1 equiv), lithium
hydroxide monohydrate (20 mg, 0.49 mmol, 5 equiv), and 10 mL THF:methanol:H2O
(2:1:1). The reaction mixture was stirred at room temperature for 40 hr. A mixture of
saturated aqueous ammonium chloride (5 mL) and H2O (4 mL) was added and the
aqueous layer was extracted with ethyl acetate (2 x 50 mL) and chloroform/methanol
(5:1; 2 x 30 mL). The combined organics were dried over sodium sulfate, filtered, and
evaporated via rotary evaporation to afford I-28 in 82% yield (25 mg).

Compound I-28
1

H-NMR (500 MHz, DMSO-d6): d 10.64 (s, 1H), 7.98-7.97 (2H, d, J 5 Hz), 7.75-7.73

(2H, d, J 10 Hz), 7.37-7.34 (2H, t, J 5, 15 Hz), 7.12-7.09 (1H, t, J 5, 15 Hz), 7.02-6.96
(1H, t, J 10, 15 Hz);
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C-NMR (125 MHz, DMSO-d6): d 172.1, 164.3, 161.0, 139.3,

136.0, 133.8, 129.2, 124.1, 123.6, 120.3, 118.4, 115.3; IR (cm-1; NaCl salt plate): 2923,
2852, 1674, 1655, 1638, 1596, 1544, 1509, 1498, 1491, 1465, 1439, 1377, 1324, 1257,
1182, 1155, 1071, 744, 685; melting point = decomposes above 213 ˚C. HRMS
(C14H9NO3Se): EXPECTED: 318.1978; FOUND: 317.9662.

Synthesis of I-30
O
O

OCH3
N
H

I

46

To a dry, 100 mL round-bottomed flask was added a 2-iodobenzoic acid (500 mg,
2.02 mmol, 1.0 equiv), 5 mL dry DCM, and triethylamine (0.56 mL, 4.04 mmol, 2.0
equiv). The solution was cooled to 0 ˚C, then thionyl chloride (1 M in DCM) (2 mL, 2.2
mmol, 1.1 equiv) was added and the solution stirred at 0 ˚C for 30 min. The solvent was
evaporated by rotary evaporation and the residue reconstituted in 5 mL dry DCM.
Triethylamine (0.56 mL, 4.04 mmol, 2.0 equiv) was added and the solution was cooled to
0 ˚C after which para-amino methyl benzoate (335 mg, 2.2 mmol, 1.1 equiv) was added.
The reaction was then refluxed overnight under N2. Then, the reaction mixture was
cooled to room temperature and evaporated by rotary evaporation. The residue was taken
up in 50 mL ethyl acetate and washed sequentially with 50 mL 1 M HCl, 100 mL
saturated sodium bicarbonate, and 100 mL saturated sodium chloride. The aq. layer was
neutralized with saturated sodium bicarbonate to pH 7 and then washed with 2 x 50 mL
ethyl acetate. The combined organics were dried over sodium sulfate, filtered, evaporated
onto silica gel. Product I-30 was obtained in an 89% yield (682 mg) via column
chromatography with 0-75% ethyl acetate in hexanes followed by recrystallization from
1:1 DCM:hexanes.

Compound I-30
1

H-NMR (500 MHz, CDCl3): d 8.09-8.08 (2H, s), 7.95-7.94 (1H, d, J 5 Hz), 7.76-7.74

(2H, d, J 10 Hz), 7.72 (1H, s), 7.56-7.55 (1H, s), 7.49-7.46 (1H, t, J 5, 15 Hz), 7.21-7.18
(1H, t, J 5, 15 Hz), 3.94 (3H, s);

13

C-NMR (125 MHz, CDCl3): d 167.2, 166.5, 141.7,

141.6, 141.2, 131.8, 130.9, 128.7, 128.5, 126.3, 119.2, 92.2, 52.1; IR (cm-1; NaCl salt
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plate): 3299, 2949, 2923, 2852, 1717, 1687, 1669, 1597, 1560, 1528, 1474, 1459, 1434,
1407, 1364, 1323, 1311, 1281, 1255, 1191, 1176, 1107, 1039, 1016, 965, 897, 855, 769,
742, 697, 635, 622; melting point = 170-172 ˚C; Rf (1:1 ethyl acetate:hexanes) = 0.67.

Synthesis of I-31
O
O

N
H

OCH3

I

To a dry, 100 mL round-bottomed flask was added 2-iodobenzoic acid (250 mg,
1.01 mmol, 1.0 equiv), 5 mL dry DCM, and triethylamine (0.28 mL, 2.0 mmol, 2.0
equiv). The solution was cooled to 0 ˚C,, then thionyl chloride (1 M in DCM) (1.1 mL,
1.11 mmol, 1.1 equiv) was added. The resulting solution was stirred at 0 ˚C for 30 min.
The solvent was evaporated and the residue was reconstituted in 5 mL dry DCM.
Triethylamine (0.28 mL, 2.0 mmol, 2.0 equiv) was added and the solution was cooled to
0 ˚C. Next, meta-amino methyl benzoate (152 mg, 1.01 mmol, 1.1 equiv) was added, and
the reaction refluxed overnight under N2. The reaction mixture was cooled to room
temperature and evaporated. The residue was taken up in 50 mL ethyl acetate and washed
sequentially with 50 mL 1 M HCl, 100 mL saturated sodium bicarbonate, and 100 mL
saturated sodium chloride. The aq. layer was neutralized to pH 7 with saturated sodium
bicarbonate and then was washed with 2 x 50 mL ethyl acetate. The combined organics
were dried over sodium sulfate, filtered, and evaporated directly onto silica. Product I-31
was obtained as an oil in a 62% yield (238 mg) via column chromatography with 0-55%
ethyl acetate in hexanes.
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Compound I-31
1

H-NMR (300 MHz; CDCl3): d 8.18 (s, 1H), 8.10-8.09 (2H, d, J 3 Hz), 7.89-7.88 (2H, d,

J 3 Hz), 7.83-7.82 (2H, d, J 3 Hz), 7.51-7.45 (2H, m), 7.42-7.39 (1H, t, J 3, 9 Hz), 7.157.12 (1H, t, J 3, 9 Hz), 3.83 (3H, s); 13C-NMR (75 MHz; CDCl3): d 167.5, 166.8, 141.9,
140.1, 137.9, 131.6, 130.9, 129.3, 128.5, 128.3, 125.8, 124.7, 121.1, 92.4, 52.3; IR (cm-1;
NaCl salt plate): 3424, 2932, 2878, 1718, 1663, 1599, 1540, 1490, 1437, 1409, 1389,
1324, 1282, 1256, 1225, 1176, 1103, 1063, 1016, 771, 758, 698, 663; Rf (1:1 EtOAc:Hex)
= 0.63.

Synthesis of I-33
O
N
S
O
H 3CO

To a dry, 100 mL round-bottomed flask 3 mL anhydrous DMF, copper (I) iodide
(60 mg, 0.313 mmol, 0.5 equiv), and 1,10-phenanthroline (56 mg, 0.313 mmol, 0.5
equiv). The mixture was stirred for 15 minutes at room temperature.
After 15 minutes, I-31 (239 mg, 0.626 mmol, 1.0 equiv), sulfur powder (25 mg,
0.783 mmol, 1.25 equiv), and anhydrous potassium carbonate (104 mg, 0.751 mmol, 1.2
equiv) (i.e. dried in oven overnight at 140 ˚C) were added sequentially. The solution was
stirred at room temperature for 15 minutes under nitrogen, and then brought to 110 ˚C
and stirred overnight.
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The reaction mixture was cooled to room temperature and then poured into 100
mL saturated brine. The suspension was stirred at room temperature until a thin organic
layer of DMF and product was detected above the aqueous layer (typically occurs within
three or four hours). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The
combined organics were dried over sodium sulfate, filtered, and evaporated onto silica.
The reaction mixture was purified via column chromatography with 0-55% ethyl acetate
in hexanes to afford I-33 in 65% yield (117 mg).

Compound I-33
1

H-NMR (300 MHz; CDCl3): d 8.18 (s, 1H), 8.12 (1H, s), 8.09-8.07 (1H, d, J 6 Hz),

7.87-7.86 (1H, d, J 3 Hz), 7.81-7.79 (1H, d, J 6 Hz), 7 .51-7.39 (4H, m), 3.93 (3H, s);
13

C-NMR (75 MHz; CDCl3): d 166.6, 164.6, 137.8, 134.8, 131.9, 131.1, 130.6, 130.5,

130.5, 129.3, 127.4, 125.9, 124.6, 121.0, 52.3; IR (cm-1; NaCl salt plate): 3300, 3144,
3071, 2951, 2925, 2852, 1722, 1663, 1594, 1547, 1487, 1471, 1435, 1324, 1295, 1254,
1222, 1190, 1167, 1128, 1083, 1051, 1035, 996, 908, 805, 755, 683, 652, 594; melting
point = 136-139 ˚C; Rf (1:1 EtOAc:Hex)= 0.53. HRMS (C15H11NO3S): EXPECTED:
286.0538; FOUND: 286.0572.

Synthesis of I-34
O
O
N
Se

OCH3
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To a dry, 100 mL round-bottomed flask was added 5 mL anhydrous DMF, copper
(I) iodide (170 mg, 0.89 mmol, 0.5 equiv), and 1,10 phenanthroline (161 mg, 0.89 mmol,
0.5 equiv). The mixture was stirred for 15 minutes at room temperature.
After 15 minutes, I-30 (682 mg, 1.79 mmol, 1.0 equiv), selenium powder (177
mg, 2.24 mmol, 1.25 equiv), and anhydrous potassium carbonate (297 mg, 2.15 mmol,
1.2 equiv) (i.e. dried in oven overnight at 140 ˚C) were added in that order. The solution
was stirred at room temperature for 15 minutes under nitrogen, and then brought to 110
˚C and stirred overnight.
The reaction mixture was cooled to room temperature and then poured into 100
mL saturated brine. The suspension was stirred at room temperature until a thin organic
layer of DMF and product was detected above the aqueous layer (typically occurs within
three or four hours). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The
combined organics were dried over sodium sulfate, filtered, and evaporated onto silica.
The reaction mixture was purified via column chromatography with 0-55% ethyl acetate
in hexanes to afford I-34 in 46% yield (276 mg).

Compound I-34
1

H-NMR (300 MHz, CDCl3): d 8.15-8.08 (3H, m), 7.82-7.77 (2H, d, J 15 Hz), 7.71-7.69

(2H, m, J 6 Hz), 7.53-7.47 (1H, m), 3.95 (3H, s); 13C-NMR (75 MHz, CDCl3): d 166.3,
165.8, 143.6, 137.2, 133.0, 130.8, 129.5, 127.5, 126.8, 124.0, 123.7, 52.2; IR (cm-1; NaCl
salt plate): 3341, 2921, 2850, 1723, 1699, 1620, 1592, 1539, 1506, 1437, 1412, 1305,
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1278, 1179, 1130, 1105, 1013, 958, 853, 765, 727, 695, 668; melting point = 142-145 ˚C;
Rf (1:1 EtOAc:Hex)=0.56-0.53.

Synthesis of I-35
O
N
Se
O
H 3CO

To a dry, 100 mL round-bottomed flask was added 3 mL anhydrous DMF, copper
(I) iodide (42 mg, 0.22 mmol, 0.5 equiv), and 1,10 phenanthroline (40 mg, 0.22 mmol,
0.5 equiv). The mixture was stirred for 15 min at room temperature.
After 15 min, I-31 (170 mg, 0.44 mmol, 1.0 equiv), selenium powder (44 mg,
0.56 mmol, 1.25 equiv), and anhydrous potassium carbonate (74 mg, 0.53 mmol, 1.2
equiv) (i.e. dried in oven overnight at 140 ˚C) were added sequentially. The solution was
stirred at room temperature for 15 min under N2 and then brought to 110 ˚C and stirred
overnight.
The reaction mixture was cooled to room temperature and then poured into 100
mL of saturated brine. The suspension was stirred at room temperature until a thin
organic layer of DMF and product was detected above the aqueous layer (typically
occurring within three or four hours). The aqueous layer was extracted with ethyl acetate
(3 x 25 mL). The combined organics were dried with sodium sulfate, filtered, and
evaporated onto silica. The reaction mixture was purified via column chromatography
with 0-55% ethyl acetate in hexanes to afford I-35 in 43% yield (63 mg).
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Compound I-35
1

H-NMR (500 MHz; CDCl3): d 8.24 (1H, s), 8.16-8.14 (1H, d, J 10 Hz), 7.99-7.95 (2H,

m), 7.71-7.70 (2H, m), 7.56-7.49 (2H, m), 3.96 (3H, s); 13C-NMR (125 MHz; CDCl3): d
166.3, 165.9, 139.4, 137.5, 132.9, 131.5, 129.7, 129.5, 129.4, 127.7, 127.2, 126.74, 126.2,
123.8, 52.4; IR (cm-1; NaCl salt plate): 3299, 3072, 2952, 2922, 2851, 1722, 1662, 1594,
1548, 1488, 1435, 1324, 1296, 1223, 1168, 1127, 1109, 1083, 1051, 1035, 997, 908, 805,
755, 730, 683, 652, 594; melting point = 142 ˚C; Rf (1:1 EtOAc:Hex) = 0.63-0.53.

Synthesis of I-36
O
O
N
S

OH

To a dry, 20 mL vial was added I-32 (301 mg, 1.1 mmol, 1.0 equiv), and 4 mL of
a 2:1:1 mixture of THF:methanol:H2O. Then, lithium hydroxide monohydrate (231 mg,
5.5 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature
for 40 h. The reaction mixture was then extracted with 1 M aq. HCl (50 mL) and ethyl
acetate (5 x 50 mL). The combined organics were washed with 50 mL saturated brine
then dried over sodium sulfate, filtered, and evaporated. Product I-36 was obtained in a
79% yield (234 mg) and may be recrystallized from a 1:1 mixture of diethyl ether:ethanol
(if necessary).

53

Compound I-36
1

H-NMR (300 MHz, DMSO-d6): d 10.81 (s, 1H), 7.92-7.89 (2H, d, J 9 Hz), 7.83-7.79

(2H, d, J 12 Hz), 7.65-7.62 (1H, d, J 9 Hz), 7.46-7.41 (2H, m), 7.29-7.26 (1H, d, J 9 Hz);
13

C-NMR (75 MHz, DMSO-d6): d 167.4, 167.1, 143.4, 139.4, 134.6, 133.1, 131.3, 130.7,

128.5, 127.8, 126.1, 119.5; IR (NaCl salt plate): 3423, 3283, 2923, 1719, 1701, 1685,
1676, 1655, 1638, 1628, 1609, 1561, 1543, 1525, 1509, 1499, 1491, 1476, 1459, 1422,
1406, 1316, 1290, 1178; melting point = decomposes above 230 ˚C. HRMS
(C14H9NO3S): EXPECTED: 272.2978; FOUND: 272.0372.

Synthesis of I-37
O
N
S
O
HO

To a dry, 20 mL vial was added I-33 (93 mg, 0.327 mmol, 1.0 equiv), and 4 mL
of a 2:1:1 mixture of THF:methanol:H2O. Then, lithium hydroxide monohydrate (69 mg,
1.635 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature
for 40 hours. The reaction mixture was monitored by TLC and another aliquot of lithium
hydroxide monohydrate (69 mg, 1.635 mmol, 5.0 equiv) was added. The reaction mixture
was stirred at room temperature for 48 hours. The solvent was evaporated and then a
mixture of 5 mL saturated ammonium chloride and 4 mL H2O was added to the residue.
The aqueous material was extracted with ethyl acetate (2 x 25 mL). The aqueous layer
was then washed with 5:1 chloroform:methanol (2 x 30 mL). The combined organics was
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dried over sodium sulfate, filtered, and concentrated by rotary evaporation. Product I-37
was obtained in a 71% yield (63 mg) and may be recrystallized from a 1:1 mixture of
diethyl ether:ethanol, if necessary.

Compound I-37
1

H-NMR (300 MHz; DMSO-d6): d 10.72 (1H, s), 8.41 (1H, s), 7.92-7.90 (1H, d, J 6 Hz),

7.71-7.69 (1H, d, J 6 Hz), 7.63-7.58 (2H, m), 7.54-7.48 (3H, m);

13

C-NMR (75 MHz;

DMSO-d6): d 167.6, 165.6, 139.6, 137.2, 131.9, 131.7, 130.4, 130.2, 129.5, 129.4, 127.7,
125.1, 124.2, 120.9; IR (cm-1; NaCl salt plate): 3282, 2921, 2849, 1691, 1648, 1590,
1548, 1530, 1486, 1467, 1436, 1414, 1298, 1261, 1164, 1130, 1078, 1047, 1024, 950,
919, 883, 755, 725; melting point = decomposes above 252 ˚C; Rf (1:1 ethyl
acetate:hexanes) = 0.34. HRMS (C14H9NO3S): EXPECTED: 271.0303; FOUND:
270.0217 (<3 ppm).

Synthesis of I-38
O
O
N
Se

OH

To a dry, 20 mL vial was added I-34 (95 mg, 0.287 mmol, 1.0 equiv), and 4 mL
of a 2:1:1 mixture of THF:methanol:H2O. Then, lithium hydroxide monohydrate (60 mg,
1.435 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature
for 40 h, and then concentrated by rotary evaporation. A mixture of 5 mL saturated
ammonium chloride and 4 mL H2O was added to the residue. The resulting aqueous
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suspension was extracted with ethyl acetate (2 x 25 mL). The organic layer was
discarded, then the aqueous layer was acidified with 1 M HCl and extracted with ethyl
acetate (25 mL). The organic layer was dried over sodium sulfate, filtered, and
concentrated by rotary evaporation. Product I-38 was obtained in an 84% yield (77 mg)
and may be recrystallized from a 1:1 mixture of diethyl ether:ethanol if necessary.

Compound I-38
1

H-NMR (500 MHz; DMSO-d6): d 10.85 (s, 1H), 7.96-7.94 (2H, d, J 10 Hz), 7.86-7.84

(2H, d, J 10 Hz), 7.63-7.59 (2H, m), 7.55-7.52 (1H, t, J 5, 15 Hz), 7.49-7.46 (1H, t, J 5,
15 Hz);

13

C-NMR (125 MHz; DMSO-d6): d 167.4, 165.8, 143.3, 137.1, 131.8, 130.9,

130.4, 130.2, 129.4, 127.8, 126.3, 119.4; IR (cm-1; NaCl salt plate): 3281, 2924, 2853,
1674, 1594, 1520, 1458, 1431, 1406, 1319, 1288, 1178, 1115, 855, 769, 686; melting
point = decomposes above 260 ˚C; Rf (1:1 ethyl acetate:hexanes) = 0.10.

Synthesis of I-39
O
N
Se
O
HO

To a dry, 20 mL vial was added I-35 (63 mg, 0.188 mmol, 1.0 equiv), and 4 mL
of a 2:1:1 mixture of THF:methanol:H2O. Then lithium hydroxide monohydrate, (39 mg,
0.94 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature
for 40 h and then concentrated by rotary evaporation. A mixture of 5 mL saturated
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ammonium chloride and 4 mL H2O was added to the residue. The aqueous material was
washed with ethyl acetate (2 x 25 mL). The combined organics were dried over sodium
sulfate, filtered, and evaporated. Product I-39 was obtained in 91% yield (54 mg) and
may be recrystallized from a 1:1 mixture of diethyl ether:ethanol if necessary.

Compound I-39
1

H-NMR (300 MHz; DMSO-d6): d 10.71 (s, 1H), 8.40 (1H, s), 7.92-7.88 (1H, d, J 12

Hz), 7.71-7.68 (1H, d, J 9 Hz), 7.63-7.57 (2H, m), 7.55-7. 46 (3H, m); 13C-NMR (75
MHz; DMSO-d6): d 167.6, 165.6, 139.5, 137.2, 131.9, 131.7, 130.4, 130.1, 129.5, 129.4,
127.8, 125.1, 124.2, 120.8; IR (NaCl salt plate): 3417, 2922, 2852, 2256, 2129, 1668,
1592, 1554, 1487, 1436, 1325, 1268, 1049, 1025, 1000, 825, 762; melting point = 248–
249 ˚C.
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1.6.3

GENERAL PROCEDURE FOR SOLID PHASE PEPTIDE SYNTHESIS
OF I-40 TO I-49
Peptides were assembled according to the generalized scheme presented above in

Scheme 1.7.
Resin Swelling: Fmoc-Leu-Wang resin was loaded into the barrel of a fritted 10 mL
syringe and was swelled by first washing with 3 mL DCM, followed by soaking in
another 5 mL DCM for five minutes. The residual DCM was washed away with DMF (3
x 5 mL).
Fmoc Deprotection Sequences: The Fmoc protecting group of the terminal amino acid of
the growing peptide was removed by three sequential one-minute treatments with 5 mL
of a 30% solution of 4-methylpiperidine in DMF. The deprotected resin was then washed
three times with 5 mL of DMF.
HCTU amino acid couplings: Five equiv (relative to resin loading) of the appropriate
Fmoc-amino acid was added to a three-dram vial, along with five equiv of HCTU. The
solids were dissolved in 1 mL DMF and 5 equiv of diisopropylethylamine was added.
This mixture was then taken up into the syringe and agitated for two minutes. The first
treatment of the coupling mixture was then ejected from the syringe, and the resin was
subsequently treated with a second aliquot of the same amino acid coupling mixture for
another two minutes. After the double coupling protocol, the resin was washed with
DMF (3 X 5 mL). After this coupling procedure was complete, the newly added Fmocamino acid was deprotected and prepared for further coupling steps as described above.
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Fmoc-Gly-OPfp coupling (for peptides I-40 to I-47): The required glycine coupling
using the more reactive Fmoc-Gly-OPfp (see Scheme 1.7 above) was achieved in the
following manner: five equiv of Fmoc-Gly-OPfp and five equiv of HOBt were charged
to two sets of three-dram vials and taken up in 1 mL of DMF. This mixture was taken up
into the syringe containing the resin and was agitated for one hour. The first treatment of
the coupling mixture was then ejected from the syringe, and the resin was subsequently
treated with a second aliquot of the same amino acid coupling mixture for another one
hour. After the double coupling protocol, the resin was washed with DMF (3 X 5 mL).
After this coupling procedure was complete, the newly added Fmoc-Gly residue was
deprotected and prepared for further coupling steps as described above. This process was
repeated for the incorporation of each of the desired amino acids in the sequence. FmocAEEP-OH was substituted for Fmoc-Gly-OH for the installation of a diethylene glycol
tether (for peptides II-48 and II-49) using the same protocol as that described above.
Drug Installation:

Each peptide was capped with the appropriate EbSe/EbS drug

candidate in the following manner:

Five equiv (relative to resin loading) of the

appropriate EbSe/EbS carboxylic acid was added to a three-dram vial, along with five
equiv of HCTU. This mixture was taken up into the syringe containing the resin and was
agitated overnight. After the coupling protocol, the coupling solution was ejected from
the syringe and the resin was further processed as described below.
Peptide Cleavage and Isolation: The resin containing the fully assembled peptide-drug
conjugate was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), and methanol (3 x 5 mL).
Residual solvents were dried using suction and then the resin was further dried under
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vacuum (i.e. in a 25 ˚C vacuum oven) overnight. After drying the resin was treated with
1.5 mL of a standard peptide cleavage cocktail comprised of trifluoroacetic
acid:H2O:methanol (95:4.5:0.5) for 1.5 h. The resulting solution containing the liberated
peptide was then ejected into a 1 mL Eppendorf tube and evaporated under a steady
stream of nitrogen. The peptide was then precipitated from the resulting oil on the
addition of ice-cold diethyl ether. The precipitate was then localized at the bottom of the
tube by centrifugation, the ether portion was decanted, and the precipitation procedure
was repeated two more times to afford the desired peptide-drug conjugates. The identity
of the peptide-drug conjugates was then confirmed by MALDI-TOF mass spectrometry
(Table 1.3).
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Peptide Number

Condensed
Molecular
Formula

Expected m/z

Experimental
m/z

I-40

C 33H 43N 7O8S

698.3

698.4

I-41

C33H 43N 7O8Se

746.2

746.3

I-42

C 33H 43N 7O8S

698.3

698.4

I-43

C33H 43N 7O8Se

746.2

746.4

I-44

C 33H 43N 7O8S

698.3

698.2

I-45

C33H 43N 7O8Se

746.2

746.2

I-46

C28H 41N 7O8S

635.7

636.3

I-47

C 28H 41N 7O8Se

684.2

684.5

I-48

C 36H 50N 6O9S

742.3

742.5

I-49

C36H 50N 6O9Se

790.8

791.6

Table 1.3: MALDI-TOF data for peptides I-40 to I-49.
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CHAPTER TWO
SYNTHESIS AND EVALUATION OF POTENT TRYPANOCIDES BASED ON
BENZAMIDOBENZOIC ACID (BABA) INHIBITOR SCAFFOLD
2.1

INTRODUCTION
As was described in Chapter One of this thesis, human African trypanosomiasis

(HAT), or African sleeping sickness, is caused by bloodstream form (BSF) Trypanosoma
brucei (T. brucei; trypanosomes) and is transmitted by the tsetse fly vector.1-3 The disease
has the potential to affect millions in sub-Saharan Africa, resulting in approximately
9,000 deaths as of 2010.4,5 Many of the treatments that are employed today are ineffective
against the parasite once it crosses the blood-brain barrier.1,4 This portion of the thesis
work will continue the narrative described in the first part of this thesis work. Whereas
the discussion in the first part of this thesis focused on the use of Ebselen derivatives
conjugated to a peptidic scaffold to ideally demonstrate increased potency against a
hexokinase, TbHK1, and trypanosomes, this work will focus on a novel lead drug
candidate that was evaluated as an in vitro probe, ML205 (II-1), which is part of the
novel benzamidobenzoic acid (BABA) drug suite.6,7 Furthermore, the work reported by
Lin, et al. that was shown to target therapeutics coupled to a peroxisomal targeting
sequence (PTS) to the glycosome where the hexokinase is housed will be a central focus
for our ultimate goal of focused drug delivery of the BABA drug suite.8
As was described in Chapter One, TbHK1 was previously genetically and
chemically validated as a suitable therapeutic target for the design and synthesis of kinase
inhibitors.2 Three classes of inhibitors were discovered from a high-throughput screening
campaign

of

over

220,000

compounds,

64

including

the

isobenzothiazolinone,

isobenzoselenazolinone, and BABA drug suites, the latter of which will be described in
this part of the thesis. Although the BABA scaffold is one that is relatively novel, several
analogues were synthesized and screened through structure-activity relationship (SAR)
assays by the Golden group that will be described here to highlight the optimal structure
necessary to achieve high potency against both our target enzyme, TbHK1, and our target
parasite. The BABA scaffold possesses certain features that are amenable to substitution
to increase inhibition of enzymatic activity in trypanosomes, with the goal of preparing a
class of highly trypanocidal therapeutics (shown in Figure 2.1).9-11 The results from the
SAR assay demonstrated that only certain substitutions allow for high inhibition of
enzymatic activity. Furthermore, these substitutions only served to moderately increase
the activity of the BABA drug suite against the BSF parasite as described below.
Critical toward activity
Cl

Substitution
enhances
potency

Other heterocycles not tolerated.
Optimal: para-branched alkyl
O
Cl

N
H
HO

Br

O

Tetrazole tolerated (required for cellular assays)

O
N
H

HO

O

ML205; II-1

Figure 2.1: Key features of the BABA derivatives are shown on the left; ML205 (II-1) lead drug
10,11
candidate (IC50 = 0.98 ± 0.07 µM) shown on right.

Compound II-1 (ML205) had a BSF percent growth inhibition of 6.9 ± 3.0% and
a TbHK1 IC50 of 0.98 ± 0.067 µM. With respect to the single-digit IC50 displayed by II1, the goal was to translate the enzyme potency displayed by this inhibitor into a potent
trypanocide by varying the substitution pattern on II-1. Substituents were chosen based
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on changing the electronic character, steric bulk, and solubility of the II-1 lead
candidate.10 Initially, the tert-butyl group was replaced with electron donating groups.
Replacement with an ethyl ether moiety (II-1a in Table 2.1) led to a higher percent
growth inhibition of BSF parasites (64.1 + 3.8% at 10 µM), but an increased IC50 value
for TbHK1 inhibition (4.8 ± 0.38 µM). Incorporation of an ethyl group (II-1b) in place of
the t-butyl moiety led to a similar result with a 68.7 ± 4.1% growth inhibition of the BSF
parasite and an IC50 for TbHK1 inhibition of 4.0 ± 0.20 µM. Modulation to a propyl
group (II-1c) at that position led to a moderately lower IC50 value against the hexokinase
(3.6 ± 0.12 µM) and a reduced BSF growth inhibition (52.6 ± 9.5%). A derivative
bearing an isopropyl group (II-1d) led to a TbHK1 IC50 of 7.1 ± 0.47 µM and a BSF
percent growth inhibition of 54.9 ± 4.2%. Substitution of the tert-butyl aryl group on II-1
with a 1,2,3,4-tetrahydronapthenyl moiety (II-1e) increased the TbHK1 IC50 to 9.9 ± 0.64
µM with a BSF percent growth inhibition of 82.1 ± 2.3%. After this screening, it was
determined that a tert-butyl aryl group was the most tolerable and demonstrated the
highest potency against TbHK1.9-12
Replacement of the carboxylic acid in II-1 with a bioisostere, such as tetrazole
(II-1f in Table 2.1), displayed a TbHK IC50 of 5.2 ± 0.14 µM and a BSF percent growth
inhibition of 40.7 ± 17.1%. Although the tetrazole (II-1f) was potent, the carboxylic acid
was optimal in achieving high potency against both the enzyme and the BSF parasite.
Substitution of the bromine in II-1 with a fluorine (II-1g) or chlorine (II-1h) lead to
higher IC50 values of 2.79 ± 0.098 µM and 1.36 ± 0.06 µM, respectively. Although the
bromine correlated to a good single-digit micromolar enzyme inhibition, substitution of
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the halide with an aryl group did increase its ability as a potent BSF trypanocide as is
evidenced by the low %BSF inhibition for II-1g of 32 ± 11% and for II-1h of 35 ± 11%
in Table 2.1. Substitution of the bromine in II-1 with phenyl (II-1i), 2-hydroxyphenyl
(II-1j), and 2-methoxyphenyl (II-1k) groups demonstrated 84.1 ± 0.1%, 96.2 ± 0.51%,
and 83.3 ± 0.67% percent inhibition of rTbHK1, respectively. In addition, the phenyl
analog II-1i exhibited an IC50 of 0.28 ± 0.002 µM against rTbHK1 (isolated from E.
coli). Preliminary studies of the aryl-substituted analogues of II-1 showed that this
molecular class exhibits greater than 80% inhibition of rTbHK1 at 10 µM. Furthermore,
the phenyl (II-1i), 2-hydroxyphenyl (II-1j), and 2-methoxyphenyl (II-1k) substituted
analogues of II-1 demonstrated 95.4 ± 0.83%, 28.4 ± 7.8%, and 90.7 ± 0.93% percent
growth inhibition of whole cell trypanosomes, respectively.9-12 A BSF LD50 of 2.0 ± 0.22
µM was determined for II-1k. Substitution with a 4-fluoro-phenyl (II-1l) or 4-chlorophenyl (II-1m) group displayed a TbHK1 percent inhibition of 27.5 ± 6.0% and 30.3
± 2.7%, respectively, and a percent growth inhibition of the BSF parasite of 82.2 ± 13.9%
and 76.7 ± 10.4%, respectively at 10 µM concentration. Substitution of the bromine on
II-1 with a 4-trifluoromethyl-arene (II-1n) afforded a lower inhibition of TbHK1 (15.9 ±
2.8%) with a high inhibition of the BSF parasite (93.6 ± 0.41%).9-12 A BSF LD50 was
determined for II-1n of 1.3 ± 0.1 µM. Substitution of the bromine on II-1 for an electronwithdrawing 4-nitro-arene group (II-1o) showed moderate activity against TbHK1
(66.1 ± 8.4%) and good inhibition of the BSF parasite (83.8 ± 4.0%).9-12 This
demonstrates that an electron-withdrawing group installed in the location of the bromine
on II-1 serves to inhibit BSF trypanosomes to a high degree, but demonstrates low
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inhibition of the enzyme, TbHK1, possibly due to off-target effects. Furthermore, the use
of another electron-withdrawing group, 4-carboxyphenyl (II-1p), in place of the bromine
in II-1 increased the TbHK1 percent inhibition to 93.6 ± 2.8% with an IC50 of 3.5 ± 0.33
µM with a BSF parasite percent growth inhibition of 51.0 ± 14.3%.9-12 The substitution
with a 4-carboxyarene group was of greater interest toward this thesis work as it allows
us to incorporate a peroxisomal targeting sequence (PTS) on the BABA scaffold, which
will now be explained in greater detail.
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Cl

Cl

Br

X

O

O
N
H

N
H
HO

O

HN
N
N N
II-1f
TbHK1 IC 50 = 5.2 ± 0.14 µM
%BSF inhibit. = 40.7 ± 17.1%

Y

II-1 (for X = Br and Y = t-Bu)

Entry

X=

Y=

%TbHK1 inhibit.

TbHK1 IC 50 (µM)

%BSF inhibit.

II-1a

Br

ethyl ether

-

4.8 ± 0.38 µM

64.1 ± 3.8%

II-1b

Br

ethyl

-

4.0 ± 0.20 µM

68.7 ± 4.1%

II-1c

Br

propyl

-

3.6 ± 0.12 µM

52.6 ± 9.5%

II-1d

Br

isopropyl

-

7.1 ± 0.47 µM

54.9 ± 4.2%

II-1e

Br

1,2,3,4tetrahydronapthenyl

-

9.9 ± 0.64 µM

82.1 ± 2.3%

II-1g

F

tert-butyl

-

2.79 ± 0.098 µM

32 ± 11%

II-1h

Cl

tert-butyl

-

1.36 ± 0.06 µM

35 ± 11%

II-1i

phenyl

tert-butyl

84.1 ± 0.1%

0.28 ± 0.002 µM

81.4 ± 5.6%

II-1j

2-hydroxy-phenyl

tert-butyl

96.2 ± 0.51%

1.2 ± 0.1 µM

28.4 ± 7.8%

II-1k

2-methoxy-phenyl

tert-butyl

83.3 ± 0.67%

4.6 ± 0.32 µM

90.7 ± 0.93%

II-1l

4-F-phenyl

tert-butyl

30.3 ± 2.7%

-

76.7 ± 10.4%

II-1m

4-Cl-phenyl

tert-butyl

27.5 ± 6.0%

-

82.2 ± 13.9%

II-1n

4-CF3-phenyl

tert-butyl

15.9 ± 2.8%

-

93.6 ± 0.41%

II-1o

4-nitro-phenyl

tert-butyl

66.1 ± 8.4%

-

83.8 ± 4.0%

II-1p

4-carboxy-phenyl

tert-butyl

93.6 ± 2.8%

3.5 ± 0.33 µM

51.0 ± 14.3%

Table 2.1: SAR data for substituted analogues of II-1.

Based on the preliminary results from the SAR (described above), we endeavored
to synthesize a novel BABA drug candidate (Scheme 2.1). The goal in this chapter was to
synthesize a BABA derivative that demonstrated potency against TbHK1, but that also
would demonstrable potency against the parasite. The BABA analogues described above
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were potent enzyme inhibitors, but many were ultimately weakly active against BSF
trypanosomes. The goal of this thesis work was to use this potency against TbHK1 and to
translate it into a species that was equally trypanocidal. Our method for accomplishing
this task was to incorporate a peptide-based peroxisomal targeting sequence (PTS)
scaffold using Solid Phase Peptide Synthesis (or SPPS; described in Chapter One Section
1.2) similar to the strategy employed for the enhancement of the Ebselen drug suite.13-15
Previously, the Morris and Christensen groups validated the use of a PTS attached to a
fluorescent dye (fluorescein isothiocyanate [FITC]) in carrying molecular cargo to the
glycosomal compartment of the trypanosomes.8 We wanted to use a similar strategy to
incorporate our BABA derivatives by first installing a PTS to a tether that was ultimately
capped with the desired BABA drug candidate.
Based on the results of the SAR and the data related to II-1 as indicated in Figure
2.1, we envisioned a BABA analog that had three key components: a tert-butyl benzamide
group, an aryl chloride, and a carboxylic acid ortho to the benzamide group.9-12 However,
the carboxylic acid on II-1, as well as its arylated analogues, was the therapeutically
active residue. Therefore, we referred to the SAR to develop a strategy by which we
could install another carboxylic acid for the selective incorporation of a peptidic scaffold
(that is, the PTS1). We envisioned that because the 4-carboxyarene substitution for
bromine in II-1 was tolerated with respect to enzyme inhibition, we could substitute the
bromine with a carboxyarene functionality that would possess a carboxylic acid
(highlighted in blue in Scheme 2.1) to which a peptide sequence could be attached while
maintaining the therapeutically relevant distal benzoic acid . The therapeutically relevant
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carboxylic acid (highlighted in green in Scheme 2.1) would remain masked as a methyl
ester until such time where it could be saponified to reveal the desired, active functional
group. A more detailed synthetic outline can be found in Section 2.3.
Furthermore, upon analyzing II-1, we discovered additional synthetic challenges
that would provide two additional locations to which a peptide scaffold could be attached.
First, we envisioned replacing the tert-butyl group on II-1 with a carboxylic acid to
incorporate a peptide bond (highlighted in red in Scheme 2.1). Additionally, we could
directly attach a peptidic scaffold to the therapeutically active carboxylic acid on II-1
highlighted green in Scheme 2.1 to evaluate the effectiveness of II-1 when the
therapeutically active carboxylic acid is capped with the peptidic marker. With the
synthetic targets established, we decided to make peptidic scaffolds possessing a PTS1 to
target the molecular cargo to the glycosomal compartment where the glycolytic
machinery, i.e. TbHK1, is housed. As was the case with the Ebselen strategy reported in
Chapter One, our PTS1 in this work consisted of C-LKA-N. Our tether with respect to the
PTS1-BABA conjugates was either a diglycine or a diethylene glycol tether.
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HO

O

BABA
%TbHK1 inhibition = 93.6 ± 2.8%
TbHK1 IC 50 = 3.5 ± 0.33 µM
%BSF inhibition = 51.0 ± 14.3

II-1
TbHK1 IC 50 = 0.98 ± 0.067 µM
%BSF inhibition = 6.9 ± 3.0%

Scheme 2.1: On the right is II-1 to which a carboxyarene could be appended in lieu of the bromine to
allow for the incorporation of a peptide (carboxylic acid of interest is highlighted in blue). Note that the
tert-butyl group (highlighted red) on II-1 could also be replaced with a carboxylic acid to form another
BABA analog that would allow for incorporation of a peptide bond in that position. Although the
carboxylic acid highlighted in green is the therapeutically active residue in II-1, as well as BABA, we
envisioned attaching a peptidic scaffold to the carboxylic acid on II-1. On the left are two of the
peptidic scaffolds that were envisioned for coupling to the synthesized BABA derivatives bearing either
a diglycine or diethylene glycol tether with a PTS1 consisting of C-LKA-N.

We hoped that conjugation to a PTS would direct the molecular cargo to the
glycosome where the kinase (TbHK1) is housed. We also wanted to make use of a
fluorophore, FITC, to visualize distribution of our PTS1-BABA conjugates into the
trypanosome (Scheme 2.1). This will be described in greater detail in Section 2.3.2. This
would allow us to accomplish two major goals. The first is synthesizing and evaluating a
highly potent enzyme inhibitor, identified by a low, single-digit, micromolar IC50, that is
also equally highly trypanocidal. The second is gaining a better understanding of the
mechanism of action regarding both the PTS1 in its role in allowing passage of molecular
cargo beyond the trypanosomal membrane toward the glycosomal machinery in the
parasite and the BABA drug suite. Although the work by Morris and Christensen
demonstrated uptake of a fluorophore-conjugated PTS1, it is not well understood how the
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PTS1 operates nor do we understand how the BABA drug suite (without the PTS1) can
exhibit high potency against TbHK1 and BSF trypanosomes. We also do not understand
what role, if any, the tether plays in allowing passage of PTS-drug conjugate across the
trypanosome membrane. Our hope was that the work reported herein would allow for the
synthesis of a highly potent BABA analog that, when coupled to a PTS, will exhibit high
potency against TbHK1 and will act as a potent BSF trypanocide while also allowing for
visualization of the PTS1-BABA peptide in the trypanosome through incorporation of a
fluorescent dye (FITC). With a positive implementation of the PTS1-BABA drug delivery
strategy, we can begin to formulate an in vivo drug strategy that overcomes the drug
toxicity issues reported with the use of melarsoprol and eflornithine (see Chapter One).16
The results of our synthetic efforts are described below in detail, followed by a discussion
of the potential to extend our work toward other neglected diseases caused by the
Trypanosomatidae family, including Chagas disease and Leishmaniasis, mentioned in the
Conclusions for this chapter of the thesis work.16
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Scheme 2.2: In order to visualize delivery of the PTS1-BABA conjugates in the trypanosome, we
envisioned coupling FITC to the PTS1 on two peptide conjugates shown on the right. We also envisioned
producing a PTS1-BABA conjugate wherein the fluorescent dye was installed adjacent to the PTS1 using
a lysine-glycine tether, rather than a diglycine tether.

2.2

RESULTS AND DISCUSSION

2.2.1

COMPLETED BABA SYNTHESES
A retrosynthetic analysis of the desired novel benzamidobenzoic acid candidate is

shown in Figure 2.2. It was envisioned that a halogenated aniline derivative II-3 or II-4
could be coupled to a variety of boronic acids II-2 by means of Suzuki coupling, thus
revealing a biaryl aniline derivative II-5. Following the initial Suzuki coupling, an
acylation with 4-tert-butyl benzoic acid II-6 would reveal a bis-ester BABA candidate II7. Selective cleavage of one ester in II-7 would reveal the desired BABA candidate II-8,
primed for coupling with the requisite peptide sequence by means of conventional SPPS.
Desired BABA candidate II-8 was conjugated to a peptidic scaffold via SPPS to afford
PTS1-conjugated BABA methyl ester II-9a. This methyl ester was then saponified with
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aqueous lithium hydroxide to afford PTS-BABA acid II-9b with the therapeutically potent
carboxylic acid revealed. PTS1-BABA-methyl ester II-9a and PTS1-BABA-acid II-9b
were subsequently evaluated against TbHK1 and BSF trypanosomes through an in vitro
assay.

O

PTS

Cl
OMe
O

NH

Y = CO 2tBu, CO 2Me, CO 2Bn

O

Y
HO

II-9a

O

Y

O

Y

O

O

II-2
HO
Cl

PTS

Cl

O
O

NH

O
II-8

Cl

OCH3
O

NH

O
II-7

OCH3
NH 2 O
+
HO

NH

X
Cl

II-5

OCH3
NH 2 O

O

X = Br (II-3)
X = I (II-4)

OH
O

OH

+

Cl

OCH3

B

O
II-6
II-9b

Figure 2.2: Retrosynthetic analysis of successful synthetic strategy affording desired BABA methyl ester
II-8 (outlined in detail below) and PTS1-BABA conjugates II-9a and II-9b.

Since the carboxylic acid moiety on the central tetra-substituted arene is required
for activity against the enzyme, we desired to protect it as an ester derivative while
leveraging the distal carboxylic acid to facilitate the incorporation of the linker-PTS1
sequence by SPPS.13-15 As is evident in the retrosynthesis depicted in Figure 2.2, we
ultimately employed a methyl ester to protect the pharmacologically relevant carboxylate.
Nonetheless, we initially targeted the more readily removable t-butyl protecting group,
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since that moiety would cleave during the final acid-mediated resin cleavage step of the
SPPS incorporation of the PTS1-linker peptide.12-14
Thus, our initial forays into the synthesis of a BABA candidate of PTS
modification targeted the t-butyl ester analog of methyl ester II-8. These synthetic efforts
started with the bromination of methyl 2-amino-4-chloro benzoate II-10 (Scheme 2.3).18
Similar to brominated aniline derivative II-3, iodinated aniline derivative II-4 could be
obtained in quantitative yield via a shorter reaction with ease of purification that could
subsequently be used in the Suzuki couplings and acylation reactions described herein
with great success.17 The brominated aniline derivative II-3 (isolated in 94% yield) was
then acylated with 4-tert-butyl-benzoic acid to provide II-11 in 39% yield. Hydrolysis of
the methyl ester afforded a carboxylic acid II-1 in 81% yield).18,19
I
Cl
OCH3

I 2 (5.7 eq)
Ag2SO 4 (5.7 eq)

Cl

Absolute ethanol (0.05-0.1 M),
45 m, rt

NH 2 O
II-4

~100%

Br
OCH3

N-bromosuccinimide
(1 eq)

NH 2 O

Cl
OCH3

Acetic Acid, o/n, rt
NH 2 O

94%

II-10

II-3
Br

Br

Cl

Br

Cl

Cl

OCH3
OCH3
NH 2 O

II-3

4-t-butyl benzoyl chloride (1.1 eq)
triethylamine (2.0 eq)

O

DCM, rt, o/n

NH

OH

O

1 M LiOH (1 eq)

II-11

THF (25 mL), rt, 48 h

O

NH

O

II-1

81%

39%

Scheme 2.3: Bromination of 2-amino-4-chloro-methyl benzoate (II-10), followed by acylation and
hydrolysis of II-3. The synthesis of iodinated derivative II-4 also shown. Both II-3 and II-4 were used in
17-19
subsequent reactions with similar results.
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The difficulty following this protocol was in the subsequent esterification of
carboxylic acid II-1 to the desired tert-butyl ester II-12. Repeated attempts to effect the
transformation failed. One possible difficulty might arise due to the potential for
intramolecular hydrogen bonding that could activate the desired ester product toward
facile hydrolysis after formation (Scheme 2.4, dashed box). The initial esterification
attempt involved reaction with thionyl chloride to generate the acyl chloride intermediate
followed by nucleophilic displacement with tert-butyl alcohol. Unfortunately, this route
failed to provide the desired tert-butyl ester. Two different sources of the nucleophile,
tert-butyl alcohol or potassium tert-butoxide, were investigated for this method, but the
transformation was unsuccessful.20 Attempts at a Steglich esterification, promoted by a
carbodiimide (e.g. EDC), and a routine Fischer esterification were also unsuccessful.21
Ultimately, the synthesis of an acyl imidazole via reaction with carbonyl diimidazole,
followed by nucleophilic displacement with tert-butyl alcohol was successful.22
Nevertheless, the resultant tert-butyl ester was unstable toward standard organic
purification methods, such as column chromatography. A column was necessary due to
the failure of both recrystallization and extraction to separate the desired, clean tert-butyl
ester II-12 from carboxylic acid II-1. The tert-butyl ester II-12 was sensitive to the
relatively acidic silica gel, unless otherwise doped with eight percent triethylamine. An
alumina column was successful; however, the change in stationary phase led to
significant product loss. Ultimately, the product was obtained in only 17% yield after the
triethylamine-saturated silica gel column and less than 10% yield after the alumina oxide
column.
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i) thionyl chloride (excess)
triethylamine (1.5 eq)
DCM, 0 ˚C, 30 m
ii) tert-butyl alcohol (2 eq)
triethylamine (1.5 eq)
DCM, 0 ˚C to reflux
i) thionyl chloride (excess)
triethylamine (1.5 eq)
DCM, 0 ˚C, 30 m
ii) potassium tert-butoxide
(1.1 eq)
triethylamine (1.5 eq)
DCM, 0 ˚C to reflux

Br

Br

Cl

Cl

OH

O
O

N

O

O

NH

H

O

i) carbonyl diimidazole
(1.0 eq)
DMF, 1 h, 80 ˚C

Br
Cl
Ot-Bu
O

NH

O

ii) tert-butyl alcohol (2.0 eq)
DBU (1.0 eq)
DMF, 24 h, 80 ˚C
17%
II-1

DCC (1.0 eq)
DMAP (0.05 eq)
tert-butyl alcohol (1.2 eq)

II-12

DCM, rt, overnight
20-22

Scheme 2.4: Several methods for the esterification of carboxylic acid II-1 were attempted.
Intramolecular hydrogen-bond framework emphasized in left-most figure.

Despite the difficulties encountered for its synthesis, tert-butyl ester II-12 was
subjected to Suzuki coupling conditions. Based on our retrosynthetic analysis, the Suzuki
coupling of II-12 would facilitate the incorporation of a third aryl ring bearing a
carboxylic acid, thus incorporating the carboxylic acid handle that would allow us to
couple a PTS1 peptide sequence to the BABA candidate via SPPS (refer to Figure 2.2).
The Suzuki coupling of II-12 was first attempted under basic conditions catalyzed by
[1,1’-bis(di-tert-butylphosphino)ferrocene] dichloropalladium (II) [PdCl2(dtbpf)] in the
presence of 4-carboxyphenylboronic acid, either heated under conventional reflux
conditions or by means of microwave irradiation (Scheme 2.5). Both methods led to the
decomposition of starting material and a failure to isolate desired product II-13. The
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decomposition was monitored via NMR in which the loss of the benzamide functional
group was observed to afford the starting benzoic acid and tert-butyl ester II-12, which
had been hydrolyzed to the starting acid II-1. Given the significant difficulties
encountered in the preparation of II-12, and its failure to engage productively in the
subsequent Suzuki coupling, our approach was altered to operate with a methyl ester
protecting group in lieu of the problematic tert-butyl ester, as the former is also labile
under specific deprotection conditions in SPPS.23
HO

O

Br
Cl

O

NH

Cl
4-carboxyphenyl boronic acid
(1.2
eq)
OtBu
PdCl 2(dtbpf) (2 mol%)
K 2CO3 (1.5 eq)
O
O

II-12

6:4 acetonitrile:H2O
reflux, 24 h

Ot-Bu
NH

O
II-13

18

Scheme 2.5: Suzuki coupling of tert-butyl ester II-12 and 4-carboxyphenylboronic acid. Carboxylic
acid highlighted red to emphasize functionality required for SPPS; ester highlighted blue to emphasize
masked carboxylic acid that will be revealed post-SPPS.

It was thought that the Suzuki coupling of II-11, conducted under the
aforementioned

conditions,

with

either

4-carboxyphenylboronic

acid

or

4-

methoxycarbonylphenylboronic acid would afford II-14 (Scheme 2.6). Nevertheless, the
high content of water in the standard reaction protocol (~40%) led to the undesirable
hydrolysis of the ester situated ortho to the amide, rendering the reaction intractable.
Several examples are provided in the literature of Suzuki couplings between halogenated
aniline derivatives and boronic acids in acetonitrile mixtures containing ~10-20%
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water.24 The Suzuki coupling between II-11 and 4-carboxyphenylboronic acid still
suffered significant side reactions after the amount of water was decreased according to
literature precedents. Nonetheless, the Suzuki coupling between II-11 and 4methoxycarbonylphenylboronic acid was successful in the installation of the third aryl
ring (Scheme 2.6). Unfortunately, after careful NMR studies, it was revealed that, even
after employing decreased water content in the reaction, the ester positioned ortho to the
amide was hydrolyzed (i.e. II-15 in Scheme 2.6 obtained in 55% yield). It is possible that
this hydrolysis might be promoted by the internal stability afforded by the ortho
positioning of the carboxylic acid relative to the amide analogous to the labile t-butyl
ester depicted in dashed box of Scheme 2.4. To address this problem, the order of
operations in the synthesis was rearranged to account for the sensitivity of the ester
during the Suzuki coupling.
R = OH,
OMe
H 3CO

H 3CO

O

R

O

O

R

O

Br
Cl

HO
OH

O

NH

O
II-15

B

Cl
OH

(1.2 eq)
PdCl 2(dtbpf) (2 mol%)
K 2CO3 (1.5 eq)

OMe
II-11 O

NH

O

HO

B

OH

(1.2 eq)
PdCl 2(dtbpf) (2 mol%)
K 2CO3 (1.5 eq)
6:4 acetonitrile:H2O
reflux, 24-48 h

9:1 acetonitrile:H2O
reflux, 24-48 h

Cl
OMe
O

NH

O
II-7

55%

Scheme 2.6: Failed Suzuki coupling between II-11 and 4-carboxy- or 4-methoxycarbonylphenylboronic acid (top). Suzuki coupling between II-11 and 4-methoxycarbonylphenyl boronic acid
18,24
was successful in adding third aryl ring, but hydrolyzed methyl ester ortho to amide (bottom).
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Accordingly, the Suzuki coupling was attempted on the brominated aniline
derivative II-3 (Scheme 2.7). This proved to be a much more facile method for the
incorporation of the second aryl system bearing the carboxylic acid that would be needed
for SPPS. The aniline derivative II-3 could be coupled to either 4-carboxyphenylboronic
acid or 4-methoxycarbonylphenylboronic acid in moderate yields affording II-16 and II17, respectively, albeit at prolonged reaction times. Thionyl chloride was reacted with 4tert-butyl benzoic acid to provide the acyl chloride that was used in the acylation of II-16
and II-17 in the presence of triethylamine (Scheme 2.7). Aniline derivative II-16 was
unreactive toward acylation, possibly due to the formation of a zwitterion that masks the
nucleophilic amine as an ammonium ion that is rendered unreactive under the acylation
conditions in Scheme 2.8. Dissolution of II-16 in pyridine, in the hopes that the base
would reveal the nucleophilic amine, followed by acylation with 4-tert-butyl benzoyl
chloride (Scheme 2.8) also did not provide product II-8. The acylation of methyl ester II17 was successful in a moderate 34% yield; however, there was no readily available
method for the necessary, selective monohydrolysis of the resultant diester II-18
(Scheme 2.8).
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O
4-methoxycarbonylphenyl boronic acid
(1.2 mmol)
PdCl 2(dtbpf) (2 mol%)
Cl
K 2CO3 (1.5 eq)
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OCH3
NH 2 O
II-17

OCH3

9:1 acetonitrile:H2O
reflux, 72 h
35%

4-carboxyphenyl boronic acid
(1.2 eq)
PdCl 2(dtbpf) (2 mol%)
K 2CO3 (1.5 eq)

Cl
OCH3

9:1 acetonitrile:H2O
reflux, 72 h
43%

NH 2 O
II-3

NH 2 O
II-16

Scheme 2.7: Suzuki coupling of II-3 with 4-carboxyphenylboronic acid (affording II-16) and 418,24
methoxycarbonylphenylboronic acid (affording II-17).
Possible zwitterion of II-8
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HO

O
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OCH3
O

NH 2 O
II-16
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Triethylamine (0.75 eq)
DCM, 0 ˚C to rt

DCM, 0 ˚C to rt
34%

Cl
OCH3
O

NH

O
II-8

Scheme 2.8: Acylation of II-16 and II-17 with 4-tert-butyl benzoyl chloride (II-6).18

An alternative route involving the deprotonation of II-16 with n-butyl lithium
followed by attempted acylation with 4-tert-butyl benzoyl chloride was also unsuccessful
(Scheme 2.9). Under these conditions, the 4-tert-butyl benzoyl group was successfully
installed, but the methyl ester ortho to the amide also suffered alkylation as determined
by NMR analysis.
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Triethylamine (1.5 eq)
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THF, 0 ˚C, 30 m

THF, 0 ˚C to rt

Cl
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O

NH

O

II-8
1 eq

Scheme 2.9: Alternative method for the acylation of aniline derivative II-16 with 4-tert-butyl benzoyl
18
chloride.

The next plan was to use 4-benzyloxycarbonylphenylboronic acid in the Suzuki
coupling, as benzyl groups are common protecting groups in organic transformations that
can often be removed by means of hydrogenolysis under neutral conditions (Scheme
2.10). The Suzuki coupling followed the aforementioned protocol represented in Scheme
2.7 and afforded benzyl ester II-19 in 46% isolated yield. The acylation followed the
same protocol depicted in Scheme 2.8, with refluxing of the reaction mixture being
necessary, and afforded II-20 in 28% yield. Stirring of II-20 with palladium on carbon at
ambient temperature under a hydrogen gas atmosphere yielded a product that, after
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several days, had not only lost the benzyl group, but had also lost the chlorine that is a
critical element for therapeutic activity (Figure 2.1).6,9-12 Hydrogen gas was proven to be
an ineffective means for cleavage of the benzyl ester. Another method for cleavage of
benzyl ester II-20 at ambient temperature with chlorotrimethylsilane and sodium iodide
was also ineffective, but did allow for recovery of II-20.25-27
Ph
O

Br
Cl
OCH3
NH 2 O

Cl

9:1 acetonitrile:H2O
reflux, 72 h

II-3

OCH3

46%

NH 2 O
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Cl
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SOCl2 (1.1 eq)
NEt 3 (1.5 eq)
DCM, 0 ˚C, 30 m

II-6

II-19
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O

O

O

4-phenoxycarbonylphenyl boronic acid
(1.2 eq)
PdCl 2(dtbpf) (2 mol%)
K 2CO 3 (1.5 eq)

II-19
OCH3

O

Cl

Cl

NH 2 O
1 eq
NEt 3 (1.5 eq)
DCM, 0 ˚C to
reflux, overnight

HO

O

OCH3

OCH3
O

NH

Pd/C (5 mol %)/H2

O
II-20

O

NH

O

MeOH, rt
II-8

28%

Scheme 2.10: Suzuki coupling of II-3 with 4-benzyloxycarbonylphenylboronic acid yielding II-19;
acylation of II-19 with 4-tert-butyl benzoyl chloride (II-6); deprotection of II-20 with hydrogen gas
6,9-12,17,18,24-27
and palladium on carbon.

As 4-methylcarbonylphenylboronic acid and 4-benzyloxycarbonylphenylboronic
acid were ineffective options, another route incorporating a tert-butyl ester was
discovered

(Scheme

2.11).

Using

commercially

available

4-tert-

butyloxycarbonylphenylboronic acid in the Suzuki coupling with iodinated aniline
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derivative II-4 afforded tert-butyl aniline derivative II-21 in 96% yield. The aniline
derivative II-21 was then slowly added to an ice-cold mixture of freshly prepared 4-tertbutylbenzoyl chloride and triethylamine. After purification, the transformation afforded
the desired tert-butyl ester BABA candidate II-22 in 54% yield. Deprotection of the tertbutyl ester II-22 with trifluoroacetic acid finally afforded the desired BABA drug
candidate II-8 that was ready for SPPS. The BABA drug candidate II-8 could be
saponified with 1 M aqueous lithium hydroxide to afford the BABA diacid II-23 in 84%
yield (as shown in Scheme 2.12).18
t-BuO
I
Cl
OMe

O

4-tert-butyloxycarbonylbenzene boronic acid (1.2 eq)
Pd(dtbpf)Cl 2 (2 mol%)
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Scheme 2.11: Suzuki coupling of II-4 with 4-tert-butyloxycarbonylphenylboronic acid yielding II21; acylation of II-21 with 4-tert-butyl benzoyl chloride to afford bis-ester II-22; deprotection of
6,9-12,17,18,24
II-22 with trifluoroacetic acid.
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Scheme 2.12: Hydrolysis of methyl ester II-8 to diacid II-23.18 Note that II-1p in Table 2.1 is the
same as II-23.

Our synthetic strategy described above appended the peptidic scaffold to a
carboxylic acid on the opposite terminus of the benzamide functional group. This was
thought to be the ideal position based on the results of our SAR of the PTS1-free BABA
derivatives that were evaluated against TbHK1 and the BSF parasite. However, we have
not previously evaluated substitution of the tert-butyl group with an electron-withdrawing
carboxylic acid. Furthermore, this substitution (t-Bu to COOH) merits installation of a
peptidic scaffold, which would be on the opposite terminus when compared to PTS1BABA conjugates II-9a and II-9b. It was thought that this substitution would enhance the
trypanocidal properties of the potent TbHK1 inhibitor, II-1. Using brominated aniline
derivative II-3 in an acylation with the freshly–prepared acyl chloride of terephthalic acid
(II-24) and thionyl chloride led to II-26, in which we installed a carboxylic acid in the
place of a tert-butyl group on II-1 (Scheme 2.13).17,18,19 The methyl ester II-26 was
saponified using 1 M aqueous lithium hydroxide to afford the diacid II-27. Both
compounds were evaluated against TbHK1 and the BSF parasite as were their respective
peptide conjugates.17,18,19
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Scheme 2.13: Acylation of terephthalic acid (II-24) with brominated aniline derivative II-3 affording
17,18,19
II-26 in modest yield. Hydrolysis of II-26 with aqueous lithium hydroxide affords diacid II-27.

2.3

COMPLETED

PEPTIDE

SYNTHESES

AND

DEFINITION

OF

VARIABLES
Next, BABA methyl ester II-8 was coupled to a peptide sequence of C-LKAGG-N
or C-LKA(ethylene glycol)-N using SPPS. The methyl ester was saponified by action of
lithium hydroxide to afford the carboxylic acid of both analogues as shown in Schemes
2.14 (for II-28 and II-29) and 2.15 (for II-30 and II-31). Subsequently, BABA derivative
II-26 was coupled to a PTS1 with a diglycine tether to attach the peptidic scaffold
directly on the benzamide group (for II-32). This derivative was hydrolyzed by action of
lithium hydroxide to afford the therapeutically active carboxylic acid (II-33 in Scheme
2.16). These efforts produced eight PTS1-BABA conjugates (II-28 to II-35) that were
evaluated against both TbHK1 and trypanosomes in whole-cell assays.
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Scheme 2.14: Hydrolysis of PTS1-BABA-diglycine methyl ester II-28 to afford PTS1-BABA9-15,17,18
diglycine carboxylic acid II-29.
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Scheme 2.16: Hydrolysis of PTS1-BABA-diglycine methyl ester of II-32 affording PTS1-BABA-diglycine
9-15,17,18
carboxylic acid II-33.

This screening yielded four results: percent TbHK1 inhibition, percent BSF
growth inhibition, percent cell viability, and BSF EC50. The non-conjugated drugs and
peptide-drug conjugates were screened against TbHK1 and BSF parasites at a standard
concentration of 10 µM (the limit of detection). The rTbHK1 cultures were incubated
with the drug or peptide-drug conjugates with the percent inhibition of the enzyme being
recorded. BSF growth inhibition refers to the cell percentage in a trypanosome culture
that has been affected by either the drug or the peptide-drug conjugate. In contrast,
percent cell viability refers to the trypanosome percent cell survival after exposure to the
drug or peptide-drug conjugate. BSF EC50 refers to a measure of drug or peptide-drug
conjugate potency against trypanosomes over a specified exposure period.
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2.3.1

EVALUATION OF PTS1-CONJUGATED BABA CONJUGATES
The synthesis of the peptide-conjugated BABA derivatives followed the general

method illustrated in Scheme 1.7 in Chapter One.9-15,28,29 Figure 2.3 shows the
synthesized BABA peptide-drug derivatives that were screened against TbHK1 and whole
cell BSF trypanosomes (II-28 to II-35). The data concerning the non-conjugated BABA
derivatives and the peptide-conjugated BABA derivatives is described in detail below.
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The BABA diacid II-23 elicited a 93.6 ± 2.8% inhibition of TbHK1.6,9-12 In
comparison, the diesters II-18, II-20, and II-22 did not show any TbHK1 inhibition at 10
µM. The monoacid BABA candidate II-8 inhibited TbHK1 by 32.42 ± 17.3% at 10 µM.
This result demonstrates that the presence of a para-carboxyphenyl moiety (required for
peptide conjugation) does not appreciably affect the activity of the drug scaffold against
the hexokinase; however, esterification of the carboxylic acid adjacent on the tetrasubstituted arene does have a strong effect in decreasing activity against the enzyme.
Esterification of this carboxylic acid, as in II-18, II-20, and II-22, eliminated potency
against the enzyme. PTS1-BABA-methyl ester II-28 was ineffective against TbHK1,
while its acid analog II-29 displayed a 26.33 ± 3.77% TbHK1 inhibition. Replacing the
diglycine tether with a diethylene glycol tether afforded conjugate II-30 with a 10.49 ±
3.55% TbHK1 inhibition. Hydrolysis of ester II-30 led to conjugate II-31 with a 67.52
± 4.60% TbHK1 inhibition. This data shows that the diethylene glycol tether in
conjunction with the therapeutically potent carboxylic acid positioned ortho to the amide
tert-butyl benzoyl group enhances potency against TbHK1.
Coupling of II-1 to the PTS1 with a diglycine tether did not yield any activity
against the enzyme (II-34). Furthermore, conjugation of the BABA scaffold directly to the
PTS sequence without an intervening linker region (i.e. peptide-drug conjugate II-35) led
to poor inhibition of TbHK1 at 10 µM (10.23 ± 0.27%). ML205 derivative II-26 was
generated via substitution of the tert-butyl group with a carboxylic acid and exhibited a
7.57 ± 3.99% TbHK1 inhibition. The diacid II-27 displayed a 29.95 ± 29.95% TbHK1
inhibition. As expected from the SAR data, replacement of the tert-butyl group decreased
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potency against TbHK1.6,9-12 While peptide-drug conjugate II-32 exhibited 10.97
± 0.44% TbHK1 inhibition, conjugate II-33 exhibited a TbHK1 inhibition of 15.75
± 12.61% TbHK1 inhibition. This reflects that positioning of the peptidic scaffold off the
benzamide functional group (II-32 and II-33) does not appreciably enhance the activity
of the PTS1-BABA conjugate against TbHK1 when compared to PTS1-BABA conjugate
II-30 and II-31, bearing an ethylene glycol tether (data in Table 2.2). The inhibition of
TbHK1 demonstrated by II-32 is interesting when compared with II-28, bearing a
diglycine tether, which did not display any activity against the enzyme. The activity
against TbHK1 of II-33 was slightly decreased when compared to II-29, bearing a
diglycine tether. A TbHK1 IC50 value of 6.83 ± 0.23 µM was only realized for II-31, the
most potent enzyme-inhibiting PTS1-BABA conjugate.
With respect to BSF growth inhibition, and from the SAR conducted by Morris et
al., the diacid II-23 showed 51.0 ± 14.3% BSF growth inhibition and ML205 displayed
6.9 ± 3.0% BSF growth inhibition. BABA methyl ester II-18 and benzyl ester II-20 had
BSF growth inhibitions of 8.91 ± 12.26% and 9.57 ± 9.73%, respectively. BABA tertbutyl ester II-22 displayed a BSF growth inhibition of 14.81 ± 7.69%. On the other hand,
BABA monoacid II-8 had a BSF growth inhibition of 24.50 ± 6.77%. ML205 (II-1)
derivative II-26 revealed a 29.11 ± 6.08% BSF growth inhibition with its corresponding
diacid II-27 demonstrating a 23.63 ± 1.31% BSF growth inhibition. It is clear based on
this data of the non-conjugated drugs that the most potent candidate in a whole cell assay
against trypanosomes was BABA diacid II-23. ML205 (II-1) derivative II-26 had a
similar potency when compared to II-8 against trypanosomes, while II-27 demonstrated a
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significantly reduced potency in comparison to both II-8 and II-23. This showed that
more potency was achieved by substitution of the bromine on II-1 (Figure 2.1) with a
carboxyphenyl ring, rather than replacement of the tert-butyl group with a carboxylic
acid (data in Table 2.2). Based on these results, both the carboxyphenyl ring and the tertbutyl group are necessary. Peptide-drug conjugates II-28 and II-29 (possessing a
diglycine tether) and II-35 (BABA directly coupled to PTS1) showed 0% BSF growth
inhibition. The most potent analog of all BABA conjugates was II-30 that showed 100%
BSF growth inhibition via substitution of the diglycine tether with a diethylene glycol
tether. The corresponding acid II-31 showed a lower BSF growth inhibition of 38.96
± 11.14%. We hypothesize, based on this result, that PTS1-BABA methyl ester II-30 acts
as a pro-drug (a therapeutic precursor that is metabolized into the active drug within the
cell) that is hydrolyzed within the cell to reveal the active PTS1-BABA acid II-31 that
inhibits TbHK1, though this hypothesis must be confirmed. Peptide-drug conjugates II32 and II-33, wherein PTS1 was attached to the benzamide group, displayed 0% BSF
growth inhibition, indicating that migration of the peptide to the opposite terminus of the
BABA scaffold did not enhance the PTS1-BABA conjugate’s potency. Peptide-drug
conjugate II-34 in which II-1 was directly attached to C-LKAGG-N was not active
against BSF trypanosomes demonstrating 9.97 ± 6.79% BSF growth inhibition. A BSF
EC50 was only detected for one BABA peptide-drug conjugate (C-LKA-diethylene glycolBABA (methyl ester)-N) II-30 (6.76 ± 1.53 µM), with the other samples yielding values
greater than the limit of detection of 10 µM.
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Structure

TbHK1%
inhibition (10
µM)

TbHK1 IC 50
(10 µM)

% BSF Growth
Inhibition (10 µM)

BSF EC 50
(µM)

II-8

32.42 ± 17.30

22.95 ± 11.81

24.50 ± 6.77

>10

II-18

0

>10

8.91 ± 12.26

>10

II-20

0

>10

9.57 ± 9.73

>10

II-22

0

>10

14.81 ± 7.69

>10

II-23

93.60 ± 2.80

3.50 ± 0.33

51.00 ± 14.30

-

II-26

7.57 ± 3.99

>10

29.11 ± 6.08

>10

II-27

29.95 ± 6.63

>10

23.63 ± 1.31

>10

II-28

0

>10

0

>10

II-29

26.33 ± 3.77

>10

0

>10

II-30

10.49 ± 3.55

>10

100

6.76 ± 1.53

II-31

67.52 ± 4.60

6.83 ± 0.23

38.96 ± 11.14

>10

II-32

10.97 ± 0.44

>10

0

>10

II-33

15.75 ± 12.61

>10

0

>10

II-34

0

>10

9.97 ± 6.79

>10

II-35

10.23 ± 0.27

>10

0

>10

Table 2.2: Biological data on BABA derivatives and PTS1-BABA peptide conjugates.

2.3.2

FITC-COUPLED PTS1-BABA PEPTIDE CONJUGATES
Additional peptide conjugates were prepared bearing a fluorophore to

demonstrate localization of our most potent peptide conjugates within the trypanosome,
specifically into the glycosome, the organelle where the enzyme of interest, TbHK1, is
housed.6,9-12,28,29 One conjugate (II-36 in Figure 2.4) was prepared in which a
fluorophore, FITC, was attached to the PTS1 with a diglycine linker and II-1 (Figure
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2.4).28,29 Another peptide conjugate (II-37 in Figure 2.4) was prepared in which the FITC
was attached to a lysine residue via replacement of the first glycine in the tether, i.e. the
PTS1 was free of molecular cargo. A control peptide was also synthesized bearing FITC
on the PTS1 and a diglycine tether that was capped with an acetyl group in lieu of II-1.
These peptide conjugates were screened against TbHK1 and BSF trypanosomes (as
shown in Table 2.3). We discovered that greater enzyme inhibition was achieved in
response to a PTS1-FITC-BABA conjugate that was free of molecular cargo on the PTS1
(20.53 ± 10.19% for II-36 compared to 61.0 ± 4.23% for II-37 in Table 2.3). Installation
of FITC adjacent to the PTS1 also demonstrated greater potency against BSF parasites
(29.39 ± 15.9% for II-36 compared to 46.1 ± 10.86% for II-37 in Table 2.3). The control
peptide II-38, bearing FITC on the PTS1 with a diglycine tether capped by an acetyl
group, was ineffective against TbHK1 and BSF trypanosomes. Coupling FITC to our
most potent PTS1-BABA conjugate (II-30) against BSF parasites resulted in a PTS1FITC-BABA conjugate (II-39 in Figure 2.4) that had lost its effectiveness against the
BSF parasite and demonstrated marginal activity against TbHK1 (3.48 ± 1.15%
inhibition).
Use of FITC allowed for visualization of our PTS1-FITC-BABA conjugate within
both procyclic and BSF trypanosomes. Figure 2.5 shows an image of a procyclic
trypanosome (panel A). Panel B in Figure 2.5 shows localization of our PTS1-FITCBABA II-37 in the procyclic trypanosome. Panel C in Figure 2.5 shows the expression of
PTS2-mCherry in the glycosomal compartment of the procyclic trypanosome. mCherry is
expressed as a transgene introduced by electroporation.12 The fusion protein, a PTS-2
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bearing mCherry protein, is targeted, post-synthesis, to the glycosome via assistance from
chaperone proteins.12 Finally, Panel D in Figure 2.5 is a composite image that
demonstrates that our peptide co-localizes with the glycosomal compartment of the
trypanosome where TbHK1 is housed.
As is shown in Figure 2.6, the peptide conjugate II-37 did indeed localize within
the glycosomal compartment of the BSF trypanosomes. The expression of PTS2mCherry in the glycosomal compartment of trypanosomes is evidenced in panel B of
Figure 2.6. The expression of our FITC-conjugated peptide derivative II-37 is shown to
localize within the trypanosomes in panel C in Figure 2.6. Composite images (panels D
and E) demonstrate that our peptide conjugate does in fact localize within the glycosome
of trypanosomes. Although functionalization of the PTS1 with FITC did not hinder entry
of the peptide conjugate within the trypanosome, it was more effective against TbHK1
and the BSF parasite to conjugate the fluorophore adjacent to the PTS1 rather than place
the molecular cargo directly onto the PTS1 (as evidenced by the data presented in Table
2.3).
Conjugation of FITC to our most potent PTS1-BABA conjugate (II-30) afforded
PTS1-FITC-BABA conjugate II-39, which showed a complete loss of activity toward the
inhibition of BSF trypanosomes (Figure 2.7). The expression of PTS2-mCherry in the
glycosome of procyclic and BSF trypanosomes is evidenced in panels B and F,
respectively. The expression of our FITC-conjugated peptide derivative II-39 is shown to
localize within the trypanosomes in panel C (procyclic trypanosomes) and panel G (BSF
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trypanosomes). Composite images (panels D and H) demonstrate that our peptide
conjugate localizes within the glycosome of trypanosomes.
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Figure 2.4: Peptide conjugates prepared bearing FITC to identify localization within glycosomal
28,29
compartment of trypanosomes.

Structure

TbHK1% inhibition
(10 µM)

TbHK1 IC 50 (10
µM)

% BSF Growth
Inhibition (10 µM)

BSF EC 50
(µM)

II-36

20.53 ± 10.19

>10

29.39 ± 15.9

>10

II-37

61.0 ± 4.2

4.26 ± 0.77

46.1 ± 10.86

>10

II-38

0

>10

0

>10

II-39

3.48 ± 1.15

>10

0

>10

Table 2.3: Biological data for FITC-tagged peptide conjugates.
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procyclic T. brucei. (B) Green fluorescent PTS1-FITC-BABA conjugate II-37 localized into glycosomes.
(C) PTS2-mCherry localized into glycosomes (D) Merged images of B and C.
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2.4

CONCLUSIONS AND FUTURE DIRECTIONS
Trypanosomes are highly virulent parasites that are responsible for HAT, a

disease that has the potential to affect a large population of people in sub-Saharan Africa.
BABA is a novel therapeutic scaffold that has been shown to be potent against TbHK1
and trypanosomes through a SAR by Sharlow, et al.6,9-12 This portion of the thesis work
detailed the synthesis of a variety of novel, esterified BABA derivatives (II-18, II-20, and
II-22), as well as a novel BABA derivative II-8, followed by a discussion of a library of
novel PTS1-BABA conjugates that were screened against both TbHK1 and BSF
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trypanosomes. In contrast to our work with the Ebselen drug suite as discussed in Chapter
One, our results with the BABA drug suite indicate a positive result with respect to our
hypothesis for the targeted delivery of our therapeutic across the trypanosome membrane
toward the glycosome where the TbHK1 is house via utilization of PTS1. We conjugated
our BABA derivative to the PTS1 using a diglycine tether and were not able to detect
marginal activity against the enzyme (II-28 in Table 2.2) and we did not detect any
activity against the BSF parasite (II-29 in Table 2.2). Appending the peptidic scaffold to
the benzamide group did not improve this result (II-32 and II-33 in Table 2.2).
Amazingly, substitution of the tether with the more polar diethylene glycol species
enhanced the potency of the PTS1-BABA conjugate through complete inhibition of the
BSF parasites (II-30 in Table 2.2). The conjugate acid of this PTS1-BABA conjugate (II31 in Table 2.2) demonstrated a high degree of TbHK1 inhibition. It is hypothesized that
PTS1-BABA methyl ester II-30 acts as a pro-drug and is metabolized by the trypanosome
into the active PTS1-BABA acid II-31 within the cell. It is also thought that perhaps the
PTS1-BABA peptide is metabolized as soon as it crosses the trypanosome membrane to
release the BABA therapeutic in the trypanosome. The PTS1 in this scenario merely acts
as a carrier to facilitate passage of BABA across the trypanosome membrane. A
combination of FITC on the PTS1 and Alexa Fluor 647 positioned on either the tether or
the BABA drug candidate may allow us to validate this claim and allow for the
visualization of the decomposition of the peptide within the parasite, if that is the mode
by which the drug is being introduced to the BSF trypanosome. If the whole PTS1-BABA
conjugate is being delivered to the glycosomal compartment of the trypanosome, no
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fluorescence would be observed due to quenching of the two fluorescent markers. If the
PTS1 is being cleaved from the BABA therapeutic, fluorescence of either one or both
fluorescent markers would be observed. The most important result from this thesis work
is the demonstration of a drug-delivery strategy based on tagging potent enzyme
inhibitors with a PTS1 sequence that can localize the drug in the appropriate cellular
compartment that may signal the beginning of a novel treatment strategy for patients
suffering from African sleeping sickness.
Another route for modification of this drug suite is use of a different PTS1. The
PTS1 used in the work reported herein is C-LKA-N; however, homologous modifications
might lead to more potent peptide-drug conjugates.13-15 For instance, the leucine can be
replaced with an isoleucine; the lysine can be replaced with an amino acid bearing a basic
side-chain (or acidic at neutral pH), such as asparagine, glutamine, or histidine; and the
alanine can be replaced with a similarly-sized or nonpolar amino acid, such as valine,
cysteine, or serine.13-15 In order to determine the most effective PTS1, a standard tether
(such as diglycine or diethylene glycol) would need to be used to ensure that any change
in potency of the peptide-drug conjugate can be attributed solely to a change in the PTS1.
Our advantageous result with respect to PTS1-BABA conjugates II-30 and II-31
alerts us to the role the tether plays in delivering molecular cargo across the trypanosomal
membrane. The tether could be just as important as the PTS1 and the drug itself;
however, this must be further evaluated with modifications to the tether. Once a potent
PTS1 is determined, then a variety of tethers can be screened to further increase potency
of the peptide-drug conjugate. Two tethers that would make for an interesting study are
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lysine-glycine (used with respect to our PTS1-FITC-BABA conjugates) and triethylene
glycol, a longer version of the successful diethylene glycol tether that was employed with
II-30. Furthermore, one can envision that unnatural amino acids (ones that are not
coded), such as formylmethionine or pyrrolysine, could also be incorporated into the
tether. As fluorine derivatives are prevalent throughout the medicinal chemistry literature,
use of fluorinated amino acids in the tether, such as a trifluoromethylated analog of
alanine, would make for an interesting case study with respect to the novel BABA drug
suite reported herein.
Additionally, the value of the most active BABA-peptide conjugate II-30 with
respect to mouse modeling and cell imaging studies will be critical as this conjugate
transitions from an in vitro to in vivo therapeutic. In order to circumvent the degradation
of the peptide scaffold in living organisms and to ensure that the molecular cargo reaches
its destination, it will be important to test more stable peptide-like backbones. Two such
scaffolds that would be interesting from a biological perspective and for assays would be
peptoids and peptidines. Peptoids have been well-characterized for their stability in
aqueous environments, but work related to the applicability of peptidines is in its
infancy.30 Whereas a peptoid has a peptide bond in which the nitrogen of the amide is
functionalized with the R group of an amino acid, peptidines possess di-substituted
glycine-derived amidines (Figure 2.8). The use of peptidines with respect to our potent
BABA analog would lead to an interesting case study with respect to the marketability of
these derivatives as potent therapeutics against BSF trypanosomes.30
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Figure 2.8: General structures for peptoid and peptidine.

With the results reported in hand, the medicinal relevance of the BABA drug suite
can be extended to other infectious diseases, such as leishmaniasis. Leishmaniasis is
prevalent in 98 countries with over 100 million people at risk for infection in East Asia,
East Africa, and Brazil.16 Leishmania protozoa belong to the Trypanosomatidae family,
with over 20 species showing pathogenicity in mammals.16 The disease is transmitted by
hematophagous sand flies, in contrast to the tsetse fly responsible for the transmission of
HAT, with the same mode of transmission as that depicted in Figure 1.1 in Chapter One.
Similar to HAT, kinase targets in both humans and mammals are useful for the
development of therapeutic inhibitors of kinetoplastid parasites, such as Leishmania sp.
Another disease that may be of greater interest to residents of the United States is Chagas
disease, also called American Trypanosomiasis, caused by Trypanosoma cruzi.31 Unlike
HAT, which is caused by the transmission of trypanosomes via a tsetse fly vector, Chagas
disease is caused by the transmission of T. cruzi via blood-sucking triatomine bugs.31 As
both diseases are caused by a parasite within the Trypanosomatidae family, future work
related to the extension of the BABA drug suite toward the inhibition of other
trypanosomal species responsible for infectious diseases will allow for the development
of novel BABA therapeutics that will highlight the potential of this novel drug
scaffold.16,31
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One of the difficulties associated with our study of the BABA drug suite is that we
do not fully understand the biochemistry (or the mechanism of action) of the PTS, the
tether, nor the BABA drug itself. Although this is a topic available for further evaluation,
we endeavored to obtain some preliminary understanding of whether our peptide-drug
conjugates were targeting the hexokinase TbHK1 (the desired target) via conjugation of
FITC to our PTS1, followed by attachment of the diglycine tether capped by (+)-biotin
(II-40 in Figure 2.9). The trypanosomes will be exposed to the PTS1-FITC-(+)-biotin
conjugate, followed by lysing of the cells. The cell lysate will then be passed through a
streptavidin column that will ideally bind to the PTS1-FITC-(+)-biotin conjugate bound
to TbHK1. It is expected that the PTS1-FITC-(+)-biotin conjugate will bind to other
transport and chaperone proteins on its way to the glycosomal compartment of the
trypanosome. Following isolation of the PTS1-FITC-(+)-biotin-protein complexes, mass
spectrometry can be used to determine which proteins have bound to the PTS1-FITC-(+)biotin conjugate. Our preliminary results with II-40 suggest weak enzyme inhibition
(%TbHK1 inhibition is equal to 6.984 ± 0.182%) as would be expected with this peptide
conjugate, as (+)-biotin is not a potent TbHK1 inhibitor compared to BABA. With this
data in hand, the next phase with respect to this investigation will be to utilize II-40 as a
preliminary molecular probe to investigate the cellular machinery that is responsible for
PTS-1 mediated uptake in trypanosomes. 3,32
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as desired.
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2.5

EXPERIMENTAL

2.5.1

TRYPANOSOME GROWTH AND VIABILITY ASSAYS

BSF 90-13 T. brucei, a 427 strain, was grown as described previously.33,34 To score
viability, parasites (1 x 104/mL BSF) were seeded into 96-well clear-bottomed
polystyrene plates in 200 µL HMI-9 supplemented with 10% fetal bovine serum and 10%
Serum Plus (Sigma-Aldrich, St. Louis, MO) and grown in the presence of compound (2
µL) or equivalently diluted carrier for 3 days in 5% CO2 at 37 ˚C. All assays were
performed in triplicate. After incubation (72 hr, at 37 °C), CellTiter-Blue (Promega) was
added and fluorescence measured (560Ex/590Em).
Purification of Bacterially Expressed TbHK1 and enzyme assay:
For purification of bacterially expressed TbHK1 (rTbHK1), a starter culture of E. coli
M15(pREP) harboring pQE30 (Qiagen, Valencia, CA) with the TbHK1 gene cloned in
frame of a 6-His tagging sequence was grown to an OD of ~1 and then induced for 24 h
at room temperature with 0.25 µM isopropyl β-D-1-thiogalactopyranoside (IPTG) and
purified as described previously.35
HK assays were performed in triplicate as described using a coupled reaction to
measure enzyme activity.35,36 In short, the coupled assay uses glucose-6-phosphate
dehydrogenase (G6PDH) to convert glucose-6-phosphate (G6-P) generated by HK to 6phosphogluconate with coincident reduction of NADP to NADPH, which is monitored
spectrophotometrically at 340 nm. Note that the drugs were found to be ineffective in a
counterscreen for inhibition of G6PDH.

Kinetic analyses were performed using

KaleidaGraph 4.1 (Synergy Software, Reading, PA).
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2.5.2

SYNTHESIS OF DRUGS AND PEPTIDE-DRUG CONJUGATES

All reagents were purchased from commercial suppliers and used without further
purification. All isolated products were purified via flash column chromatography using
silica gel SDS 60 C.C. 40-63 µm. 1H and

13

C NMR spectra were collected at ambient

temperature on a 300 (Bruker Avance) or 500 MHz NMR spectrometer (Bruker Avance
or JEOL Eclipse). Chemical shifts are reported in parts per million (ppm) and referenced
to residual solvent peaks (i.e., d 7.28 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3;
2.54 ppm for 1H NMR, 40.45 ppm for

13

C NMR in DMSO-d6). Data are presented as

follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet),
and integration. Infrared (IR) spectra, reported in cm-1, were collected using a Fourier
transform spectrophotometer. Compounds II-1,18 II-3,18 II-4,17 II-1118, and II-2318 were
prepared using known methods and exhibited spectral data consistent with previously
reported syntheses.
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Synthesis of 4-chloro-5-[4-carboxyphenyl]-[2-tert-butylbenzamido]-methyl benzoate (II8)
HO

O

Cl
OCH3
HN

O

O

To a dry, 100 mL round-bottomed flask was added a stirbar, II-22 (411.9 mg,
0.789 mmol, 1 equiv), and 0.1 M anhydrous DCM. To the round-bottomed flask was
added trifluoroacetic acid (2.6 mL, 37.5 mmol, 44.1 equiv). The reaction mixture was
stirred overnight under N2 at room temperature. The solvent was evaporated the
following day. Ice-cold diethyl ether (10 mL) was added to the mixture and evaporated.
This procedure was repeated twice more. The residue was dissolved in 25 mL ethyl
acetate and washed with 25 mL 1 M aq. HCl and 25 mL saturated sodium chloride. The
combined aqueous layers were washed with ethyl acetate (2 x 25 mL). The combined
organics were dried with sodium sulfate, filtered, and evaporated onto silica. Product II-8
was obtained in 97% yield (356.1 mg) after column chromatography with hexanes:ethyl
acetate (1 to 50% then 50% doped with 3% acetic acid).
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Compound II-8
1

H-NMR (500 MHz, DMSO-d6): d 12.99 (s, 1H), 11.71 (s, 1H), 8.87 (s, 1H),

8.04-8.02 (d, 2H), 7.93 (s, 1H), 7.87-7.85 (d, 2H), 7.61-7.59 (d, 2H), 7.55-7.54 (d,
2H), 3.89 (s, 3H), 1.312 (s, 9H); 13C-NMR (125 MHz, DMSO-d6): d 167.7, 167.4,
165.3, 156.1, 142.0, 141.3, 137.5, 133.7, 133.4, 131.4, 130.8, 129.9, 129.8, 127.4,
126.4, 121.4, 115.8, 53.4, 35.3, 31.3. IR (cm-1; NaCl salt plate): 2958, 2923, 2853,
1732, 1685, 1653, 1636, 1608, 1579, 1559, 1541, 1519, 1507, 1491, 1457, 1437,
1419, 1377, 1312, 1268, 1233; Rf (1:1 ethyl acetate:hexanes with 3% acetic
acid)= 0.43; melting point = decomposed above 260 ˚C; HRMS: EXPECTED
466.9378; FOUND: 466.1248.

Synthesis of II-1118
Br
Cl
OCH3
O

NH O

To a dry, 250 mL round-bottomed flask was added a stirbar, II-3 (3.34 g, 12.6
mmol, 1 equiv), triethylamine (3.52 mL, 25.2 mmol, 2.0 equiv), and 50 mL anhydrous
DCM. Then, 4-tert-butyl-benzoyl chloride (5.85 mL, 13.9 mmol, 1.1 equiv) was added
dropwise at room temperature and the resultant solution was stirred overnight under
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nitrogen. The reaction mixture was cooled and the precipitate that formed was filtered.
The filtrate was then evaporated and the residue was taken up in 50 mL ethyl acetate. The
reaction mixture was washed sequentially with saturated aq. sodium bicarbonate (100
mL) and saturated aq. brine (100 mL). The combined aqueous layers were washed with
ethyl acetate (1 x 75 mL). The combined organics were dried with sodium sulfate,
filtered, and evaporated onto silica. Product II-11 was obtained by column
chromatography with hexanes:ethyl acetate (0 to 20%) in 39% yield (2.07 g).

Compound II-1118
1

H-NMR (500 MHz, CDCl3): d 11.89 (s, 1H), 9.14 (s, 1H), 8.18 (s, 1H), 7.94-7.89

(d, 2H), 7.55-7.51 (d, 2H), 3.94 (s, 3H), 1.37 (s, 9H);

13

C-NMR (125 MHz,

CDCl3): d 167.4, 165.6, 162.5, 158.5, 156.0, 141.5, 141.2, 135.3, 131.3, 130.6,
127.2, 126.2, 125.9, 121.8, 114.9, 114.7, 53.2, 35.31, 35.1, 31.3; IR (cm-1; NaCl
salt plate): 3421, 2961, 2868, 1699, 1683, 1596, 1573, 1493, 1437, 1371, 1305,
1271, 1253, 1228, 1123, 1088, 1105, 1023, 932, 899, 850, 788, 766, 697, 657; Rf
(20% ethyl acetate:hexanes) = 0.44; melting point = decomposes above 260 ˚C.
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Synthesis of 4-chloro-5-bromo-[2-tert-butylbenzamido]-tert-butyl benzoate (II-12)
Br
Cl
OtBu
O

NH O

To a dry, 500 mL round-bottomed flask was added a stirbar, II-11 (5.81 g, 9.1
mmol, 1 equiv), and 65 mL DMF. Then, N,N-carbonyldiimidazole (1.47 g, 1 mmol, 1
equiv) was added the solution stirred at 80 ˚C for 22 hours under nitrogen (monitored by
TLC). N,N-carbonyldiimidazole (1.47 g, 1 mmol, 1 equiv) was added again and the
solution was stirred at 80 ˚C for 1 h. Next, tert-butyl alcohol (1.79 mL, 18.2 mmol, 2
equiv) and DBU (1.36 mL, 9.1 mmol, 1.0 equiv) were added and the solution stirred at 80
˚C overnight. The reaction mixture was cooled to RT and diluted with 100 mL diethyl
ether. The reaction mixture was washed sequentially with 10% aq. HCl (40 mL),
saturated aq. brine (50 mL), and saturated aq. sodium bicarbonate (50 mL). The
neutralized aqueous layer was washed with diethyl ether (100 mL). The combined
organics were dried with sodium sulfate, filtered, and then evaporated onto silica. Product
II-12 was obtained via column chromatography using hexanes and ethyl acetate as eluent
(gradient: 0-100% ethyl acetate (doped with 4% triethylamine) in 17% yield (1.11 g).
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Compound II-12
Rf (4% triethylamine/ethyl acetate) = 1.0
1

H-NMR (500 MHz, CDCl3): d 9.19 (s, 1H), 8.19 (s, 1H), 7.98-7.96 (d, 2H),

7.563-7.55 (d, 2H), 1.66-1.65 (s, 9H), 1.37-1.34 (s, 9H);

13

C-NMR (125 MHz,

CDCl3): d 166.4, 165.5, 155.8, 141.6, 140.3, 135.37, 131.5, 129.4, 127.3, 127.2,
125.8, 125.3, 121.8, 116.5, 114.6, 83.7, 35.0, 31.18, 28.2; IR (cm-1; NaCl salt
plate): 3293, 3246, 3112, 2964, 2869, 1720, 1682, 1637, 1655, 1647, 1593, 1572,
1491, 1394, 1371, 1314, 1272, 1251.86, 1199.26, 1157, 1122, 1106, 1087, 1016,
906, 850, 789, 767, 697, 659; Rf (4% triethylamine/ethyl acetate) = 1.0; melting
point = 149–152 ˚C.

Synthesis of 4-chloro-5-[4-methoxycarbonylphenyl]-[2-tert-butylbenzamido]-benzoic
acid (II-15)
H 3CO

O

Cl
OH
O

NH

O

To a dry, 100 mL round-bottomed flask was added a stirbar, II-11 (0.100 g, 0.153
mmol, 1.0 equiv), 4-methoxycarbonylphenylboronic acid (33.0 mg, 0.18 mmol, 1.2
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equiv), Pd(dtbpf)Cl2 (1.99 mg, 0.003 mmol, 0.02 equiv), K2CO3 (32.0 mg, 0.23 mmol,
1.5 equiv), and 30 mL of a 3:2 mixture of acetonitrile:water. The solution was refluxed
overnight under nitrogen. The reaction mixture was cooled to room temperature and
evaporated. The residue was dissolved in 50 mL DCM. The reaction mixture was washed
with 50 mL saturated aq. sodium bicarbonate and 50 mL saturated aq. brine. The
combined aqueous layers were washed with 10 mL DCM. The combined organics were
dried with sodium sulfate, filtered, and evaporated onto silica. The monoester II-15 was
obtained in 55% yield (62.4 mg) via column chromatography with dichloromethane:(010%) methanol.

Compound II-15
Rf (10% methanol/DCM) = 0.4
1

H-NMR (500 MHz, DMSO-d6): d 8.94 (s, 1H), 8.16 (s, 1H), 8.02-8.00 (d, 2H),

7.98-7.96 (d, 2H), 7.58-7.53 (m, 4H), 3.87 (s, 3H), 1.30 (s, 12H);

13

C-NMR (75

MHz, DMSO-d6): d 170.1, 166.9, 165.3, 155.4, 143.9, 142.1, 141.5, 136.4, 132.4,
132.2, 130.2, 129.6, 129.1, 127.8, 125.9, 123.5, 120.3, 119.7, 52.5, 35.3, 31.4; IR
(cm-1; NaCl salt plate): 3113, 2963, 2869, 2586, 2499, 1720, 1679, 1608, 1581,
1519, 1493, 1462, 1436, 1411, 1367, 1276, 1235, 1205, 1107, 1021, 996, 938,
918, 907, 858, 847, 827, 795, 771, 730, 715, 701; Rf (10% methanol/DCM) = 0.4;
melting point = decomposes above 200 ˚C.
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Synthesis of 4-chloro-5-[4-carboxyphenyl]-[2-amino]-methyl benzoate
(II-16)
HO

O

Cl
OCH3
NH 2 O

To a dry, 100 mL round-bottomed flask was added a stirbar, II-3 (0.250 g, 0.945
mmol, 1 equiv), 4-carboxyphenylboronic acid (0.188 g, 1.134 mmol, 1.2 equiv),
anhydrous potassium carbonate (0.198 g, 1.418 mmol, 0.53 equiv), and [1,1’-bis(di-tertbutylphosphino)ferrocene]dichloropalladium(II) (0.012 g, 0.019 mmol, 0.02 equiv). The
solids were taken up in a 9:1 mixture of acetonitrile:H2O and refluxed under N2 for 48 h.
The reaction mixture was cooled to room temperature and filtered through a plug of
Celite. The Celite cake was rinsed with ethyl acetate (100 mL), DCM (100 mL), and
MeOH (100 mL). The filtrate was then dried with sodium sulfate, filtered, and evaporated
onto silica. The reaction mixture was isolated in 43% yield (124.3 mg) after purification
via column chromatography with dichloromethane:(0-10%) methanol to obtain the
desired aniline derivative.

Compound II-16
1

H-NMR (500 MHz, DMSO-d6): d 8.01-7.99 (d, 2H), 7.71 (s, 1H), 7.47-7.46 (d,

2H), 7.03 (s, 1H), 6.88 (s, 2H), 3.79 (s, 3H);
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13

C-NMR (125 MHz, DMSO-d6):

d 167.6, 167.4, 151.9, 143.1, 137.2, 133.8, 129.9, 129.6, 129.0, 125.8, 117.3,
108.8, 52.2; IR (cm-1; NaCl salt plate): 2919, 2850, 1693, 1652, 1605, 1574, 1557,
1506.47, 1489, 1456, 1433, 1373, 1234, 1184, 1102, 1018, 924, 773.32, 710.90;
Rf (10% methanol/DCM) = 0.56-0.54; melting point = decomposes above 244 ˚C.

Synthesis of 4-chloro-5-[4-methoxycarbonylphenyl]-[2-amino]-methyl benzoate
(II-17)
H 3CO

O

Cl
OCH3
NH 2 O

To a dry, 100 mL round-bottomed flask was added a stirbar, II-3 (0.250 g, 0.945
mmol, 1 equiv), 4-methoxycarbonylphenylboronic acid (204 mg, 1.134 mmol, 1.2 equiv),
anhydrous potassium carbonate (0.198 g, 1.418 mmol, 1.5 equiv), and [1,1’-bis(di-tertbutylphosphino)ferrocene]dichloropalladium(II) (0.012 g, 0.019 mmol, 0.02 equiv). The
solids were taken up in a 9:1 mixture of acetonitrile:H2O and refluxed under N2 for 48
hours. The reaction mixture was cooled to room temperature and filtered through a plug
of Celite. The Celite cake was rinsed with ethyl acetate (100 mL), DCM (100 mL), and
MeOH (100 mL). The filtrate was then dried with sodium sulfate, filtered, and evaporated
onto silica. The reaction mixture was purified via column chromatography with
dichloromethane:(0-5%) methanol to obtain II-17 in 35% yield (0.107 g).
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Compound II-17
1

H-NMR (500 MHz, CDCl3): d 8.11-8.09 (d, 2H), 7.89 (s, 1H), 7.53-7.51 (d, 2H),

6.84 (s, 1H), 5.89 (s, 2H), 3.97 (s, 3H), 3.89 (s, 3H);

13

C-NMR (125 MHz,

CDCl3): d 167.8, 166.9, 150.4, 143.4, 138.1, 133.8, 129.7, 129.3, 128.9, 127.8,
117.2, 109.8, 52.1, 51.8; IR (cm-1; NaCl salt plate): 2917, 2848, 1706, 1653, 1625,
1608, 1590, 1545, 1521, 1507, 1489, 1474, 1457, 1434, 1419, 1396, 1374, 1335,
1289, 1253, 1234, 1189, 1094, 1019, 967, 924, 848, 835, 785, 772, 746, 731, 713,
700; Rf (10% methanol/DCM) = 0.97; melting point = 162–164 ˚C.

Synthesis of 4-chloro-5-[4-methoxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl
benzoate (II-18)
H 3CO

O

Cl
OCH3
O

NH

O

To a dry, 100 mL round-bottomed flask was added a stirbar, 4-tert-butyl benzoic
acid (21 mg, 0.118 mmol, 1 equiv), and 5 mL anhydrous DCM. To this solution was
added triethylamine (0.025 mL, 0.177 mmol, 1.5 equiv). The solution was then cooled to
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0 ˚C in an ice/water bath, then thionyl chloride (1 M in DCM) (0.130 mL, 0.130 mmol,
1.1 equiv) were added. The solution was stirred at 0 ˚C for 30 min. and the solvent was
evaporated. The residue was re-dissolved in 5 mL anhydrous dichloromethane and
triethylamine (0.025 mL, 0.177 mmol, 1.5 equiv). The solution was cooled to 0 ˚C, then
II-17 (37.6 mg, 0.118 mmol, 1 equiv) in 5 mL anhydrous DCM and triethylamine (0.025
mL, 0.177 mmol, 1.5 equiv) was added to the acyl chloride slowly. The reaction mixture
was stirred at 0 ˚C for 30 min., then brought to room temperature under nitrogen for 48
hours. The reaction mixture was then evaporated directly onto silica and purified via
column chromatography with DCM:(0-5%) methanol to afford II-18 in 34% (19.4 mg).

Compound II-18
1

H-NMR (500 MHz, CDCl3): d 12.079 (s, 1H), 9.24 (s, 1H), 8.15-8.14 (d, 2H),

8.09 (s, 1H), 8.03-8.02 (d, 2H), 7.60-7.59 (d, 2H), 7.57-7.55 (d, 2H), 3.997 (s,
3H), 3.98 (s, 3H), 1.39 (s, 9H);

13

C-NMR (125 MHz, CDCl3): d 168.3, 166.8,

165.7, 155.9, 142.8, 142.1, 139.2, 133.7, 133.1, 131.5, 129.6, 129.5, 127.3, 125.9,
121.7, 113.8, 52.7, 52.2, 35.1, 31.2; IR (cm-1; NaCl salt plate): 2955, 2925, 2869,
1723, 1696, 1682, 1653, 1608, 1581, 1540, 1518, 1492, 1456, 1435.75, 1408,
1397, 1379, 1311, 1275, 1233, 1192, 1182, 1111, 1019, 967, 932, 899, 850, 829,
791, 775, 754, 717, 699, 626, 603; Rf (1:1 ethyl acetate:hexanes) = 0.79-0.70;
melting point = decomposed above 142 ˚C.
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Synthesis of 4-chloro-5-[4-benzyloxycarbonylphenyl]-[2-amino]-methyl benzoate (II-19)
Ph
O

O

Cl
OCH3
NH 2 O

To a dry, 100 mL round-bottomed flask was added a stirbar, II-3 (0.250 g, 0.945
mmol, 1 equiv), 4-benzyloxycarbonylphenylboronic acid (0.259 g, 1.134 mmol, 1.2
equiv), anhydrous potassium carbonate (0.198 g, 1.418 mmol, 1.5 equiv), and [1,1’bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (0.012 g, 0.019 mmol, 0.02
equiv). The solids were taken up in a 9:1 mixture of acetonitrile:H2O and refluxed under
N2 for 48 hours. The reaction mixture was cooled to room temperature and filtered
through a plug of Celite. The Celite cake was rinsed with ethyl acetate (100 mL), DCM
(100 mL), and MeOH (100 mL). The filtrate was then dried with sodium sulfate, filtered,
and evaporated onto silica. The reaction mixture was purified via column
chromatography with dichloromethane:(0-1%) methanol to obtain II-19 in 46% yield
(0.266 g).
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Compound II-19
1

H-NMR (500 MHz, CDCl3): d 7.88 (s, 1H), 7.52-7.50 (d, 2H), 7.47-7.44 (d, 2H),

7.40-7.37 (m, 3H), 7.07-7.06 (d, 2H), 6.83 (s, 1H), 5.82 (s, 2H), 5.15 (s, 2H), 3.89
(s, 3H); 13C-NMR (125 MHz, CDCl3): d 168.0, 158.1, 149.8, 138.6, 137.0, 133.8,
131.6, 130.8, 128.7, 128.5, 128.1, 127.8, 127.6, 117.1, 114.4, 109.8, 70.1, 51.7;
IR (cm-1; NaCl salt plate): 2922, 2851, 1684, 1653, 1623, 1609, 1576, 1554, 1517,
1482, 1466, 1453, 1438, 1420, 1396, 1384, 1331, 1309, 1282, 1256, 1231, 1191,
1181, 1099, 1018, 977, 924, 845, 832, 787, 753, 736, 700; Rf (10%
methanol/DCM) = 1.0; melting point = 135–137 ˚C.

Synthesis of 4-chloro-5-[4-benzyloxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl
benzoate (II-20)
Ph
O

O

Cl
OCH3
O

NH

O

To a dry, 100 mL round-bottomed flask was added a stirbar, 4-tert-butyl benzoic
acid (35.2 mg, 0.197 mmol, 1 equiv), and 5 mL anhydrous DCM. To this solution was
added triethylamine (0.038 mL, 0.269 mmol, 1.5 equiv). The solution was then cooled to
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0 ˚C in an ice-water bath, then thionyl chloride (1 M in DCM) (0.220 mL, 0.215 mmol,
1.1 equiv) were added. The solution was stirred at 0 ˚C for 30 min., then the solvent was
evaporated. The residue was re-dissolved in 5 mL anhydrous dichloromethane and
triethylamine (0.038 mL, 0.269 mmol, 1.5 equiv). The solution was cooled to 0 ˚C, then
II-19 (71 mg, 0.179 mmol, 1 equiv) was added to the acyl chloride slowly. The reaction
mixture was stirred at 0 ˚C for 30 min., then the solution was refluxed under nitrogen
overnight. The reaction mixture was cooled to room temperature and the residue was
dissolved in 150 mL diethyl ether. The organic layer was washed with 100 mL saturated
sodium bicarbonate. The bicarbonate layer was washed with diethyl ether (2 x 25 mL).
The combined organics were washed with 100 mL saturated brine. The brine layer was
washed with diethyl ether (2 x 25 mL). The combined organics were dried with sodium
sulfate, filtered, and evaporated onto silica. Purification via column chromatography
afforded II-20 in 28% yield (28.3 mg) using hexanes:(0-50%) ethyl acetate.

Compound II-20
1

H-NMR (500 MHz, CDCl3): d 12.04 (s, 1H), 9.19 (s, 1H), 8.08 (s, 1H), 8.03-8.02

(d, 2H), 7.60-7.58 (d, 2H), 7.51-7.49 (d, 2H), 7.46-7.41 (m, 4H), 7.41-7.38 (t,
1H), 7.09-7.07 (d, 2H), 5.15 (s, 2H), 3.98 (s, 3H), 1.39 (s, 9H);

13

C-NMR (125

MHz, CDCl3): d 168.5, 165.7, 158.6, 158.0, 155.9, 141.2, 139.5, 137.1, 136.9,
134.5, 133.8, 133.2, 131.7, 130.9, 130.7, 128.6, 128.6, 128.0, 127.9, 127.8, 127.5,
127.5, 127.3, 125.9, 121.5, 115.2, 114.6, 113.7, 70.1, 52.6, 35.0, 31.2; IR (cm-1;
NaCl salt plate): 3297, 3256, 3114, 3034, 2958, 2925, 2868, 1693, 1680, 1652,
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1609, 1582, 1492, 1456, 1437, 1418, 1380, 1310, 1285, 1267, 1234, 1178, 1122,
1107, 1093, 1016, 970, 931, 916, 900, 885, 851, 834, 790, 767, 736, 697, 647,
623, 604; Rf (1:1 ethyl acetate:hexanes) = 0.77-0.74; melting point = decomposed
above 145 ˚C.

Synthesis of 4-chloro-5-[4-tert-butyloxycarbonylphenyl]-[2-amino]-methyl benzoate (II21)
t-BuO

O

Cl
OCH3
NH 2 O

To a dry, 100 mL round-bottomed flask was added a stirbar, II-4 (250 mg, 0.802
mmol, 1 equiv), tert-butylcarbonylbenzeneboronic acid (214 mg, 0.962 mmol, 1.2 equiv),
PdCl2(dtbpf) (10.5 mg, 0.016 mmol, 0.02 equiv), and potassium carbonate (168 mg,
1.203 mmol, 1.5 equiv) (ground and dried in an oven overnight at 140 ˚C). Added 9.5 mL
acetonitrile:0.5 mL water and refluxed 48 hours under N2. Cooled to room temperature
and filtered through Celite cake. The Celite cake was rinsed with 100 mL ethyl acetate,
100 mL DCM, and 100 mL methanol. The filtrate was dried with sodium sulfate, filtered,
and evaporated onto silica gel doped with 1% triethylamine. Product II-21 was obtained
as a waxy solid in 96% yield (262 mg) after column chromatography with DCM doped
with 1% triethylamine.
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Compound II-21
1

H-NMR (500 MHz, CDCl3): d 8.05-8.03 (d, 2H), 7.87 (s, 1H), 7.49-7.47 (d, 2H),

6.83 (s, 1H), 5.88 (s, 2H), 3.89 (s, 3H), 1.64-1.63 (s, 9H);

13

C-NMR (125 MHz,

CDCl3): d 167.9, 165.7, 150.4, 142.9, 138.2, 133.9, 130.8, 129.6, 129.2, 127.9,
117.3, 109.8, 81.1, 51.9, 28.3; IR (cm-1; NaCl salt plate): 3473, 3364, 2977, 1698,
1616, 1580, 1548, 1477, 1437, 1394, 1368, 1297, 1252, 1232, 1165, 1119, 1100,
1019, 926, 848, 777, 761, 713; Rf (DCM:1% NEt3): 0.633; melting point = waxy
solid. Melting point not possible to ascertain; HRMS: EXPECTED 362.8298;
FOUND: 362.1179.

Synthesis of 4-chloro-5-[4-tert-butyloxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl
benzoate (II-22)
t-BuO

O

Cl
OCH3
O

NH

O

To a dry, 100 mL round-bottomed flask was added a stirbar, 4-tert-butyl benzoic
acid (193 mg, 1.084 mmol, 1.1 equiv), and 5 mL anhydrous DCM. To this solution was
added triethylamine (0.227 mL, 1.626 mmol, 1.65 equiv). The solution was then cooled
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to 0 ˚C in an ice/water bath, then thionyl chloride (1 M in DCM) (1.2 mL, 1.192 mmol,
1.21 equiv) were added. The solution was stirred at 0 ˚C for 30 min., then the solvent was
evaporated. The residue was re-dissolved in 5 mL anhydrous dichloromethane and
triethylamine (0.227 mL, 1.626 mmol, 1.65 equiv). The solution was cooled to 0 ˚C, then
II-21 (356 mg, 0.986 mmol, 1 equiv) in 5 mL anhydrous DCM and triethylamine (0.227
mL, 1.626 mmol, 1.65 equiv) was added to the acyl chloride slowly. The reaction mixture
was stirred at 0 ˚C for 30 min., then the solution was refluxed under nitrogen overnight.
The reaction mixture was cooled to room temperature and evaporated. The residue was
taken up in 50 mL and washed with saturated sodium bicarbonate (3 x 50 mL) and
saturated brine (50 mL). The aq. layer was washed with ethyl acetate (50 mL). The
combined organics were dried with sodium sulfate, filtered, and evaporated onto silica.
Product II-22 was obtained in 54% yield (338 mg) via column chromatography with
hexanes:(0-75%) ethyl acetate with 1% triethylamine.

Compound II-22
1

H-NMR (500 MHz, CDCl3): d 12.05 (s, 1H), 9.2 (s, 1H), 8.09 (s, 1H), 8.07-8.06

(d, 2H), 8.01-7.99 (d, 2H), 7.58-7.56 (d, 2H), 7.52-7.50 (d, 2H), 3.97 (s, 3H),
1.63-1.62 (s, 9H), 1.38 (s, 9H);

13

C-NMR (125 MHz, CDCl3): d 168.4, 165.7,

165.5, 156.0, 142.3, 141.9, 139.2, 133.9, 133.2, 131.5, 131.4, 129.5, 129.4, 127.4,
125.9, 121.6, 113.8, 81.3, 52.8, 35.1, 31.2, 28.3; IR (cm-1; NaCl salt plate): 3299,
3261, 2966, 2931, 1711, 1686, 1656, 1638, 1608, 1580, 1545, 1516, 1492, 1459,
1438, 1409, 1392, 1367, 1294, 1269, 1234, 1166, 1117, 1019, 932, 899, 849, 790,
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777, 761, 699; Rf (1:1 ethyl acetate:hexanes with 1% triethylamine) = 0.83;
melting point = 140–142 ˚C; HRMS: EXPECTED: 523.0458; FOUND: 522.2051.

Synthesis of 4-chloro-5-bromo-2-[4-carboxybenzamido]-methyl benzoate (II-26)
Cl
Br

O
N
H

H 3CO

OH

O
O

To a dry, 100 mL round-bottomed flask was added a stirbar, terephthalic acid (II24) (69.1 mg, 0.416 mmol, 1.1 equiv), 4 mL anhydrous DCM, and triethylamine (0.232
mL, 1.664 mmol, 4 equiv). The reaction mixture was cooled to 0 ˚C in an ice/water bath.
Slowly added thionyl chloride (1 M in DCM) (0.998 mL, 0.998 mmol, 2.4 equiv) and
stirred at 0 ˚C under N2 for 30 minutes. The solvent was evaporated and the residue was
dissolved in 3 mL anhydrous DCM and triethylamine (0.232 mL, 1.664 mmol, 4 equiv) at
0 ˚C. A solution of II-3 (100 mg, 0.378 mmol, 1 equiv) in 1 mL anhydrous DCM and
triethylamine (0.232 mL, 1.664 mmol, 4 equiv) at 0 ˚C was added slowly to the acyl
chloride. Stirred at 0 ˚C for 1 hour, then refluxed overnight under N2. The reaction
mixture was cooled to room temperature and then evaporated. The residue was dissolved
in 25 mL ethyl acetate and washed sequentially with 50 mL 1 M HCl, 100 mL saturated
sodium bicarbonate, and 50 mL saturated sodium chloride. The neutral aq. layer with
ethyl acetate (2 x 50 mL) and DCM (2 x 25 mL). The combined organics were dried
sodium sulfate, filtered, and evaporated onto silica. Product II-26 was isolated with
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column chromatography using a gradient of hexanes:(0-55%, then 40-45% with 1%
acetic acid) ethyl acetate in 25% yield (38.3 mg).

Compound II-26
1

H-NMR (300 MHz; DMSO-d6): d 13.32 (s, 1H), 11.57 (s, 1H), 8.74 (s, 1H),

8.23 (s, 1H), 8.15-8.12 (d, 2H), 8.04-8.01 (d, 2H), 3.90 (s, 3H);

13

C-NMR (75

MHz; DMSO-d6): d 167.0, 166.6, 164.8, 140.2, 139.2, 137.8, 135.5, 134.7, 130.4,
129.9, 127.9, 122.8, 118.8, 115.7, 53.6; IR (cm-1; NaCl salt plate): 2915, 2847,
1686, 1569, 1508, 1490, 1421, 1259, 1211, 1107, 1014, 937, 900, 866, 751, 695;
Rf (1:1 ethyl acetate:hexanes)=0.45; melting point = decomposed above 260 ˚C.

Synthesis of 4-chloro-5-bromo-2-[4-carboxybenzamido]-benzoic acid (II-27)
Cl
Br

O
N
H

HO

OH

O
O

To a dry, 20 mL vial was added a stirbar, II-26 (37.3 mg, 0.090 mmol, 1 equiv),
and 2 mL anhydrous THF. Added 1 M aq. LiOH (0.452 mL, 0.452 mmol, 5 equiv) and
stirred under N2 overnight for 48 hours at room temperature, then the solvent was
evaporated. The residue was dissolved in 25 mL ethyl acetate and washed with 10 mL 1
M aq. HCl. The organic layer was separated and then the acidic aq. layer was washed
with ethyl acetate (2 x 25 mL) and DCM (50 mL). The combined organics were dried
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with sodium sulfate, filtered, and evaporated. Product II-27 was obtained as an off-white
solid in >99% yield (39.8 mg).

Compound II-27
1

H-NMR (300 MHz; DMSO-d6): d 13.29 (s, 1H), 12.49 (s, 1H), 8.92 (s, 1H),

8.26 (s, 1H), 8.13-8.10 (d, 2H), 8.04-8.01 (d, 2H);

13

C-NMR (75 MHz; DMSO-

d6): d 167.1, 166.9, 164.6, 141.1, 138.6, 137.9, 135.9, 134.9, 130.4, 129.9, 127.8,
121.6, 114.9; IR (cm-1; NaCl salt plate): 3252, 2955, 2921, 2850, 2671, 2548,
1688, 1597, 1576, 1512, 1498, 1458, 1432, 1374, 1308, 1267, 1129, 1107, 1087,
1016, 933, 913, 874, 786, 712, 685, 665, 610; Rf (1:1 ethyl acetate:hexanes) =
0.364-0; melting point = decomposed above 260 ˚C.
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2.5.3

GENERAL PROCEDURE FOR SOLID PHASE PEPTIDE SYNTHESIS
OF II-28 TO II-40

Peptides were assembled according to the generalized schemes presented above (i.e.
Scheme 1.7 in Chapter One).
Resin Swelling: Fmoc-Leu-Wang resin was loaded into the barrel of a fritted 10 mL
syringe and was swelled by first washing with 3 mL DCM, followed by soaking in
another 5 mL DCM for five minutes. The residual DCM was washed away with DMF (3
x 5 mL).
Fmoc Deprotection Sequences: The Fmoc protecting group of the terminal amino acid of
the growing peptide was removed by three sequential one-minute treatments with 5 mL
of a 30% solution of 4-methylpiperidine in DMF. The deprotected resin was then washed
three times with 5 mL of DMF.
HCTU amino acid couplings: Five equiv (relative to resin loading) of the appropriate
Fmoc-amino acid was added to a three-dram vial, along with five equiv of HCTU. The
solids were dissolved in 1 mL DMF and 5 equiv of diisopropylethylamine was added.
This mixture was then taken up into the syringe and agitated for two minutes. The first
treatment of the coupling mixture was then ejected from the syringe, and the resin was
subsequently treated with a second aliquot of the same amino acid coupling mixture for
another two minutes. After the double coupling protocol, the resin was washed with
DMF (3 X 5 mL). After this coupling procedure was complete, the newly added Fmocamino acid was deprotected and prepared for further coupling steps as described above.
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Fmoc-Gly-OPfp coupling (for peptides II-28 to II-29 and II-32 to II-35): The required
glycine coupling using the more reactive Fmoc-Gly-OPfp (see Scheme 1.7 in Chapter
One) was achieved in the following manner: five equiv of Fmoc-Gly-OPfp and five
equiv of HOBt were charged to two sets of three-dram vials and taken up in 1 mL of
DMF. This mixture was taken up into the syringe containing the resin and was agitated
for one hour.

The first treatment of the coupling mixture was then ejected from the

syringe, and the resin was subsequently treated with a second aliquot of the same amino
acid coupling mixture for another one hour. After the double coupling protocol, the resin
was washed with DMF (3 X 5 mL).

After this coupling procedure was complete, the

newly added Fmoc-Gly residue was deprotected and prepared for further coupling steps
as described above. This process was repeated for the incorporation of each of the desired
amino acids in the sequence. Fmoc-AEEP-OH was substituted for Fmoc-Gly-OH for the
installation of a diethylene glycol tether (for peptides II-30 and II-31) using the same
protocol as that described above.
Drug Installation: Each peptide was capped with the appropriate BABA drug candidate in
the following manner: Five equiv (relative to resin loading) of the appropriate BABA
carboxylic acid was added to a three-dram vial, along with five equiv of HCTU. This
mixture was taken up into the syringe containing the resin and was agitated overnight.
After the coupling protocol, the coupling solution was ejected from the syringe and the
resin was further processed as described below.
Fluorophore Installation (for peptides II-36 to II-40): Each peptide was capped with
FITC in the following manner: Five equiv (relative to resin loading) of FITC was added
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to a three-dram vial in a minimal amount of 0.12:0.07:0.05 pyridine:DMF:DCM. This
mixture was taken up into a syringe wrapped in aluminum foil containing the resin and
was agitated overnight. A second coupling was applied for 72 hours and a third coupling
was applied for 48 hours. After the coupling protocol, the coupling solution was ejected
from the syringe and the resin was further processed as described below.
Peptide Cleavage and Isolation: The resin containing the fully assembled peptide-drug
conjugate was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), and methanol (3 x 5 mL).
Residual solvents were dried using suction and then the resin was further dried under
vacuum (i.e. in a 25 ˚C vacuum oven) overnight. After drying the resin was treated with
1.5 mL of a standard peptide cleavage cocktail comprised of trifluoroacetic
acid:H2O:methanol (95:4.5:0.5) for 1.5 h. The resulting solution containing the liberated
peptide was then ejected into a 1 mL Eppendorf tube and evaporated under a steady
stream of nitrogen. The peptide was then precipitated from the resulting oil on the
addition of ice-cold diethyl ether. The precipitate was then localized at the bottom of the
tube by centrifugation, the ether portion was decanted, and the precipitation procedure
was repeated two more times to afford the desired peptide-drug conjugates. The identity
of the peptide-drug conjugates was then confirmed by MALDI-TOF mass spectrometry
(Table 2.4).
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Peptide Number

Condensed Molecular Formula

Expected m/z

Experimental m/z

II-28

C 45H 58ClN7O10

892.4

892.5

II-29

C 44H 56ClN7O10

878.4

878.5

II-30

C 48H 65ClN6O11

937.5

937.5

II-31

C 47H 63ClN6O11

924.5

924.2

II-32

C 35H 45BrClN 7O10

840.2

840.5

II-33

C 34H 43BrClN 7O10

826.0

826.3

II-34

C 37H 51BrClN 7O8

838.2

838.2

II-35

C 40H 50BrClN 5O8

765.3

765.4

II-36

C58H 62BrClN 8O13S

1225.4

1225.4

II-37

C62H 71BrClN 9O13S

1297.7

1296.9

II-38

C 42H 49N 7O12S

875.9

877.4

II-39

C69H 76ClN7O16S

1326.9

1326.6

II-40

C50H 61ClN9O13S2

693.8

693.4

Table 2.4: MALDI-TOF data for peptides II-28 to II-40. Please note that the [M]+ m/z is shown for
+
peptides II-28 to II-39 while the [M+Na] m/z is shown for peptide II-40.
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CHAPTER THREE
SYNTHESIS AND UTILITY OF A NOVEL CHIRAL BORONATE ESTER IN THE
INTRAMOLECULAR DIELS-ALDER REACTION
3.1

INTRODUCTION
The Diels-Alder (DA) reaction is a well-known example of a carbon-carbon bond

forming reaction in organic chemistry. The DA reaction consists of a [4+2] cycloaddition
between a dienophile, e.g. alkene or alkyne, and a diene leading to a cyclohexene
cycloadduct that is often formed with predictable regio- and diastereoselectivity.1
Traditionally, the reaction consists of a mixture of the dienophile and diene in an aprotic
solvent under thermal or Lewis acid (LA) activation.1 The reaction can occur in both
inter- and intra-molecular fashions; the variation in DA adducts (i.e. products) arises from
the substituents present on the dienophile and/or diene.
In a traditional intermolecular Diels-Alder cycloaddition, an electron-rich diene,
such as 1-methoxybutadiene, can be utilized in conjunction with an electron-poor
dienophile, such as ethyl acrylate (Figure 3.1).1-3 In general, the better the donor
substituents on the diene and the stronger the acceptor substituents on the dienophile, the
faster the cycloaddition proceeds.1 Maleic anhydride, quinones, and nitroalkenes are other
well-known dienophiles that can participate in the DA reaction.1 Chiral catalysts (or
auxiliaries), such as oxazolidinone, can be appended onto dienophiles to increase the
enantio- and diastereo-selectivity of the cycloaddition reactions.1,2 In addition, vinyl
esters and vinyl ethers bearing chiral auxiliaries (see Figure 3.2) have been used to exert
stereochemical control in the DA reaction; however, they may require the use of
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additional synthetic operations or purification protocols.1-3 Vinyl silanes have also
received attention in the intermolecular Diels-Alder cycloaddition for their role as
acetylene equivalents.4 Although highly reactive vinyl silanes do exist, they are hindered
by their low preparative yields and harsh reaction conditions (see Figure 3.2).1,3,4
In contrast, an inverse electron demand Diels-Alder cycloaddition reverses the
roles of the reactants where an electron-rich dienophile, such as a vinyl silyl ether, will
react with an electron-poor diene, such as 2,4-pentadienoic acid ethyl ester (Figure 3.1).
In an inverse electron demand Diels-Alder cycloaddition, the highest occupied molecular
orbital (HOMO) of an electron-rich dienophile interacts strongly with the lowest
unoccupied molecular orbital (LUMO) of an electron-poor diene. This contrasts with a
traditional Diels-Alder cycloaddition, in which the HOMO of an electron-rich diene
interacts strongly with the LUMO of an electron-poor dienophile. In either reaction (i.e.
traditional or inverse electron demand Diels-Alder cycloaddition), it is expected that a
mixture of endo:exo products would be observed.
Diels-Alder cycloaddition:
OMe

OMe O

O

OEt

OEt

Inverse electron demand Diels-Alder cycloaddition:
O

EtO

OEt
OTBDMS

O
OTBDMS

Figure 3.1: General schemes shown for traditional Diels-Alder (top) and an inverse electron demand
Diels-Alder (bottom). Wavy bonds are used to indicate that a mixture of endo:exo products would be
1-6
observed.
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vinyl ether

vinyl ester
O

vinyl silane

vinyl boronate

O
N

B(pin) 2

SiPH2Cl

OTBDMS
O

PhH 2C

CO2Et

O

O
N

O

CO2H

OEt
Me 3Si

O
B

O

CO2Et

1-6

Figure 3.2: Examples of vinyl derivatives that can participate in the Diels-Alder cycloaddition.

Recently, boronates have gained attention in the literature as substrates in the
Diels-Alder cycloaddition due to the ease of their preparation and their ability to act as a
Lewis acid.1-3,5,6 Additional Lewis acids, such as EtAlCl2, can be added to promote a
traditional Diels-Alder cycloaddition through the activation of a dienophile species that
can readily accept the boronate diene.1,2 Furthermore, boronate esters can be tailored with
a variety of groups, including small alkyl moieties, such as ethyl or 1,3-butadienyl
substitutions, or even large hydrocarbons, such as anthracene, that can be incorporated
onto either the diene or dienophile to impart greater reactivity and/or stereocontrol to the
substrate.1 One of the major drawbacks in using boronate esters as dienes, such as 1boronobutadienes (described in greater detail below), arises from the steric and electronic
deactivating effect exerted by the boronate substituent which necessitates the need for
highly-activated dienophiles in the Diels-Alder cycloaddition (e.g. maleic anhydride) and,
potentially, Lewis acid activation.2 Nonetheless, vinyl boronate esters participating as
dienophiles have shown remarkable results (see Figure 3.2). In an investigation authored
by Bonk and Avery, the use of a dioxygenated boronate as a dienophile was successful in
the synthesis of a norbornenyl alcohol III-3 through a Diels-Alder cycloaddition with
cyclopentadiene III-1 and boronate tartrate ester III-2 (Scheme 3.1). In this reaction,
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cyclopentadiene was heated at 200 ˚C in benzene in a sealed tube with 1% phenothiazine
(as a stabilizer) followed by oxidation of the boronate with hydrogen peroxide and
sodium hydroxide to afford the desired norbornenyl alcohol III-1 (endo:exo 37:35) as
shown in Scheme 3.1. Although this method was successful in employing the DielsAlder cycloaddition to a vinyl boronate ester, additional investigations will now be
presented in which boronate esters (participating as either the diene or dienophile) were
used to exert stereocontrol in the Diels-Alder cycloaddition to enhance the selectivity for
either the endo or exo products. This introduction will be followed by an explanation of a
major aim for this thesis chapter followed by a discussion of the successful synthetic
route implemented thus far in the synthesis of a novel, chiral boronate ester that can
participate in the intramolecular Diels-Alder cycloaddition (IMDA).
CO2Et
O
B
+
3 eq
III-1

O

1 eq
III-2

CO2Et
190-200 ˚C
1 h, benzene
1% phenothiazine
then H 2O2/NaOH

OH
III-3
endo:exo = 37:35

Scheme 3.1: Diels-Alder cycloaddition between cyclopentadiene (3 eq) and diethyl boronotartrate (1
3
eq) to afford norbornenyl alcohol III-3.

Matteson and Waldbillig investigated the use of ethylene boronic esters as
dienophiles for their electron-withdrawing power in the Diels-Alder cycloaddition.6 As is
shown in Table 3.1, the use of dibutyl ethylene boronate (Entry 3 where R = t-butyl) and
excess cyclopentadiene heated to reflux gave a good mixture of the dibutyl endo- and
exo-5-norbornene-2-boronates. Based on the results in Table 3.1, a less bulky boronic
ester lead to a higher proportion of the endo adduct than the bulkier ester. Entry 1 in
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Table 3.1, where R = H, shows a higher endo:exo ratio (1.70) than that obtained with
Entries 2 and 3 (for R = n-butyl and t-butyl the values are 0.64 and 0.37, respectively).
This result was obtained after heating the boronic acid with cyclopentadiene in benzene
at 80 ˚C for 4.5 hours, versus the boronate esters that were heated neat for longer time
periods (in excess of 7.5 hours) at higher temperatures (in excess of 100 ˚C).
Furthermore, use of a boronic acid gave a higher amount of the endo product (Entry 1 in
Table 3.1), whereas use of a boronate ester gave the opposite result with a higher
population of the exo product (Entries 2 and 3 in Table 3.1).6 Furthermore, refluxing the
dibutyl ethylene boronate with isoprene in benzene or diglyme did not result in the DielsAlder adduct; however, heating the two samples in a sealed tube at 140 ˚C afforded the
Diels-Alder adduct in 85% yield (Scheme 3.2; no endo:exo ratio provided by the
authors).6 Kinetic control in the isomerization of the endo:exo products (see Entries 1, 2,
and 3 in Table 3.1) was observed through the failure of the dibutyl endo- or exo-5norbornene-2-boronate to isomerize at 120 ˚C (no change in endo:exo ratio).6 This
investigation demonstrated that the dialkoxyboryl group has a moderate activating effect
with the potent diene, cyclopentadiene, in the Diels-Alder cycloaddition through the
isolation of diastereomeric cyclohexenyl derivatives.
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III-1

benzene,
diglyme,
or heat

+

B(OR) 2
H
+

Δ,
4.5 to 22 h

H

B(OR) 2

B(OR) 2

Entry

R

endo:exo

Temp
(˚C)

Time
(h)

Solvent

Yield (%)

1

H

1.7

80

4.5

Benzene

62

2

butyl

0.64

100

4

neat

83

3

tertbutyl

0.37

100

7.5

neat

83

Table 3.1: Several examples of a DA reaction between cyclopentadiene (III-1) and a vinyl boronate
6
acid or ester (shown above), used as a chiral auxiliary, are displayed.

+
B(Ot-Bu)2

140 ˚C
85%

B(Ot-Bu)2

Scheme 3.2: Diels-Alder cycloaddition between isoprene and dibutyl ethylene boronate.6

In a later work, Vaultier and co-workers demonstrated the use of 1,3-substituted
dienes in the Diels-Alder cycloaddition, as this would install allylboronates in the
cyclohexenyl product in a stereodefined way for further reactions as part of a tandem, or
multi-component, reaction (Scheme 3.3).7 In this investigation, Vaultier heated methyl
acrylate with 2-methyl-1,3-butadienylboropinacolate (III-2) in toluene at 100 ˚C for 100
hours to afford the cyclohexenyl adduct in 69% yield (Scheme 3.3; endo:exo ratio
observed was 1:1.8).7 The resultant cyclohexenyl product was then oxidized by action of
trimethylamine-N-oxide to give the ß-hydroxyester which allowed the investigators to
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establish the regiochemistry of the final product by X-ray crystallography (no yield
provided by the authors).

O
+
III-4

B
O

O
OEt

B

O
OH
CO2CH 3

O

Me 3N +O-

CO2CH 3

69%
endo:exo (1:1.8)

Scheme 3.3: Diels-Alder between 2-methyl-1,3-butadienylboropinacolate (III-4) and methyl acrylate,
7
followed by hydrolysis of the pinacol ester with trimethylamine-N-oxide.

Based on the precedent set by Vaultier and co-workers (described above), Gao
and Hall reported the use of 1-boronobutadienes as substrates in the Diels-Alder
cycloaddition.2 They demonstrated the cycloaddition of these versatile dienes with a good
dienophile, followed by allylboration with an aldehyde component to provide a final
hydroxyalkyl-substituted cyclohexene product with high diastereoselectivity. In their
investigation,

Gao

and

Hall

demonstrated

the

use

of

ether-substituted

1-

boronopinacolates in the Vaultier tandem reaction (Scheme 3.4).2 As is evidenced in
Table 3.2, diene III-5 reacted with maleimides (III-6) and methyl acrylate to provide
Diels-Alder cycloadducts III-7 at relatively high temperature (in toluene at 80 ˚C), but
the allylboration product III-8 was not observed even after the mixture was heated at
higher temperatures (up to 120 ˚C, after which decomposition of the product was
observed) possibly due to steric hindrance by the methoxy group on III-5.2 Use of diene
III-7 afforded the desired allylboration product after diene III-7 and the desired
maleimide (III-6) were heated in toluene between 80 ˚C for 16-24 hours (endo-selectivity
though the authors did not provide the endo:exo ratio), followed by the addition of the
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desired aldehyde (descriptions for maleimide and aldehyde are shown in Table 3.2).2 The
doubly-activated dienophiles, such as N-phenyl and N-methyl maleimide, participated
efficiently in the Diels-Alder cycloaddition, followed by addition of either aliphatic or
aromatic aldehydes that afforded the desired b-hydroxy-cyclohexenyl product III-12
(Scheme 3.4). When N-phenyl-maleimide was used, higher yields for the tandem reaction
product were obtained with the use of 4-nitrophenyl-, 4-methoxyphenyl-, or 4bromophenyl-substituted aldehyde (92% for Entry 2, 82% for Entry 3, and 93% for Entry
4) than with benzaldehyde (76% for Entry 1). Using N-methyl-maleimide, yields for the
tandem reaction product were lower than those obtained with N-phenyl-maleimide when
the same aldehydes were screened (89% for Entry 5, 67% for Entry 6, 78% for Entry 7).2

O

B

O

+

B

toluene
(1 M)

O
+

III-9
1 eq

III-6

1.1 eq

O

TESO

NR1
O

III-5 OMe
1 eq

O

O

O

B

OMe

B

R 2CHO

(1.1 eq)
OH OMe
III-8

O
NR1

III-11

O

O

O

TESO

NR1

R2

O
III-7

toluene
III-10 (1 M)

O
1.1 eq

O

O
NR1

O

NR1

O

O

R 2CHO (1.1 eq)
R2

HO

NR1

OTES

O

III-12

Scheme 3.4: Tandem [4+2] cycloaddition between diene III-5 or III-9 and maleimide (see Table 3.2
1 2
for R ).
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Entry

Dienophile (R1)

Aldehyde (R 2)

Temperature (˚C)

Time (h)

Yield (%)

1

Ph

C6H 5

80

16

76

2

Ph

4-NO2-C6H 4

80

24

92

3

Ph

4-MeO-C6H 4

100

16

82

4

Ph

4-Br-C6H 4

80

16

93

5

Me

4-NO2-C6H 4

80

24

89

6

Me

4-MeO-C6H 4

100

16

67

7

Me

4-Br-C6H 4

80

16

78

1

Table 3.2: Cycloaddition (see Scheme 3.4) of diene III-9 with maleimides (R = Ph or Me) followed by
2
a tandem allylboration with a benzaldehyde derivative (4-substituted aryl ring with R ).2

The cycloaddition between diene III-3 and oxazolidinone III-13 followed by a
tandem reaction with 4-nitro-benzaldehyde afforded the cyclohexenyl product (III-14) as
shown in Scheme 3.5 with high exo selectivity after heating in toluene for 18 hours at
110 ˚C.2 This investigation into the Vaultier tandem reaction showed the potential of 1boronobutadienes

towards

a

diastereoselective

synthesis

of

hydroxyalkylated

cyclohexenyl products.7 Although use of methyl acrylate did not afford the desired
tandem reaction product when used with diene III-5, the use of activated dienophiles,
maleimides, in the reaction sequence with dienes III-5 and III-9 provided a new
approach toward the diastereoselective synthesis of cyclohexenyl derivatives that could
potentially be incorporated in natural product synthesis (Scheme 3.4).2
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O
B(Opin) 2

H
O

O
+

TESO
III-9
1 eq

N

O
III-13
1.1 eq

O 2N

1.1 eq

toluene
110 ˚C, 18 h
71%
endo:exo = 1:4

O 2N

O

O
N

III-14

HO

O

OSET

Scheme 3.5: Cycloaddition between diene III-9 and oxazolidinone dienophile III-13 followed by
2
addition of 4-nitro-benzaldehyde to afford b-hydroxyalkylated cyclohexenyl derivative III-14.

Boronate esters have been used to activate and influence the regioselectivity of
phenoxy-derivatized quinones as dienophiles in Diels-Alder [4+2] cycloadditions.8
Employing chiral diols as boronate substituents is a synthetic advantage in using boronate
esters as Lewis acids for cycloadditions and subsequent transformations.8 Kennedy and
Hall investigated the effect of the boronate substituent by subjecting acrylanilide
dienophiles III-15 and III-16 (Scheme 3.6) with the highly-reactive diene
cyclopentadiene to afford cycloadducts III-17 and III-18.8 Based on the results of their
assay, dienophile III-15 reacted with greater preference for the endo product as shown in
Table 3.3.8 This is possibly due to a small self-activation effect via internal coordination
of the boronate ester and the carbonyl of the acrylanilide in III-15 (Scheme 3.7).8 To
demonstrate the effect of this self-activation of the acrylanilide, a competitive kinetic
experiment was conducted between a simultaneous reaction between III-15 and III-19
with excess cyclopentadiene in deuterated benzene at room temperature (Scheme 3.7).8
These results indicated that the consumption of III-15 was faster than III-19 to provide a
larger percentage of the ortho adducts (III-20) compared to the para adducts (III-21) to
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further corroborate the self-activation by internal coordination of the ortho-substituted
dienophile III-15 (Table 3.4).8
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O
B

NH

III-15
O

O
B O
O

O

O

H

N
H

BHT
toluene, rt

III-17

N
H
H

O

O
BHT
toluene, rt

N
H
III-16

III-18

N
H
O

B

O

Scheme 3.6: Endo:exo ratios afforded by the Diels-Alder between excess cyclopentadiene and
acrylanilide III-15 or III-16. Highlighted in the box is the internal coordination of the boronate ester
8
and the carbonyl of the acrylanilide.

Time (h)

Acrylanilide III-15

Acrylanilide III-15

Acrylanilide III-16

Acrylanilide III-16

S.M./adduct

endo:exo

S.M./adduct

endo:exo

1

3.8:1

-

No rxn

2.7:1

6

1.2:1

3.8:1

1:0.4

2.5:1

48

1:13

4.3:1

1:5

2.8:1

Table 3.3: Endo:exo ratios (see Scheme 3.6) afforded by the Diels-Alder cycloaddition between III-15
8
or III-16 and excess cyclopentadienone.
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O
B

III-15
O

O

O
O

NH

III-20

O
B

III-19

O

O

C6D 6, rt
NH

N
H

III-21

N
H

B

O
O
B
O

O

Scheme 3.7: Competitive kinetic experiment between acrylanilide derivative III-15 and III-19 and
8
excess cyclopentadiene in deuterated benzene at room temperature.

Time

para s.m.

ortho s.m.

para adducts

ortho adducts

Start point

55

45

0

0

After 17 d

43

11

10

36

Table 3.4: Data for competitive kinetic experiment (see Scheme 3.7) between III-15, III-19, and
excess cyclopentadiene III-1 showing preference for ortho product.8

Kennedy and Hall then investigated the possibility of using internal coordination
to impart stereocontrol in a long-range fashion. In this investigation, 1,8-stereoinduction
could be harnessed via internal coordination of the carbonyl of the acrylanilide to the
boron atom to form a tetrahedral stereogenic boronate complex.8 The resulting tetrahedral
boronate would be rendered stereogenic at the boron after temporary 1,4-stereoinduction
in the formation of the Diels-Alder cyclohexenyl adduct.8 Chiral 2-boronoacrylanilides
(III-22 to III-25 shown in Figure 3.3) were reacted with cyclopentadiene III-1 in the
presence of BHT (butylated hydroxytoluene) in refluxing toluene (see Entries 1 to 4 in
Table 3.5).8 The endo:exo ratio showed low selectivity (maximum endo:exo ratio
observed 3.7:1 for III-24) from Entries 1 to 4, although the greatest diastereomeric
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excess of 28% was observed with acrylanilide dienophile III-24.8 Based on the low
endo:exo selectivity observed, it can be said that the chiral information resident in the
chiral diol ligands may be positioned too far away from the dienophile to allow for
effective transmission of stereochemical information.8

1
O 3 O2
B
4 O
7
8
5 N6
H

O
Me

O
Me

III-23

C6H11 (MeO)Ph 2C

CPh2(OMe)

O
Me

O
B

O

N
H

III-22
C6H11

O
B

O
B

O

O

N
H

N
H

III-24

III-25

Figure 3.3: Chiral 2-boronoacrylanilide derivatives prepared by Kennedy and Hall. Numbering for
8
1,8-stereoinduction on III-22 according to Kennedy and Hall.

Acrylanilide
Dienophile

Yield

endo:exo

De (endo, %)

De (exo, %)

III-22

94

2.0:1

8

6

III-23

56

1.5:1

5

9

III-24

72

3.7:1

0

28

III-25

85

2.4:1

-6

22

Table 3.5: Remote 1,8-stereoinduction (numbering shown in Figure 3.3) reflected in the Diels-Alder
cycloaddition between III-22 to III-25 and excess cyclopentadienone. Reaction with III-24 was
stirred for 3 days in DCM at room temperature and reaction with III-25 stirred in DCM at room
8
temperature.
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Using molecular modeling approaches, Kennedy and Hall determined that the
chiral boronate auxiliaries drawn in Figure 3.3 are far removed from the reaction center
on the acrylamide unit to induce high levels of selectivity.8 This investigation
demonstrated that non-activated dialkoxyboronic esters can participate in the Diels-Alder
cycloaddition as weak, internal Lewis acids and thus activate carbonyl-containing
functionalities intramolecularly toward accepting a diene, such as cyclopentadiene III-1.8
Kennedy and Hall also demonstrated the effects of the internal coordination between the
carbonyl and boronate center as well as the 1,8-stereoinduction transmitted through a
tetrahedral stereogenic boronate center.8 Of interest from this investigation was the
observation of a weak activating effect (through the isolation of products with low
diastereoselectivies) despite the distance of the auxiliary (the boronate center) from the
reaction center (the dienophile, acrylanilide).8
Although the intermolecular Diels-Alder reaction is a powerful method for the
selective formation of cyclohexenyl derivatives, it is contingent upon effective matching
of the diene and dienophile reaction partners to ensure good regiocontrol and
diastereoselectivity.9 One solution is to couple the diene and dienophile together to
undergo an intramolecular Diels-Alder (IMDA). The constraining effects of the tether can
have a large effect on the overall regiochemistry and diastereoselectivity of the
cycloaddition products.9 Roush and Gillis demonstrated the effects of a Lewis acid
activated cyclization and thermally activated cyclization on trienes III-26a and III-26b
that were subjected to an IMDA (Scheme 3.8).10 Trans-triene III-26a was heated at 160
˚C for 48 hours neat to afford a 50:50 mixture of endo:exo products in 69% yield.10
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Similarly, cis-triene III-26b was heated at 180 ˚C for 3 hours to afford the endo:exo
products (55:45 mixture) in Scheme 3.8 in 71% yield.10 Trans-triene III-26a was also
exposed to the Lewis acid, ethyl aluminum dichloride (Scheme 3.9), to afford an 88:12
(endo:exo) mixture of products (III-27 and III-28) in 69% yield.10 The cis-triene III-26b
was reacted in a similar fashion to afford the opposite preference (<8:92 endo:exo in
products III-29 and III-30) in 77% yield.10
CO2CH 3

III-26a

160 ˚C
48 h
69%
50:50 endo:exo

CO2CH 3
III-26b

160 ˚C
3h
71%
55:45 endo:exo

CO2CH 3

CO2CH 3

III-27; endo

III-28; exo

CO2CH 3

CO2CH 3

III-29; endo

III-30; exo

Scheme 3.8: Intramolecular Diels-Alder cycloaddition on trienes III-26a and III-26b following
10
thermal activation.

CO2CH 3

III-26a

EtAlCl 2 (0.95 eq)
DCM, rt
68%
88:12 endo:exo

EtAlCl 2 (0.95 eq)
DCM, rt
CO2CH 3
III-26b

CO2CH 3

CO2CH 3

III-27; endo

III-28; exo

CO2CH 3

CO2CH 3

III-29; endo

III-30; exo

77%
<8:92 endo:exo

Scheme 3.9: Intramolecular Diels-Alder cycloaddition on trienes III-26a and III-26b in the
10
presence of a Lewis acid, ethyl aluminum dichloride.
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Batey and co-workers accomplished another example of an IMDA using a borontethered substrate (Scheme 3.10).9 In this case, the boronic acid III-31 was first
transesterified to a boronate ester (III-33) with alcohol III-32 and then heated to form the
desired Diels-Alder cycloadduct (III-34) that was hydrolyzed at the boronate ester center
to reveal a free hydroxyl group (III-35).9 This was a curious investigation as this is
directly applicable to one of the major aims of this thesis work. Although a more detailed
synthetic application will be provided in Section 3.2 of this chapter, it can briefly be
stated here that the goal with this thesis work was to take a chiral diol that could be
transesterified with a boronic acid (in a similar strategy as that employed by Batey and
co-workers to synthesize III-33 in Scheme 3.10).9 Following this transesterification, we
hope to carry out an IMDA with good diastereoselectivity as that achieved by Batey and
co-workers (see Scheme 3.10 for product III-35).9

Ph

III-32
Ph
III-31

B(OH) 2

B
O

O

III-33

OH

5 mol% BHT
toluene
190 ˚C, 3 h
Me 3N +O-

Ph
OH
OH
III-35

Ph
benzene
80 ˚C, 24 h,
then water, 60 ˚C, 0.5 h
84%
endo:exo = 90:10

O
B
O

III-34

Scheme 3.10: Intramolecular Diels-Alder cycloaddition following transesterification between boronic
acid III-31 and alcohol III-32. The resulting cyclohexenyl derivative III-34 was then oxidized to the
9
diol III-35.
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3.1.1

A BRIEF BACKGROUND OF SELECTIVE DIHYDROXYLATION OF
DIENES AND TRIENES
The chiral diol that we intended to use for our investigations was prepared

according to a strategy employed by Zhang and O’Doherty.11 Previously, Sharpless
studied the asymmetric dihydroxylation of polyenes using osmium quinuclidine ligand
systems that reacted preferentially at the more electron-rich double bond of a polyene πsystem. Zhang and O’Doherty used the Sharpless asymmetric dihydroxylation (SAD)
protocol to assess the selective dihydroxylation of two conjugated dienes (III-36a and
III-36b) as shown in Schemes 3.11 (see Tables 3.6 and 3.7 for data). In general,
dihydroxylation of III-36a favored the diol product where the more electron-rich alkene
was preferentially reacted (III-37a and b) over the electron-deficient alkene (III-38a and
b) adjacent to either an ester, thioester, Weinreb amide, or ketone.11
O

OH
R1

R
O
R

R1
R1 = Me (III-36a)
Ph (III-36b)

OH
R1 = Me (III-37a)
Ph (III-37b)

OsO4
(DHQD) 2-PHAL
K 3Fe(CN) 6
MeSO 2NH 2

O
R

OH

R1
OH
R1 = Me (III-38a)
Ph (III-38b)
11

Scheme 3.11: Dihydroxylation studies of conjugated diene III-36a and III-36b.
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Entry (for III-36a)

R

Yield (%)

Ratio (III37a/III-38a)

%ee III-37a

%ee III-38a

1

OEt

78

>20:1

92

n.a.

2

Oi-Pr

45

9:2

72

96

3

Ot-Bu

76

6:1

76

n.a.

4

N(OMe)Me

82

>20:1

75

n.a.

5

Me

68

>20:1

69

n.a.

6

SMe

38

>20:1

92

n.a.
11

Table 3.6: Dihydroxylation results for conjugated diene III-36a.

Entry (for III-36b)

R

Yield (%)

Ratio (III37b/III-38b)

%ee III-37b

%ee III-38b

1

OEt

76

5:1

99

n.a.

2

Oi-Pr

50

7:3

91

98

3

Ot-Bu

62

5:3

91

99

4

N(OMe)Me

85

>20:1

99

n.a.

5

Me

68

~10:1

98

n.a.

6

SMe

31

3.7:1

99

99
11

Table 3.7: Dihydroxylation results for conjugated diene III-36b.

With respect to the dihydroxylation of conjugated diene III-36a, greater
selectivity (>20:1) was exhibited for the more electron-rich alkene when an ethyl ester
(Entry 1 in Table 3.6 resulting in 78% yield), Weinreb amide (Entry 4 in Table 3.6
resulting in 82% yield), ketone (Entry 5 in Table 3.6 resulting in 68% yield), or a
thioester (Entry 1 in Table 3.6 resulting in 38% yield) were used.11 The highest
enantioselectivity (92% ee) was observed for both R = OEt and R = SMe (Entries 1 and
6, respectively).11 Use of branched esters, such as isopropyl or tert-butyl esters (Entries 2
and 3 in Table 3.6), afforded more of the dihydroxylation product where the more
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electron-deficient alkene had been dihydroxylated (ratio of III-37a/III-38a 9:2 and 6:1,
respectively).11
Yields for the dihydroxylation of III-36b were comparable to those achieved for
III-36a.11 Nonetheless, the selectivity for the electron-rich alkene was significantly
reduced for the dihydroxylation of substrate III-36b.11 The highest selectivities were
observed for the Weinreb amide (>20:1 for Entry 4 in Table 3.7 resulting in 85% yield)
and ketone (~10:1 for Entry 5 in Table 3.7 resulting in 68% yield).11 The ethyl,
isopropyl, and tert-butyl esters (Entries 1 to 3 in Table 3.7) afforded less selectivity (ratio
of III-37b/III-38b 5:1, 7:3, and 5:3, respectively).11 In contrast to diene III-36a,
conjugated diene III-36b afforded the highest ee’s for the dihydroxylation of the
electron-rich alkene.11 Based on this data, it is thought that dihydroxylation is less
favorable on the electron-rich alkene when R = Ph (III-36b) due to disruption of
conjugation in the diene (between the Ph, a,b-alkene, and g,d-alkene) compared to III36a (R = Me).11 Furthermore, a clear trend can be observed with III-36a where an
increase in steric bulk of the ester (i.e. branched esters) coincided with a decrease in
regioselectivity (Entries 2 and 3 in Table 3.6), possibly due to steric interactions between
the branched ester and the ligand used, (DHQD)2PHAL.11
Dihydroxylation of triene III-39 also exemplified the regiocontrol of the
Sharpless protocol (Scheme 3.12).11 As is observed in Table 3.8, higher yields were
obtained for the unbranched esters (R = Me in 82% yield and Et 96% yield) as compared
to the use of branched esters (R = tert-butyl in 78% yield).11 Higher ee’s were observed
for the unbranched esters (>96% ee for Entry 1 and 2 in Table 3.8) compared to the
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branched ester that was screened.11 In all three Entries in Table 3.8, the favorability of
the electron-rich alkene was >20:1 for the dihydroxylation as compared to the electrondeficient alkene.11 In summary, this study demonstrated that the dihydroxylation of
phenyl-substituted diene III-36b afforded diol products with higher enantiomeric
excess.11 The unbranched ethyl ester III-36a (Entry 1 in Table 3.6) gave diol product
with good regiocontrol (>20:1). Use of branched esters reduced this regiocontrol
significantly.11
OsO4
(DHQD) 2-PHAL

O
R

O
R

K 3Fe(CN) 6
MeSO 2NH 2

III-39

OH

III-40

OH

11

Scheme 3.12: Dihydroxylation studies of conjugated diene III-39.

Entry

R

Yield (%)

Ratio

%ee III-40

1

Me

82

>20:1

96

2

Et

96

>20:1

99

3

t-Bu

78

>20:1

96

Table 3.8: Data for dihydroxylation (see Scheme 3.12) of triene III-39 showing preference for
11
unbranched esters.

3.2

RESULTS AND DISCUSSION

3.2.1

SYNTHETIC AIMS
With the results of the investigation by Zhang and O’Doherty in mind, we set out

to synthesize a diene that possessed both an electron-rich and electron-poor diene for a
subsequent dihydroxylation.11 Based on the results of Zhang and O’Doherty’s
investigation, we sought fit to synthesize a diene in which the electron-rich alkene was an
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a,b-unsaturated aryl group and the electron-poor diene was an a,b-unsaturated ethyl
ester, as unbranched esters afforded greater regioselectivity and enantioselectivity.11 The
aim of this molecule, alluded to earlier in Section 3.1.1, was to synthesize a diol with
good regiocontrol and enantioselectivity that could be transesterified for installation of a
boronate ester species that could participate in an IMDA (Scheme 3.13). In this scenario,
the electron-poor diene (a,b-unsaturated ethyl ester) would serve as our intramolecular
dienophile and the boronate ester would be our diene. Of interest from the investigation
by Zhang and O’Doherty was triene III-39 in Scheme 3.12, which indicated to us that
distance could be introduced between the electron-rich diene and the electron-deficient
diene for greater control over the regiochemistry and stereochemistry in the resulting diol
product.11 Nonetheless, because the resultant diol we endeavored to synthesize would be
used in an IMDA (after further transformations), the presence of the extra alkene between
the electron-rich and electron-deficient alkene in III-39 in Scheme 3.12 poses a major
geometrical constraint. We decided to synthesize an alternative diene, III-41, in Scheme
3.13 where the functional group that links our electron-rich and electron-deficient alkene
was selected to be either an ethylene linker (n = 2) or butylene linker (n = 4). It was
thought that the regiocontrol and stereocontrol afforded to the dienes produced in the
work by Zhang and O’Doherty would be transmitted in our model substrate despite the
presence of a saturated, rather than an unsaturated, linker between our two alkenes.11 We
then envisioned a Sharpless Asymmetric Dihydroxylation occurring preferentially on the
electron-rich alkene (a,b-unsaturated aryl group) in both high regiocontrol and
enantiocontrol (III-42). Following this dihydroxylation, we will have set two
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stereocenters along with two diols that can be transesterified with several unique boronic
acids (III-4 is used in Scheme 3.13). Our overall strategy hinged on the hope that easily
installed diol stereocenters resident on the boronate ester (III-43) would effectively
influence the diastereoselectivity in the subsequent IMDA cycloaddition according to the
investigations conducted by Hall and Batey (described above).2,9 The net result of this
approach would realize the facile relay of simply installed stereochemical information in
the substrate into much more complex chiral molecular scaffolds via the IMDA. The
boronate ester (III-43) that is generated can be subjected to a variety of Diels-Alder
conditions (Lewis acid activated and thermally activated methods) in an effort to produce
substrate (III-44, most likely as diastereomers) in accordance with the previously
described work by Batey and Roush.9,10
Sharpless Asymmetric Dihydroxylation

O
O
n

O

OH
* *
OH

O

n

III-42

III-41

*
O
*
B * *
O
O
O
n
* *

Intramolecular Diels-Alder Reaction
[IMDA]

B(OH) 2
B O
O
* *

O
n

O

III-43

III-44

Scheme 3.13: Proposed synthetic route for novel chiral boronate ester that can participate in IMDA
cycloaddition.

Initially, diene III-47 was produced in moderate yield according to an olefin
cross-metathesis of styrene, 1,5-hexadiene, and methyl acrylate catalyzed by a Grubbs
second generation catalyst using a method reported by Chatterjee et al. (Scheme 3.14).12
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Due to the low yield of the reaction, an alternative synthetic strategy was determined for
generating the diene.
i) Grubbs 2nd catalyst
(5 mol%)
40 ˚C, 3 h
ii) Grubbs 2nd catalyst
(5 mol%)

2 eq. III-45

O

(3 eq.)
40 ˚C, 12 h

O

42%
III-47

O III-46
1 eq.

O

12

Scheme 3.14: Synthesis of diene using ROMP catalysis. Route was abandoned due to low yield.

First, 6-bromo-1-hexanol (III-48) was oxidized using pyridinium chlorochromate
to an aldehyde (III-49) that was used without further purification and reacted via a Wittig
reaction to install an a,ß-unsaturated ester (III-50) in 78% yield (Scheme 3.15).13 It
should be noted that this reaction is operable with 4-bromo-1-butanol with similar
results.13 The brominated ester was then heated neat in the presence of
triphenylphosphine to afford the phosphonium bromide (III-51) in 97% yield.13 We next
sought to deprotonate the phosphonium bromide with a suitable base followed by
addition of benzaldehyde to install the styrenyl portion of the diene. Unfortunately, the
investigation of several bases including sodium hexamethyldisilazide (NaHMDS),
sodium hydride, potassium tert-butoxide, n-butyl lithium, while also calibrating the
temperature (e.g. room temperature, 0 ˚C, or -78 ˚C), did not facilitate the installation of
this key alkene functionality (III-52).13 A similar protocol was used (Scheme 3.16) with
both bromo-valeric acid and bromo-butyric acid (III-53), wherein the phosphonium

161

bromide (III-54) was deprotonated with NaHMDS followed by addition of benzaldehyde
at -60 ˚C, to no great effect.14 Another failed experiment (Scheme 3.17) was attempted in
which we hoped to deprotonate diethyl malonate (III-56) followed by alkylation with
cinnamyl chloride (III-57), followed by Krapcho decarboxylation, as a potential route to
styrenyl ester (III-58).15
PCC (1.2 eq.)
OH

Br

DCM (0.24 M), rt, 5 h

III-48

O

Br
III-49

O
III-52

H

Ph 3P

O
O

1.4 eq.

78% (over two steps)
(i) NaH (2 eq.)
THF, 0 ˚C, 30 m
(ii) PhCHO (1 eq.)
THF (0.1 mM), rt

O

O

Br

III-50
PPh 3, neat

O
97%
O

Ph 3P
III-51

Br

O

Scheme 3.15: Oxidation and Wittig of 6-bromo-1-hexanol; generation of phosphonium bromide;
13
attempt at Wittig.

O
Br
III-53

O

PPh 3 (1 eq.)

OH

(i) 2.2 eq. NaHMDS
THF, -60 ˚C
(ii) PhCHO, -60 ˚C to rt

Ph 3P
CH3CN, 15 h, Br
reflux

O
OH

OH

III-54

III-55

Scheme 3.16: Generation of phosphonium bromide and Wittig of bromoacid (shown for bromobutyric
14
acid).

O

cinnamyl chloride
(1 eq.)
K 2CO 3 (1.1 eq.)

O

EtO

OEt
III-56

DMF (0.72 M),
0 ˚C to rt

O
EtO

O
OEt

NaCl (2 eq.)
NaI (1 eq.)
water (40 eq.)
DMSO (0.39 M),
180 ˚C, 3 d

III-57

O
EtO
III-58

15

Scheme 3.17: Attempt at alkylation and decarboxylation of diethyl malonate.

A successful route to an appropriate diene for our strategy was initiated with the
addition of vinyl magnesium bromide to benzaldehyde affording allyl alcohol (III-60) in
quantitative yield, which was followed by a Johnson-Claisen rearrangement to afford the
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styrenyl ester (III-58) in 99% yield shown in Scheme 3.18.16 The ethyl ester was reduced
in the presence of lithium aluminum hydride to afford a primary alcohol (III-61) in 89%
yield that was oxidized to an aldehyde (III-62) via the Doering-Parikh protocol in 67%
yield.16,17 The aldehyde was reacted with triphenylcarbethoxymethylenephosphorane to
afford the desired diene in 82% yield (III-63). Product III-63 was then dihydroxylated by
the Sharpless Asymmetric Dihydroxylation (SAD) protocol to afford diol III-64 in 89%
yield.18 It should be noted that the diol was used after a basic work-up without further
purification, as it proved unstable to silica gel column chromatography, whereby the diol
product suffered decomposition to an unsaturated hydrocarbon species as judged by both
proton and carbon NMR. Following the basic work-up, diol III-64 was condensed with a
series of boronic acids to provide a suite of three boronic esters (III-65, III-66, and III67) using a room temperature mixture of the diol, the desired boronic ester, and 4 Å
molecular sieves in chloroform overnight.19 Products III-65, III-66, and III-67 represent
substrates ready for an IMDA cycloaddition, possessing both the diene and the dienophile
(Scheme 3.18).
The synthesis of the 2-methyl-1,3-butadienylboronic acid III-69 is represented in
Scheme 3.19.20,21 Hydroboration of 2-methyl-1-buten-3-yne (III-68) with pinacolborane
and the Schwartz reagent afforded the pinacol ester III-4 in 50% yield.20 Oxidative
hydrolysis of the pinacol ester was achieved in 87% yield (III-69) in the presence of
sodium metaperiodate and ammonium acetate.20,21 The boronic acid can be produced well
in advance and remains stable in the freezer.
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O

triethyl orthoacetate
(1.5 mL/mmol)
propionic acid (0.07 eq.)

OH

5 eq vinyl-MgBr

H
THF (0.2 M),
0 ˚C, 4 h, N 2
rt, o/n
quant.
OEt

III-59

Ph 3P
O
1.4 eq.

O
III-63

AD-mix-β
Me-SO 2NH 2
(2.4 eq)
tert-BuOH:H2O
(1:1)
0 ˚C, 18 h

O

H
III-62

89%

O
R
O
III-64

O

R
B

145 ˚C, overnight
99%
SO 3Py (3 eq)
NEt 3 (5 eq)

O

THF, rt, N 2
82%

OH
OH

III-60

DMSO:DCM (1:1; 0.5 M),
0 ˚C, N 2, 2 h
67%

III-58

O
OEt

LiAlH 4 (0.5 eq.)
THF, 0 ˚C to rt, o/n
89%

OH
III-61

O

B(OH) 2
1 eq.

O

O
CHCl3 (0.2 M)
rt, o/n
III-65 (R=2-methyl-1-butadien-3-yl); 84%
4 Å molecular sieves III-66 (R=2-furanyl); 91%
III-67 (R=3-furanyl); quant.

Scheme 3.18: Retooled synthesis of diene for higher mass yield. Synthesis was further retooled upon
16-19
discovering failures with the intramolecular Diels-Alder.
Pinacolborane
(1.05 eq.)
Cp 2ZrHCl (0.05 eq.)
III-68

0 ˚C (30 m),
rt, 48 h
50%

O

B
O
III-4

NH 4OAc (0.1 M)
NaIO 4 (3.0 eq.)
Acetone (0.03 M)
rt, 48 h
87%

OH
B
III-69 OH

Scheme 3.19: Hydroboration and hydrolysis of 2-methyl-1-buten-3-yne affording desired boronic acid
20,21
III-69.

Several methods were explored in an attempt to execute the desired IMDA
cycloaddition utilizing precursors III-65, III-66, and III-67.22-25 The substrates were
heated for up to three days at 160 ˚C, both neat and in toluene, resulting in isolation of
starting material. Heating the substrates neat in temperatures up to 260 ˚C resulted in
decomposition of the substrate. Stirring the compounds at room temperature for up to
four days in the presence of a Lewis acid (EtAlCl2, SnCl4, or ZnCl2) afforded starting
material. Heating these Lewis acid catalyzed reactions may be advantageous for
performing the Diels-Alder cycloaddition of our substrate; however, this was not
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attempted as part of this thesis work. Use of lanthanide Lewis acids, such as Eu[fod]3 or
Yb[fod]3, also resulted in isolation of starting material. Several of these failed attempts
are highlighted in Scheme 3.20.22-25 All of the methods represented in Scheme 3.20 were
evaluated with III-65, III-66, and III-67, respectively.

O

R
B

O
Ph

(i) EtAlCl 2 (0.9 eq), DCM:toluene (1:1), rt, 4 d
(ii) toluene (0.02 M), 160 ˚C, 65-72 h
(iii) SnCl 4 (1 eq), DCM, rt, 4 d
(iv) ZnCl2 (1 eq), DCM, rt, o/n
(v) Eu(fod) 3, (0.1 eq), TFE, rt, 48 h
(vi) Yb(fod)3, (0.1 eq), TFE, rt, 48 h

O
B O

Ph

n = 1 or 3

n = 1 or 3

R= 2-methyl-butadien-3-yl; 2-furanyl; 3-furanyl
EtO 2C

CO 2Et
22-25

Scheme 3.20: General scheme for failed Diels-Alder attempts; TFE = 2,2,2-trifluoroethanol.

Due to the failure of the IMDA cycloaddition under a number of conditions, as
evidenced in Scheme 3.20, it was thought the ethylene linker was too geometrically
restrictive to allow for the cycloaddition to occur. Therefore, another diene was
synthesized via repeating previously reported protocols to install a longer butylene linker
that would hopefully overcome this issue (Scheme 3.21).26,27 This route began with the
mono-protection of 1,6-hexanediol (III-70) with a THP group in 66% yield (III-71).
Swern oxidation of the alcohol was achieved in 77% yield (III-72) followed by a Wittig
reaction that could be carried out on a gram-scale to install the desired, unsaturated ester
in 96% yield (III-73). The THP group was cleaved via stirring the protected alcohol in
ethanol with a few drops of concentrated hydrochloric acid to afford a free alcohol in
quantitative yield (III-74). Swern oxidation of the free alcohol revealed an aldehyde in
72% yield (III-75). This synthetic route hit a roadblock when aldehyde III-75 failed to
engage in the requisite olefination necessary to install the styrenyl portion of the desired
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diene III-52, despite evaluating several olefination conditions (see Scheme 3.21).
Ultimately, this route was abandoned in favor of a more tractable route to the same target
(vide infra, Scheme 3.24).
A few other unsuccessful routes are highlighted below for posterity. First, we
envisioned accessing an appropriate aldehyde intermediate (i.e. III-75) en route to a
diene with a longer methylene tether via an alkylation strategy employing an appropriate
alkyl iodide and enamine (Scheme 3.22). The enamine was generated by one of two
methods: a.) reflux of pyrrolidine and acetaldehyde in toluene under Dean-Stark
conditions for 48 hours, and b.) allowing a solution of pyrrolidine, acetaldehyde, and
sodium sulfate to stand in the freezer overnight.28,29 The alkyl iodide III-78 was
generated via a Mitsunobu reaction of alcohol III-61. Nonetheless, the successful
alkylation of III-78 with the enamine was never realized, so this route was abandoned.30
H

O
HO

DMSO (2.9 eq)
oxalyl chloride (1.2-2.0 eq.)
-78 ˚C, 15 m
NEt 3 (7.06 eq)
-78 ˚C to rt, o/n

HO
camphorsulfonic acid (0.1 eq.)
3,4-dihydro-2H-pyran (1 eq.)

O

DCM, 4 h, rt
66%

III-70
OH

III-72

1.4 eq.

DCM, 16 h, rt
96%

Ph 3PCHPh
or
Ph
O P
EtO OEt
Ph

[Na or Li]

O
III-73

III-71
Ph 3P(Br)CH 2Ph or O P
EtO OEt

EtO 2C

Ph 3P

O
O

77%

O

CO 2Et
CO 2Et

O

Ph

(i) 0.9-1.0 eq n-BuLi
or 1.1 eq NaH
-78 ˚C, 1.5 h
(ii) NaH (1.0 eq)
THF (0.02 M)
30 m, -78 ˚C
(iii) 1 M LiHMDS (0.9 eq)
THF (0.02 M),
30 m, -78 ˚C

3 drops conc. HCl
30 mL absolute ethanol
rt, o/n
>99%
HO

EtO 2C

O
III-75

III-52

H

oxalyl chloride (1.2 eq.)
DMSO (2.9 eq.) in DCM (0.2 mM)
NEt 3 (7.06 eq), -78 ˚C
72%

III-74
EtO 2C

Scheme 3.21: Alternative route that was repeated involving THP protection, Swern, and Wittig
26,27
reactions on 1,6-hexanediol III-70.
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III-61
OH

(i) acetaldehyde (0.5 eq)
toluene, ∆, 48 h
(ii) acetaldehyde (0.97 eq),
sodium sulfite (0.92 eq),
0 ˚C, o/n

N
H

I 2 (1.5 eq.),
PPh 3 (1.5 eq.),
50% imidazole (1.5 eq.)
DCM (0.3 M),
0 ˚C to rt, 3 h
I
N
H
III-77

III-76

O

1.49 eq. III-78 H O, ∆, 8 h
2
1,4-dioxane,
∆, 16 h

work-up

H
III-79
28-31

Scheme 3.22: Attempted alkylation of alkyl iodide III-78 with enamine III-77.

In a second unsuccessful approach, we sought to incorporate a heteroatom in the
linker region separating the two alkenes of the target diene. Therefore, we attempted to
alkylate the alkoxide of alcohol III-61 with 4-bromocrotonate utilizing several basic
conditions as highlighted in Scheme 3.23. The desired alkylation event was never
realized.
(i) n-BuLi (1.1 eq), THF, 78 ˚C
ethyl bromocrotonate (1.1 eq), THF, rt
(ii) LiHMDS (1.1 eq), THF, 0˚C or -78 ˚C
ethyl bromocrotonate (1.1 eq), THF, rt
(iiI) NEt 3, rt, ethyl bromocrotonate
(1.1 eq), THF
OH
III-61

(iv) NaH (1.1 eq), ACN, 0 ˚C,
then ethyl bromocrotonate, DCM,
reflux

O

O
III-80

O

(v) NaH (XS), benzene, rt to 80 ˚C,
then ethyl bromocrotonate (1.1 eq),
benzene, 80 ˚C

Scheme 3.23: Alkylation of III-61 with ethyl 4-bromocrotonate.

Ultimately, a diene bearing a longer, 4-carbon linker was successfully prepared by
a convenient route that is depicted in Scheme 3.24. Sonogashira coupling of iodobenzene
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(III-81) and 6-heptyn-1-ol (III-82) resulted in clean arylation of the alkynyl alcohol
producing III-83 in 86% yield.32 Reduction of the alkyne to the alkene was performed in
the presence of refluxing lithium aluminum hydride to afford III-84 in quantitative
yield.33-35 The alcohol was then oxidized according to the Doering-Parikh protocol to
afford aldehyde III-79 in 69% yield.17,36,37 Wittig olefination of the aldehyde resulted in
isolation of diene III-52 in 84% yield, which was then dihydroxylated according to the
Sharpless Asymmetric Dihydroxylation (SAD) protocol using AD-mix-ß to afford diol
III-85 in 95% yield.18 Diol III-85 was then converted to the desired boronic ester III-86
in 84% yield through a room temperature reaction of the diol and boronic acid III-69 in
chloroform with 4 Å molecular sieves.19 Product III-86 represents an analog of IMDAprecursor III-65 bearing a longer, more flexible 4-C linker separating the boronate ester
diene from the a,b-unsaturated ester dienophile. Unfortunately, substrate III-86 was
subjected to the same IMDA reactions conditions described in Scheme 3.20 without
fruitful results.22-25
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Ph

Pd(PPh 3) 4 (0.5 mol%)
CuI (1.05 mol%)
NEt 3 (10.5 eq.)

I

III-81

OH
III-82

THF, rt, 12 h
86%

SO3Py (3 eq.)
NEt 3 (5 eq.)

LiAlH 4 (7.5 eq.)
THF, reflux, 96 h

HO

Ph

Ph

III-83

OH
III-84

>99%

O
H III-79

DMSO:DCM
(1:1)
0 ˚C, 2 h

Ph
O
*
B
*
* O
*

*

CO 2Et

O
IMDA

HO

B O
* * Ph

III-87
III-86

HO

B

HO

*

AD-mix-β
MeSO 2NH 2 (1 eq.)

OH

CHCl3 (0.02 M)
rt, o/n
84%

Ph

* Ph

tert-butanol:H2O (1:1)
0 ˚C, 48 h
95%
III-85
CO 2Et

EtO 2C

CO 2Et
1.4
THF,eqrt,
o/n 84%

Ph 3P

69%

III-52
CO 2Et

Scheme 3.24: Synthesis of boronate ester III-86 for use in the IMDA cycloaddition. Asterisks used to
17-19, 22-25, 32-37
emphasize absolute stereocenters set as a result of this methodology.

3.3

CONCLUSIONS AND FUTURE DIRECTIONS
The synthesis of a novel chiral boronate ester (III-86) for participation in the

IMDA cycloaddition was accomplished in the third part of this thesis work. The potential
beauty of the proposed IMDA to generate product III-87 in Scheme 3.24 is: 1.) the
potential to set several stereocenters with high diastereoselectivity as a result of the
IMDA cyclization governed by the easily installed diol stereochemistry embedded in the
boronate ester diene, and 2.) the potential to effect further transformations of the boronate
ester moiety resident in the Diels-Alder product III-87. For example, oxidative removal
of the boronate ester would reveal an alcohol that could then engage in several
transformations including etherifications, esterifications, and acylations, etc. Another
option is an allylboration, discussed previously in the work by Gao and Hall.2

169

Organometallic transformations, such as Suzuki couplings, might also be possible from
cycloadduct III-87.
In addition, an alternate synthetic route can be envisioned that allows for the
positioning of the boronate ester diene in an “exo” fashion (i.e. not part of the longest
chain on the molecule) relative to the a,b-unsaturated ester dienophile as presented in
Scheme 3.25. A 1,2-addition of phenyl lithium to caprolactone (III-88) will afford a
keto-alcohol (III-89) that can be protected as a silyl ether using conventional methods
(III-90) to accommodate for a selective Wittig olefination at the ketone carbonyl (III91).38 The silyl group can then be deprotected to reveal the starting alcohol (III-92) that
can then be oxidized to an aldehyde using the Doering-Parikh oxidation (III-93),
followed by a Wittig olefination to afford our desired unsaturated ester (III-94). The exo
alkene can then be dihydroxylated via the Sharpless protocol reported in this document to
afford a diol (with one stereocenter installed instead of the two incorporated onto III-85)
that can be transesterified to the desired boronate ester (III-96 resulting from the use of
boronic acid III-69 for the purposes of this illustration). The rationale behind this method
is that the exo positioning of the boronate ester diene may facilitate an easier
intramolecular Diels-Alder reaction with the a,b-unsaturated ester dienophile via reduced
geometrical constraint of the aliphatic tether.
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Scheme 3.25: Alternate synthetic strategy appending boronate ester diene in exo fashion to a,b32–38
unsaturated ester dienophile (III-96).

In addition, we can take advantage of the gem-dimethyl effect through the
incorporation of two methyl groups alpha to the carbonyl center on molecule III-79.
Performing the Wittig olefination, dihydroxylation, and transesterification described
above in Scheme 3.25 will produce a chiral boronate ester that will have the diene and
dienophile in closer proximity through steric repulsion caused by the two interfering
methyl groups (Scheme 3.26). As a result, this may facilitate a more facile intramolecular
Diels-Alder cycloaddition.
O

O

n-BuLi, then MeI (x2)
H

III-79

THF

O
H

III-97

OEt
III-98

Scheme 3.26: Addition of two methyl groups on III-79 to facilitate gem-dimethyl effect for IMDA.

Although the reaction shown in Scheme 3.24 depicts one type of styrenyl, a,bunsaturated ester, and alkyl functionality. Multiple derivatives can be targeted through
variations of the three aforementioned functionalities. The aromatic ring could be
functionalized with electron-donating groups so that an electron-rich alkene participates
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in the SAD. Various derivatives of III-86 can be prepared by tailoring the length of the
aliphatic tether or via the introduction of a heteroatom. Although the latter idea was as yet
unsuccessful (as described above), perhaps an amine or amide linker could be useful in
enhancing the scope of this synthetic methodology toward highly-substituted organic
molecules. Furthermore, variations in tether length will help establish a maximum
distance before the IMDA cycloaddition will no longer be feasible. The source of diene
might be varied even further via migration of the boronate ester from a 1,4-position, e.g.
2-methyl-1-butadien-3-yl, as shown in Scheme 3.24, to a 1,2- or 1,3-position. These
sources for variation will supplement the utility of the projected novel, stereo-enriched
boronate adduct from the IMDA cycloaddition to the realm of complex, natural product
synthesis.
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3.4

EXPERIMENTAL

3.4.1

COMPLETED SYNTHESES

All reagents were purchased from commercial suppliers and used without further
purification. All isolated products were purified via flash column chromatography using
silica gel SDS 60 C.C. 40-63 µm. 1H and

13

C NMR spectra were collected at ambient

temperature on a 300 (Bruker Avance) or 500 MHz NMR spectrometer (Bruker Avance
or JEOL Eclipse). Chemical shifts are reported in parts per million (ppm) and referenced
to residual solvent peaks (i.e., d 7.28 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3;
2.54 ppm for 1H NMR, 40.45 ppm for

13

C NMR in DMSO-d6). Data are presented as

follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet),
and integration. Infrared (IR) spectra, reported in cm-1, were collected using a Fourier
transform spectrophotometer. Compounds III-49 to III-51,13 III-54,14 III-57,15 III-71 to
III-75,26,27 III-77,28,29 and III-7830 were prepared using known methods and exhibited
spectral data consistent with previously reported syntheses.

Synthesis of [(1E)-3-methylbuta-1,3-dien-1-yl] boronic acid pinacol ester (III-4)

O B

O

To a dry, 100 mL roundbottomed flask were added 13 mg Cp2ZrHCl (0.05 mmol; 0.05
eq) using a dry bag. The roundbottomed flask was cooled to 0 ˚C, then 0.160
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pinacolborane (1.1 mmol; 1.1 eq) was added dropwise followed by 95 µL 3-methyl-but3-en-1-yne III-68 (1 mmol; 1 eq). The reaction mixture was stirred at room temperature
for 48 hours and then loaded directly onto a column. After washing the column with (0 to
25%) ethyl acetate:hexanes, III-4 was obtained in 50% yield (40.2 mg; 0.207 mmol).

Compound III-4
1

H-NMR (500 MHz; CDCl3): d 7.13-7.09 (d, 1H, J = 20 Hz), 5.58-5.55 (d, 1H, J = 15

Hz), 5.17 (s, 2H), 1.86 (s, 3H), 1.29 (s, 12H);

13

C-NMR (125 MHz; CDCl3): d 152.3,

143.1, 120.2, 83.3, 24.9, 24.6, 17.8; IR (NaCl salt plate): 3064, 3030, 2965, 2932, 1718,
1682, 1625, 1572, 1535, 1506, 1472, 1393, 1370, 1344, 1313, 1280, 1226, 1152, 1137,
1120, 1105, 1069, 1043, 1002, 968, 939, 909, 878, 858, 833, 814, 780, 755, 740, 699,
683.7,20,21

Synthesis of 2-[6-phenyl-hex-5-enyl]-ethyl acrylate (III-52)

Ph

CO 2Et
To a three-dram vial were added a stirbar, 25 mg III-79 (0.133 mmol; 1 eq), 1 mL
anhydrous THF, and 65 mg triphenylcarbethoxymethylenephosphorane (0.189; 1.4 eq).
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Four total reactions were set up (used 100 mg; 0.568 mmol III-79). The solutions were
stirred at room temperature overnight. The next day, the solutions were evaporated onto
silica and the column was washed with ethyl acetate (1% to 5%):hexanes to isolate diene
III-52 (0.1149 g; 0.470 mmol) in 87% yield.

Compound III-52
1

H-NMR (500 MHz; CDCl3): d 7.37-7.35 (d, 2H, J = 10 Hz), 7.33-7.29 (t, 2H, J = 10, 20

Hz), 7.23-7.20 (t, 1H, J = 5, 15 Hz), 7.02-6.96 (m, 1H), 6.42-6.39 (d, 1H, J = 15 Hz),
6.25-6.19 (m, 1H), 5.86-5.83 (d, 1H, J = 15 Hz), 4.23-4.18 (q, 2H, J = 10, 25 Hz), 2.25
(m, 4H), 1.54-1.53 (m, 4H), 1.32-1.29 (t, 3H, J = 5, 15 Hz);

13

C-NMR (125 MHz;

CDCl3): d 166.8, 149.2, 137.8, 131.6, 130.5, 130.2, 128.6, 128.3, 126.9, 126.0, 121.5,
60.2, 32.8, 32.1, 28.9, 27.6, 14.4; IR (NaCl salt plate): 3080, 3057, 3024, 2979, 2929,
2855, 1719, 1654, 1598, 1577, 1560, 1542, 1492, 1459, 1447, 1390, 1367, 1307, 1264,
1182, 1145, 1096, 1071, 1042, 980, 965, 913, 853, 799, 745, 693.

Synthesis of (4E)-ethyl-5-phenylpent-4-enoate (III-58)
O
OEt

To a high-pressure glass tube was added 670.9 mg III-60 (5 mmol; 1 eq), 7.5 mL triethyl
orthoacetate (1.5 mL/mmol), and 26 µL propionic acid (0.347 mmol; 0.07 eq). The
reaction mixture was stirred overnight at 145 ˚C. The next day, the reaction mixture was
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cooled to room temperature and diluted with 5 mL ethyl acetate. The organic layer was
washed sequentially with 5 mL 1 M HCl, 5 mL water, and 5 mL saturated brine. The
organic layer was dried with sodium sulfate, filtered, and concentrated to afford III-58 in
99% yield (1.0214 g; 5 mmol).

Compound III-58
1

H-NMR (300 MHz; CDCl3): d 7.40-7.29 (m, 4H), 7.25-7.20 (m, 1H), 6.48-6.43 (d, 1H,

J = 15 Hz), 6.28-6.18 (m, 1H), 4.21-4.14 (q, 2H, J = 6, 21 Hz), 2.57-2.50 (m, 4H), 1.311.26 (t, 3H, J = 9 Hz); 13C-NMR (75 MHz; CDCl2): d 172.9, 137.5, 130.9, 128.6, 127.2,
126.9, 126.1, 60.4, 34.1, 28.4, 14.2; IR (neat): 1735, 1596, 1489, 1444, 1372, 1252, 1189,
1161, 965, 742, 691.39

Synthesis of 1-hydroxy-1-phenyl-prop-2-ene (III-60)

OH

To a dry, 100 mL roundbottomed flask were added benzaldehyde III-59 (0.510 mL; 5.0
mmol; 1.0 eq) and 25 mL THF (0.2 M). The solution was cooled to 0 ˚C in an ice-water
bath followed by the dropwise addition of vinylmagnesium bromide (1 M in THF; 5 mL;
5 mmol; 1 eq). The solution was stirred at 0 ˚C for 15 minutes, then at room temperature
for 4 hours. After that time, the solution was re-cooled to 0 ˚C, then quenched with the
addition of 20 mL saturated ammonium chloride. The reaction mixture was extracted
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with diethyl ether (3 x 50 mL). The combined organics were washed with 50 mL
saturated brine, then dried with sodium sulfate, filtered, and concentrated to afford III-60
in quantitative yield (0.8433 g; 6.28 mmol).

Compound III-60
1

H-NMR (500 MHz; CDCl3): d 7.29-7.27 (m, 5H), 5.98-5.93 (m, 1H), 5.28-5.25 (d, 1H,

J = 15 Hz), 5.12-5.11 (d, 1H, J = 5 Hz); 13C-NMR (125 MHz; CDCl2): d 140.4, 128.7,
127.8, 127.1, 126.4, 115.2, 75.4, 68.0; IR (neat): 3370, 1025, 990, 930, 760, 700.40

Synthesis of (E)-5-phenylpent-4-en-1-ol (III-61)
OH

To a dry, 100 mL roundbottomed flask were added 87 mg lithium aluminum hydride (2.3
mmol; 0.5 eq) using a dry bag. The roundbottomed flask was cooled in an ice-water bath
at 0 ˚C followed by the dropwise addition of 1 M diethyl ether (10 mL; 0.23 M). To this
suspension was added 0.931 g III-58 (4.6 mmol; 1 eq) in 1 M diethyl ether (4.6 mL). The
reaction mixture was stirred at 0 ˚C for 2 hours, then at room temperature overnight. The
following day, the reaction mixture was cooled to 0 ˚C in an ice-water bath. To the
suspension was SLOWLY added 1 mL water, 1 mL 3.75 M NaOH, and 3 mL water. The
suspension was filtered through a funnel and the white precipitated salts rinsed copiously
with diethyl ether (approx. 300 mL). The filtrate was evaporated to afford III-61 in 88%
yield (650.8 mg; 4.01 mmol).
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Compound III-61
1

H-NMR (500 MHz; CDCl3): d 7.40-7.27 (m, 4H), 7.21 (m, 1H), 6.46-6.43 (d, 1H, J =

15 Hz), 6.29-6.24 (m, 1H), 3.73-3.70 (5, 2H, J = 6.5, 15 Hz), 2.36-2.33 (m, 2H), 1.791.76 (m, 2H); 13C-NMR (125 MHz; CDCl2): d 130.2, 128.7, 128.6, 127.1, 127.1, 126.1,
62.5, 32.3, 29.4; IR (neat): 3347, 3024, 2935, 1597, 1494, 1447, 1057, 965, 914, 741,
692.41

Synthesis of Synthesis of (E)-5-phenylpent-4-en-1-al (III-62)
O
H

To a dry, 100 mL roundbottomed flask were added 559 mg III-61 (3.45 mmol; 1 eq), 3.5
mL anhydrous DMSO, 3.5 mL anhydrous DCM, and 2.4 mL trimethylamine (17.25
mmol; 5 eq). The solution was cooled to 0 ˚C in an ice-water bath followed by addition of
1.65 g sulfur trioxide-pyridine complex (10.35 mmol; 3 eq). The reaction mixture was
stirred at 0 ˚C for 2 hours, and then quenched using phosphate buffer solution (10 mL;
20X; pH = 7.9). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The
combined organic layer was washed combined organics with saturated brine (35 mL),
then dried with sodium sulfate, filtered, and concentrated. The residue was loaded onto a
column and III-62 was obtained after washing with hexanes:ethyl acetate (0 to 20%) in
67% yield (370.4 mg; 2.31 mmol).
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Compound III-62
1

H-NMR (500 MHz; CDCl3): d 9.85 (m, 1H), 7.37-7.35 (d, 2H, J = 10 Hz ), 7.34-7.31

(t, 2H, J = 10, 15 Hz), 7.25-7.22 (t, 1H, J = 5, 15 Hz), 6.48-6.44 (d, 1H, J = 20 Hz), 6.266.22 (m, 1H), 2.66-2.65 (m, 2H), 2.49-2.47 (m, 2H);

13

C-NMR (125 MHz; CDCl2): d

201.9, 137.3, 131.2, 128.6, 128.2, 127.3, 126.1, 43.4, 25.6; IR (neat): 3080, 3050, 3020,
2920, 2830, 2730, 1720, 1600, 1495, 1450, 970, 755, 700.27

Synthesis of 2-[4-phenyl-but-3-enyl]-ethyl acrylate (III-63)

O
O

To a dry, 3 mL vial were added 25 mg III-62 (0.156 mmol; 1 eq), 1.0 mL anhydrous
THF, and 25 mg triphenylcarbethoxymethylenephosphorane (0.218 mmol; 1.4 eq). Set up
three vials (used 75 mg; 0.326 mmol III-62). The reaction mixture was stirred overnight
at room temperature. The following day the reaction mixture was evaporated onto silica
and loaded onto a column. Product III-63 was isolated after washing with hexanes:ethyl
acetate (0 to 5%) in 82% yield (88.5 mg; 0.384 mmol).

Compound III-63
1

H-NMR (500 MHz; CDCl3): d 7.37-7.35 (d, 2H, J = 10 Hz), 7.33-7.30 (t, 2H, J = 5, 15

Hz), 7.24-7.21 (5, 1H, J = 5, 15 Hz), 7.04-7.01 (m, 1H), 6.46-6.43 (d, 1H, J = 15 Hz),
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6.23-6.20 (m, 1H), 5.91-5.88 (d, 1H, J = 15 Hz), 4.23-4.19 (q, 2H, J = 5, 20 Hz), 2.422.40 (m, 4H), 1.33-1.29 (t, 3H, J = 10, 20 Hz);

13

C-NMR (125 MHz; CDCl2): d 166.7,

148.2, 137.5, 131.0, 128.9, 128.6, 127.2, 126.1, 121.9, 60.3, 32.1, 31.5, 14.37; IR (NaCl
salt plate): 2957, 2924, 2853, 1719, 1687, 1677, 1655, 1638, 1474, 1458, 1450, 1421,
1397, 1368, 1311, 1264, 1201, 1177, 1095, 1041, 980, 701.

Synthesis of 2-[4-phenyl-3,4-butanediol]-ethyl acrylate (III-64)

OH
O
OH

O

To a dry, 100 mL roundbottomed flask were added a stirbar, 4 mL tert-butyl alcohol, 4
mL water, 166 mg (1.75 mmol; 0.49 eq) methanesulfonamide, and 5.66 g AD-mix-beta.
The solution was stirred at room temperature for 30 minutes, then brought to 0 ˚C in an
ethylene glycol bath using an immersion cooler. Once the solution had reached the
appropriate temperature, 820.9 mg (3.56 mmol; 1 eq) of III-63 in 2 mL (1:1) tert-butyl
alcohol:water was added all at once. The solution was stirred at 0 ˚C for 18 hours. After
that time, solution as quenched with 20 mL saturated sodium sulfite, then extracted with
ethyl acetate (3 x 25 mL). The combined organics were then washed with 5 mL 2 M
KOH, dried with sodium sulfate, filtered, and evaporated. Diol III-64 (942 mg; 3.56
mmol) was isolated in 89% yield.
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Compound III-64
1

H-NMR (500 MHz; CDCl3): d 7.38-7.32 (m, 5H), 6.93-6.87 (m, 1H), 5.79-5.75 (d, 1H,

J = 20 Hz), 4.45-4.44 (d, 1H, J = 5 Hz), 4.19-4.15 (q, 2H, J = 10, 20 Hz), 3.73-3.69 (m,
1H), 2.1-2.78 (broad s, 2H), 2.42-2.40 (m, 2H), 2.23-2.21 (m, 1H), 1.57-1.52 (m, 1H),
1.47-1.43 (m, 1H), 1.30-1.27 (t, 3H, J = 5, 15 Hz); 13C-NMR (125 MHz; CDCl2): d 166.7,
148.5, 140.9, 128.7, 128.3, 126.8, 121.6, 78.0, 75.1, 60.2, 30.9, 28.4, 14.3; IR (NaCl salt
plate): 3083, 3061, 3028, 2981, 2934, 1717, 1652, 1602, 1554, 1508, 1494, 1451, 1393,
1368, 1311, 1271, 1196, 1157, 1096, 1041, 981, 920, 852, 763, 702, 667, 638, 622.

Synthesis of 2-[4-phenyl-3,4-[2-methyl-1-buten-3-yl-borono]-butanediol]-ethyl acrylate
(III-65)

O

B

O

O
O

To a dry, 100 mL roundbottomed flask were added a stirbar, III-64 (95.7 mg; 0.362
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 2-methyl-1-buten-3-ylboronic acid (41 mg; 1 eq; 0.362 mmol). The solution was stirred at room temperature
overnight. The solution was then filtered and diluted with 5 mL water before extraction
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with DCM (3 x 10 mL). The combined organics were then dried with sodium sulfate,
filtered and evaporated to afford boronate ester III-65 in 96% yield (139 mg; 0.409
mmol).

Compound III-65
1

H-NMR (500 MHz; CDCl3): d 7.42-7.31 (m, 5H), 7.26-7.23 (d, 1H, J = 20 Hz), 7.02-

6.97 (m, 1H), 5.88-5.85 (d, 1H), (5.69-5.65 (d, 1H, J = 20 Hz), 5.23-5.22 (d, 2H, J = 5
Hz), 4.98-4.97 (d, 1H, J = 5 Hz), 4.22-4.18 (m, 3H), 2.51-2.49 (m, 1H), 2.41-2.35(m,
2H), 1.92 (s, 3H), 1.31-1.28 (t, 3H, J = 5, 15 Hz)13C-NMR (125 MHz; CDCl3): d 166.6,
153.5, 147.7, 143.1, 140.7, 128.9, 128.5, 126.1, 125.8, 122.2, 120.8, 84.2, 84.2, 60.34,
34.1, 28.2, 17.8, 14.3; IR (NaCl salt plate): 3082, 3062, 3028, 2978, 2929, 2855, 1716,
1652, 1624, 1600, 1495, 1451, 1368, 1342, 1294, 1181, 1096, 1041, 997, 906, 851, 804,
759, 700, 640.

Synthesis of 2-[4-phenyl-3,4-[2-furanylborono]-butanediol]-ethyl acrylate (III-66)
O
O

B

O

O
O
To a dry, 100 mL roundbottomed flask were added a stirbar, diol III-64 (26 mg; 0.1
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 2-furanylboronic acid (11.2
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mg; 1 eq; 0.1 mmol). The solution was stirred at room temperature overnight. The
solution was then filtered and diluted with 5 mL water before extraction with DCM (3 x
10 mL). The combined organics were then dried with sodium sulfate, filtered and
evaporated to afford boronate ester III-66 in 91% yield (31.1 mg; 0.09 mmol).

Compound III-66
1

H-NMR (500 MHz; CDCl3): d 7.74 (s, 1H), 7.44-7.41 (m, 4H), 7.39-7.32 (m, 1H), 7.21-

7.20 (d, 1H, J = 5 Hz), 7.02-6.96 (m, 1H), 6.52 (d, 1H), 5.88-5.85 (d, 1H, J = 15 Hz),
5.10-5.09 (d, 1H, J = 5 Hz), 4.41-4.37 (m, 1H), 4.24-4.20 (q, 2H, J = 10, 20 Hz), 2.422.41 (m, 2H), 1.99-1.95 (m, 2H), 1.32-1.29 (t, 3H, J = 5, 15 Hz); 13C-NMR (125 MHz;
CDCl3): d 166.5, 147.8, 147.4, 139.9, 128.9, 128.6, 128.5, 126.0, 125.9, 124.3, 122.2,
121.9, 110.5, 84.7, 84.7, 60.27, 33.8, 28.0, 14.3; IR (NaCl salt plate): 3063, 3030, 2930,
1717, 1653, 1624, 1577, 1507, 1485, 1456, 1390, 1369, 1341, 1316, 1279, 1228, 1203,
1160, 1096, 1076, 1042, 981, 910, 886, 833, 782, 757, 699.

Synthesis of 2-[4-phenyl-3,4-[3-furanylborono]-butanediol]-ethyl acrylate (III-67)
O

O

B

O

O
O
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To a dry, 100 mL roundbottomed flask were added a stirbar, III-64 (100 mg; 0.378
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 3-furanylboronic acid (42.3
mg; 1 eq; 0.378 mmol). The solution was stirred at room temperature overnight. The
solution was then filtered and diluted with 5 mL water before extraction with DCM (3 x
10 mL). The combined organics were then dried with sodium sulfate, filtered and
evaporated to afford boronate ester III-67 in 91% yield (142.7 mg; 0.419 mmol).

Compound III-67
1

H-NMR (500 MHz; CDCl3): d 7.89 (s, 1H), 7.53 (s, 1H), 7.42-7.33 (m, 5H), 7.02-6.99

(m, 1H), 6.68 (s, 1H), 4.33-4.32 (m, 1H), 4.22-4.19 (m, 2H), 2.53-2.51 (m, 1H), 2.412.38 (m, 2H), 1.95-1.94 (m, 2H), 1.30-1.29 (m, 3H);

13

C-NMR (125 MHz; CDCl3): d

166.6, 151.8, 147.6, 143.3, 140.4, 128.9, 128.6, 126.1, 125.9, 122.2, 113.2, 84.4, 84.4,
60.4, 34.1, 28.2, 14.3; IR (NaCl salt plate): 3064, 3030, 2965, 2932, 1718, 1682, 1625,
1572, 1535, 1506, 1472, 1393, 1370, 1344, 1313, 1280, 1226, 1152, 1137, 1120, 1105,
1069, 1043, 1002, 968, 939, 909, 878, 858, 833, 814, 780, 755, 740, 699, 683.

Synthesis of [(1E)-3-methylbuta-1,3-dien-1-yl] boronic acid (III-69)

HO B

OH

To a dry, 100 mL roundbottomed flask were added 100 mg III-4 (0.515 mmol; 1.0 eq),
17 mL acetone, and 10.4 mL 0.1 M aqueous ammonium acetate. Then was added 330 mg
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sodium metaperiodate (1.54 mmol; 3 eq). The reaction mixture was stirred overnight at
room temperature. The solution was evaporated to remove the acetone, then 5 mL 2 M
sodium hydroxide was added. The aqueous layer was washed with ethyl acetate:hexanes
(2:8; 2 x 15 mL). The aqueous layer was acidified to pH = 3 with 2 M HCl. The aqueous
layer was washed with ethyl acetate (2 x 15 mL). The organic layer was dried with
sodium sulfate, filtered, and then concentrated to afford III-69 in 82% yield (47.8 mg;
0.43 mmol).

Compound III-69
1

H-NMR (300 MHz; CDCl3): d 7.47-7.41 (d, 1H, J = 18 Hz), 5.73-5.67 (d, 1H, J = 18

Hz), 5.32-5.29 (s, 2H), 1.94 (s, 3H); 13C-NMR (75 MHz; CDCl3): d 154.8, 143.1, 121.4,
17.9; IR (NaCl salt plate): 3214, 2974, 1623, 1595, 1340, 1273, 993.20

Synthesis of (E)-7-phenyl-hept-6-en-1-al (III-79)
H
O

To a dry, 100 mL roundbottomed flask were added 509.3 mg III-84 (2.68 mmol; 1 eq),
2.7 mL anhydrous DMSO, 2.7 mL anhydrous DCM, and 1.9 mL triethylamine (13.4
mmol; 5 eq). The reaction mixture was cooled to 0 ˚C in an ice-water bath, then 1.28 g
sulfur trioxide-pyridine complex (8.04 mmol; 3 eq) was added. The reaction mixture was
stirred at 0 ˚C for 2 hours and was then quenched with 20 mL phosphate buffer solution
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(20X; pH = 7.9). The reaction mixture was extracted with ethyl acetate (3 x 25 mL). The
combined organics were washed with saturated brine (20 mL). The organics were dried
with sodium sulfate, filtered, and concentrated under reduced pressure. The residue was
loaded onto a column and was washed with hexanes:ethyl acetate (0 to 5%) to afford III79 in 69% yield (347.7 mg; 1.85 mmol).

Compound III-79
1

H-NMR (500 MHz; CDCl3): d 9.80 (m, 1H), 7.38-7.36 (d, 2H, J = 10 Hz), 7.35-7.30 (t,

2H, J = 7, 25 Hz), 7.24-7.21 (t, 1H, J = 7.5, 14.5 Hz), 6.43-6.40 (d, 1H, J = 16 Hz), 6.256.20 (m, 1H), 2.50-2.43 (t, 2H, J = 10, 35 Hz), 2.28-2.24 (q, 2H, J = 10, 20 Hz), 1.751.69 (m, 2H), 1.58-1.52 (m, 2H);

13

C-NMR (125 MHz; CDCl3): d 202.7, 137.8, 130.4,

130.2, 128.6, 127.0, 126.0, 43.9, 32.8, 28.9, 21.7; IR (NaCl salt plate): 3425, 3080, 3058,
3025, 2931, 2859, 2720, 1722, 1598, 1493, 1450, 1409, 1390, 1350, 1308, 1261, 1204,
1156, 1073, 1024, 966, 878, 800, 748, 696, 614.36,37

Synthesis of 7-phenyl-hept-6-yn-1-ol (III-83)
OH

To a dry, 100 mL roundbottomed flask were added 58 mg Ph(Ph3)4 (0.05 mmol; 0.005
eq) and 20 mg copper (I) iodide (0.105 mmol; 0.0105 eq) in a dry bag. Then were added
1.12 mL iodobenzene III-81 (10 mmol; 1 eq) and 0.628 mL 6-heptyn-1-ol III-82 (5
mmol; 0.5 eq). The reaction mixture was stirred overnight at room temperature. The
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reaction mixture was filtered through filter paper and the filtrate evaporated onto silica.
The column was washed with hexanes:diethyl ether (0 to 45%) to afford III-83 in 86%
yield (0.8064 g; 4.28 mmol).

Compound III-83
1

H-NMR (500 MHz; CDCl3): d 7.42-7.40 (m, 2H), 7.31-7.27 (m, 3H), 3.69-3.67 (t, 2H, J

= 5, 10 Hz), 2.46-2.43 (t, 2H, J = 5, 15 Hz), 1.66-1.62 (m, 4H), 1.58-1.55 (m, 2H); 13CNMR (125 MHz; CDCl3): d 131.6, 128.3, 127.6, 124.1, 90.2, 80.9, 62.9, 32.4, 28.6, 25.2,
19.5; IR (NaCl salt plate): 3332, 3056, 2936, 2860, 2234, 1598, 1571, 1490, 1460, 1441,
1331, 1156, 1070, 1052, 961, 914, 756, 692.42

Synthesis of (E)-7-phenyl-hept-6-en-1-ol (III-84)

OH

To a dry, 100 mL roundbottomed flask was added 757 mg lithium aluminum hydride
(19.95 mmol; 7.5 eq) in a dry bag. A reflux condenser was fitted to the roundbottomed
flask and the solid was cooled to 0 ˚C in an ice-water bath. Anhydrous THF (17 mL) was
added slowly. Then, 500 mg of III-83 dissolved in 8 mL anhydrous THF was added to
the roundbottomed flask. The suspension was then heated to reflux for 96 hours. The
reaction mixture was cooled to room temperature and then cooled to 0 ˚C in an ice-water
bath. The reaction mixture was SLOWLY quenched with 1 mL water, 1 mL 3.75 M
sodium hydroxide, and 3 mL water. Diethyl ether (30 mL) and 1 M HCl (30 mL) was
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added to the white suspension and the layers were separated. The acidic layer was
washed with diethyl ether (2 x 30 mL). The combined organics were dried with sodium
sulfate, filtered, and concentrated to afford III-84 in >99% yield (509.3 mg, 1.01 mmol).

Compound III-84
1

H-NMR (500 MHz; CDCl3): d 7.37-7.35 (d, 2H, J = 10 Hz), 7.33-7.31 (t, 2H, J = 5, 10

Hz), 7.22-7.20 (t, 1H, J = 5, 10 Hz), 6.42-6.39 (d, 1H, J = 15 Hz), 6.26-6.23 (m, 1H),
3.66-3.63 (t, 2H, J = 6.9, 15 Hz), 2.26-2.23 (m, 2H), 1.61-1.44 (m, 6H); 13C-NMR (125
MHz; CDCl3): d 137.9, 130.9, 130.0, 128.6, 126.9, 126.0, 62.9, 33.1, 32.7, 29.3, 25.5; IR
(NaCl salt plate): 3337, 3102, 3080, 3058, 3024, 2931, 2856, 1598, 1494, 1448, 1375,
1350, 1071, 1054, 1031, 964, 744, 713, 693, 606.35

Synthesis of 2-[6-phenyl-5,6-hexanediol]-ethyl acrylate (III-85)

HO
HO

Ph

CO 2Et
To a dry, 100 mL roundbottomed flask were added a stirbar, 4 mL tert-butyl alcohol, 4
mL water, 118.1 mg (1.24 mmol; 0.49 eq) methanesulfonamide, and 2.505 g AD-mixbeta. The solution was stirred at room temperature for 30 minutes, then brought to 0 ˚C

188

using an immersion cooler. Once the solution had reached the appropriate temperature,
320.8 mg (1.242 mmol; 1 eq) III-52 in 2 mL (1:1) tert-butyl alcohol:water were added all
at once. The solution was stirred at 0 ˚C for 48 hours. After that time, solution as
quenched with 20 mL saturated sodium sulfite, then extracted with ethyl acetate (3 x 15
mL). The combined organics were then washed with 7.5 mL 2 M KOH, dried with
sodium sulfate, filtered, and evaporated. Diol III-85 (346.1 mg; 1.18 mmol) was isolated
in 95% yield.

Compound III-85
1

H-NMR (500 MHz; CDCl3): d 7.34-7.31 (m, 5H), 6.91-6.88 (m, 1H), 5.77-5.74 (d, 1H, J

= 15 Hz), 4.40-4.39 (d, 1H, J = 5 Hz), 4.19-4.15 (m, 3H), 3.67-3.63 (m, 1H), 3.03 (broad
s, 2H), 2.14-2.10 (q, 2H, J = 5, 20 Hz), 1.66-1.64 (m, 1H), 1.50-1.32 (m, 6H), 1.29-1.26
(m, 5H); 13C-NMR (125 MHz; CDCl3): d 166.9, 149.2, 131.4, 131.6, 128.6, 128.3, 128.1,
126.9, 124.4, 78.0, 75.8, 60.3, 32.4, 32.1, 31.2, 27.9, 25.3, 14.3; IR (NaCl salt plate):
3419, 3024, 2980, 2930, 2856, 1719, 1653, 1599, 1493, 1448, 1367, 1308, 1266, 1182,
1096, 1043, 965, 744, 694.

189

Synthesis of 2-[6-phenyl-5,6-[2-methyl-1-buten-3-yl-borono]-hexanediol]-ethyl acrylate
(III-86)

O

B O
Ph

EtO 2C

To a dry, 100 mL roundbottomed flask were added a stirbar, III-85 (95.3 mg; 0.326
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 2-methyl-1-buten-3-ylboronic acid (36.5 mg; 1 eq; 0.326 mmol). The solution was stirred at room temperature
overnight. The solution was then filtered and diluted with 5 mL water before extraction
with DCM (2 x 5 mL). The combined organics were then dried with sodium sulfate,
filtered and evaporated to afford boronate ester III-86 in 84% yield (101.2 mg; 0.275
mmol).

Compound III-86
1

H-NMR (500 MHz; CDCl3): d 7.41-7.38 (m, 2H), 7.34-7.32 (m, 3H), 7.26-7.22 (d, 1H, J

= 20 Hz), 6.98-6.93 (m, 1H), 5.84-5.81 (d, 1H, J = 15 Hz), 5.69-5.66 (d, 1H, J = 15 Hz),
5.22-5.21 (m, 2H), 4.96-4.95 (d, 1H, J = 5 Hz), 4.23-4.18 (m, 3H), 2.25-2.21 (m, 2H),
1.91 (s, 3H), 1.77-1.73 (m, 2H), 1.67-1.40 (m, 4H), 1.31-1.28 (t, 3H, J = 10, 15 Hz); 13C-
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NMR (125 MHz; CDCl3): d 166.8, 153.2, 148.9, 143.1, 141.0, 131.6, 128.8, 128.3, 125.8,
121.6, 120.6, 84.9, 84.2, 60.3, 35.6, 32.1, 27.9, 24.9, 17.8, 14.4; IR (NaCl salt plate):
3082, 3063, 3029, 2979, 2935, 2860, 1718, 1653, 1624, 1600, 1495, 1454, 1435, 1342,
1369, 1319, 1295, 1233, 1183, 1093, 1039, 997, 902, 850, 761, 701, 640.
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Appendix A
NMR Spectra for Chapter One
1,2-benzisoselenazole-2(3H)-3-oxo-acetic acid (I-19)

O
HO
N
Se
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O

2-bromo-3-[(phenylamino)carbonyl]-methyl benzoate (I-24)

O
MeO
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Br

O
N
H

Ph

1,2-benzisothiazole-2,3-dihydro-2-phenyl-3-oxo-7-methyl ester (I-25)

O
N
S
MeO
O
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1,2-benzisoselenazole-2,3-dihydro-2-phenyl-3-oxo-7-methyl ester (I-26)

O
N
Se
MeO
O
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1,2-benzisothiazole-2,3-dihydro-2-phenyl-3-oxo-7-carboxylic acid (I-27)

O
N
S
HO
O
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200

1,2-benzisoselenazole-2,3-dihydro-2-phenyl-3-oxo-7-carboxylic acid (I-28)
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4-[(2-iodobenzoyl)amino]-methyl benzoate (I-30)

O
O

MeO
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H
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3-[(2-iodobenzoyl)amino]-methyl benzoate (I-31)

O
O
OMe
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N
H
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4-(3-oxo-1,2-benzisothiazol-2(3H)-yl)- methyl benzoate (I-32)
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MeO
N
S
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3-(3-oxo-1,2-benzisothiazol-2(3H)-yl)-methyl benzoate (I-33)

O
O
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N
S

4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- methyl benzoate (I-34)

O
O
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N
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3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-methyl benzoate (I-35)
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N
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4-(3-oxo-1,2-benzisothiazol-2(3H)-yl)-benzoic acid (I-36)
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3-(3-oxo-1,2-benzisothiazol-2(3H)-yl)-benzoic acid (I-37)

O
O
OH
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N
S

4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-benzoic acid (I-38)
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O
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3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-benzoic acid (I-39)

O
O
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Appendix B
NMR Spectra for Chapter Two
4-chloro-5-[4-carboxyphenyl]-[2-tert-butylbenzamido]-methyl benzoate (II-8)
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4-chloro-5-bromo-[2-tert-butylbenzamido]-tert-butyl benzoate (II-12)

Br
Cl
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NH O

213

4-chloro-5-[4-methoxycarbonylphenyl]-[2-tert-butylbenzamido]-benzoic acid
(II-15)

H 3CO

O

Cl
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NH

O

214

4-chloro-5-[4-carboxyphenyl]-2-amino-methyl benzoate
(II-16)

HO

O

Cl
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NH 2 O

215

4-chloro-5-[4-methoxycarbonylphenyl]-2-amino-methyl benzoate
(II-17)

H 3CO

O

Cl
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NH 2 O
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4-chloro-5-[4-methoxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl benzoate (II-18)
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217

4-chloro-5-[4-benzyloxycarbonylphenyl]-2-amino-methyl benzoate (II-19)

Ph
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Cl
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NH 2 O

218

4-chloro-5-[4-benzyloxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl benzoate
(II-20)
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4-chloro-5-[4-tert-butyloxycarbonylphenyl]-2-amino-methyl benzoate (II-21)

t-BuO
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Cl
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NH 2 O
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4-chloro-5-[4-tert-butyloxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl benzoate
(II-22)

t-BuO
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4-chloro-5-bromo-2-[4-carboxybenzamido]-methyl benzoate (II-26)
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4-chloro-5-bromo-2-[4-carboxybenzamido]-benzoic acid (II-27)
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Appendix C
NMR Spectra for Chapter Three
[(1E)-3-methyl-buta-1,3-dien-1-yl] boronic acid pinacol ester (III-4)
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2-[6-phenyl-hex-5-enyl]-ethyl acrylate (III-52)
Ph

CO 2Et
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(4E)-ethyl-5-phenyl-pent-4-enoate (III-58)

O
OEt
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1-hydroxy-1-phenyl-prop-2-ene (III-60)

OH
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(E)-5-phenyl-pent-4-en-1-ol (III-61)

OH
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(E)-5-phenyl-pent-4-en-1-al (III-62)
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2-[4-phenyl-but-3-enyl]-ethyl acrylate (III-63)
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2-[4-phenyl-3,4-butanediol]-ethyl acrylate (III-64)
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OH
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2-[4-phenyl-3,4-[2-methyl-1-buten-3-yl-borono]-butanediol]-ethyl acrylate (III-65)
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O
O
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2-[4-phenyl-3,4-[2-furanylborono]-butanediol]-ethyl acrylate (III-66)
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2-[4-phenyl-3,4-[3-furanylborono]-butanediol]-ethyl acrylate (III-67)
O

O

B

O

O
O
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[(1E)-3-methyl-buta-1,3-dien-1-yl] boronic acid (III-69)

HO B

OH
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(E)-7-phenyl-hept-6-en-1-al (III-79)

H
O
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7-phenyl-hept-6-yn-1-ol (III-83)

OH
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(E)-7-phenyl-hept-6-en-1-ol (III-84)

OH
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2-[6-phenyl-5,6-hexanediol]-ethyl acrylate (III-85)

HO
HO
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2-[6-phenyl-5,6-[2-methyl-1-buten-3-yl-borono]-hexanediol]-ethyl acrylate (III-86)

O

B O
Ph

EtO 2C
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